(54) Title: COMPOSITIONS AND METHODS FOR DETECTING AN RNA VIRUS

FIG. 1

(57) Abstract: The present invention provides methods for rapidly identifying an RNA viral infection using an isothermal nucleic acid amplification reaction that can be carried out extracted RNA in the context of a crude biological sample.

WO 2016/064894 A3

COMPOSITIONS AND METHODS FOR DETECTING AN RNA VIRUS

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims priority to and the benefit of U.S. Provisional Patent Application Serial Nos. 62/066,277, filed October 20, 2014, and 62/104,008 filed January 15, 2015. The entire contents of each of these applications are hereby incorporated by reference herein.

BACKGROUND OF THE INVENTION

The *Ebola* virus causes hemorrhagic fever with mortality rates reaching 50% to 90% of infected humans. *Ebola* virus (EBOV) includes four species, Zaire EBOV, Sudan EBOV, Ivory Coast EBOV, and Reston EBOV. Human infection with Ebola typically results from contact with contaminated blood, tissues, and/or excretions of animals or patients with an Ebola infection. Patients typically exhibit symptoms 4 to 10 days after Ebola infection. This long incubation period provides an opportunity for the virus to be carried to new areas before the carrier displays any signs of illness. Symptoms of Ebola include fever, chills, malaise, and myalgia. Because such symptoms are displayed in a variety of illnesses, there is a significant risk that Ebola infection may be misdiagnosed in the early stages, thereby facilitating spread of the disease. In later stages, Ebola -infected subjects typically develop vomiting, diarrhea, coughing, vascular symptoms, headache, confusion, coma, mucosal hemorrhages, bloody diarrhea and ultimately multiorgan failure, resulting in death. The bodily fluids of Ebola patients are highly infectious as are the dead bodies of Ebola patients.

Public health concerns about Ebola infection are mounting as Ebola infections in West Africa in late 2014 are predicted to rise to 10,000 people per week. Because of their exposure to the bodily fluids of Ebola patients, health care workers are at risk for catching Ebola from infected patients. The risk of infection increases as the extent and the frequency of contact increased. In a 1976 Sudan Ebola outbreak 81% of healthcare workers nursing Ebola patients were infected with the virus. In order for medical staff and health care workers to avoid unnecessary infections, early detection of Ebola is critical so that appropriate infection control measures are instituted and the risk of transmission is minimized.

To stop the spread of Ebola within West Africa and internationally, rapid diagnosis is essential so that infected subjects may be immediately quarantined and proper protective

1

equipment used by health care workers caring for these subjects. High titers of infectious filovirus are present in the blood and tissues during early stages of illness. Currently, Ebola is identified by virus isolation, reverse transcription-PCR (RT-PCR), including real-time quantitative RT-PCR, antigen-capture enzyme-linked immunosorbent assay (ELISA), antigen detection by immunostaining, and IgG- and IgM-ELISA using authentic virus antigens. Unfortunately, these tests are time-consuming because they can only be carried out on purified and isolated RNA and require access to laboratory equipment and trained technicians that are scarce in many areas where Ebola is endemic.

Accordingly, improved methods for rapidly identifying patients infected with *Ebola* virus are urgently required.

SUMMARY OF THE INVENTION

The present invention provides methods for rapidly identifying an Ebola infection using an isothermal nucleic acid amplification reaction that can be carried out on extracted RNA in the context of a crude biological sample.

In one aspect, the invention provides a method of detecting a specific target polynucleotide (e.g., RNA) in an isothermal amplification reaction coupled with reverse transcription, the method involving

(a) contacting a target polynucleotide molecule in a sample with a primer in the presence of a reverse transcriptase and dNTPs under conditions permissive for cDNA synthesis, thereby generating a cDNA;

(b) contacting the cDNA with forward and reverse primers each carrying at least one nicking enzyme recognition sequence within their respective 5'-terminal regions which specifically bind the cDNA with their respective 3'-terminal regions in the presence of a nicking enzyme, dNTPs, a detectable oligonucleotide probe, and a strand-displacement polymerase under conditions permissive for the isothermal amplification of the cDNA; and

(c) detecting a signal specific for detectable oligonucleotide probe hybridization to the amplicon, where detection of the signal indicates the presence or quantity of the target polynucleotide present in the sample and failure to detect the signal indicates the absence of target polyribonucleotide in the sample.

In another aspect, the invention provides a method of detecting an RNA virus in a sample, the method involving

2

(a) contacting an RNA virus polynucleotide molecule in a biological sample with a primer in the presence of a reverse transcriptase and dNTPs under conditions permissive for cDNA synthesis, thereby generating a cDNA;

(b) contacting the cDNA with forward and reverse primers each carrying at least one nicking enzyme recognition sequence within their respective 5'-terminal regions which specifically bind the cDNA with their respective 3'-terminal regions in the presence of a nicking enzyme, dNTPs, a detectable oligonucleotide probe, and a strand-displacement polymerase under conditions permissive for the isothermal amplification of the cDNA; and

(c) detecting a signal specific for detectable oligonucleotide probe hybridization to the amplicon, where detection of the signal indicates the presence or quantity of the RNA virus polynucleotide molecule present in the sample and failure to detect the amplicon indicates the absence of an RNA virus.

In a related aspect, the invention provides a method of detecting an Ebola virus in a sample, the method involving

(a) contacting an Ebola polynucleotide molecule in a biological sample with a primer in the presence of a reverse transcriptase and dNTPs under conditions permissive for cDNA synthesis, thereby generating a cDNA;

(b) contacting the cDNA with forward and reverse primers each carrying at least one nicking enzyme recognition sequence within their respective 5'-terminal regions which specifically bind the cDNA with their respective 3'-terminal regions in the presence of a nicking enzyme, dNTPs, a detectable oligonucleotide probe, and a strand-displacement polymerase under conditions permissive for the isothermal amplification of the cDNA; and

(c) detecting a signal specific for detectable oligonucleotide probe hybridization to the amplicon, where detection of the signal indicates the presence or quantity of the Ebola polynucleotide present in the sample and failure to detect the signal indicates the absence of Ebola polynucleotide present in the sample.

In various embodiments of the above aspects or any other aspect of the invention delineated herein, the Ebola polynucleotide is obtained by contacting a biological sample with an agent capable of extracting an RNA molecule present in the sample and an agent capable of stabilizing an RNA molecule against degradation.

In yet another aspect, the invention provides a method of detecting an Ebola virus in a sample, the method involving

3

(a) contacting a biological sample with an agent capable of extracting a polynucleotide molecule present in the sample and an agent capable of stabilizing a polynucleotide molecule against degradation;

(b) contacting the extracted and stabilized Ebola RNA with a primer in the presence of a reverse transcriptase and dNTPs under conditions permissive for cDNA synthesis, thereby generating an Ebola cDNA;

(c) contacting the Ebola cDNA with forward and reverse primers each carrying at least one nicking enzyme recognition sequence within their respective 5'-terminal regions which specifically bind the Ebola cDNA with their respective 3'-terminal regions in the presence of a nicking enzyme, dNTPs, and a strand-displacement polymerase under conditions permissive for the isothermal amplification of the cDNA, thereby generating amplicons; and

(d) detecting the amplicons, where the presence of an Ebola amplicon detects an Ebola polynucleotide in the sample and failure to detect the amplicon indicates the absence of an Ebola polynucleotide in the sample.

In yet another aspect, the invention provides a kit for detecting an RNA virus polynucleotide molecule involving primers that specifically bind an RNA viral sequence, a detectable probe that specifically binds a viral (e.g., Ebola) amplicon, a reverse transcriptase enzyme, a nicking enzyme, and a strand-displacement polymerase. In one embodiment, the primers contain the following sequences:

Forward primer:

GACTCGATATCGAGTCGCTTCCA[MeOC]AGTTATC[MeOU][MeOA][MeOC][MeOC][MeOG] (SEQ ID NO: 1)

Reverse Primer:

GACTCGATATCGAGTCGAAATGC[MeOA]ACGA[MeOC][MeOA][MeOC][MeOC][MeOU] (SEQ ID NO: 2); and the probe contains the following sequence: gctacACGACTTTYGCTGAAGgtagc (SEQ ID NO: 3).

In another embodiment, the probe has a fluorescent dye at the 5' end, and a quencher at the 3' end or vice versa. In one embodiment, the probe is

5'-CALRed$_{610nm}$- gctacACGACTTTYGCTGAAGgtagc BHQ2- 3' (SEQ ID NO: 4) or

5'-FAM or FITC - gctacACGACTTTYGCTGAAGgtagc-BHQ1-3' (SEQ ID NO: 5). In one embodiment, the 3' quencher is replaced by DABsyl.

4

In another aspect, the invention provides a kit for amplifying an Ebola polynucleotide molecule in a reverse transcriptase nicking amplification reaction, the kit containing the following primers:

Forward primer:

GACTCGATATCGAGTCGCTTCCA[MeOC]AGTTATC[MeOU][MeOA][MeOC][MeOC][MeOG] (SEQ ID NO: 1)

Reverse Primer:

GACTCGATATCGAGTCGAAATGC[MeOA]ACGA[MeOC][MeOA][MeOC][MeOC][MeOU] (SEQ ID NO: 2);

the following probe:

gctacACGACTTTYGCTGAAGgtagc (SEQ ID NO: 3);

a reverse transcriptase enzyme, a nicking enzyme, a strand-displacement polymerase, and directions for use of the aforementioned primers, probes and enzymes for detecting an Ebola polynucleotide molecule.

In one embodiment, the kit further contains a capillary tube that may or may not contain lyophilized lysis or RNA stabilization reagents for viral polynucleotide extraction. In another embodiment, the kit further contains one or more vessels containing a buffer suitable for carrying out a reverse transcriptase and/or amplification reaction. In another embodiment, the kit further contains vessels containing the reverse transcriptase enzyme, nicking enzyme, and strand-displacement polymerase in lyophilized form.

In yet another aspect, the invention provides a method of diagnosing a human or animal subject with an RNA virus, the method involving

(a) contacting a sample of the subject with an agent capable of extracting an RNA virus present in the sample and an agent capable of stabilizing the extracted polynucleotide molecule against degradation;

(b) contacting the polynucleotide molecule with a reverse transcriptase primer in the presence of a reverse transcriptase and dNTPs under conditions permissive for cDNA synthesis, thereby generating a cDNA copy of the polynucleotide molecule;

(c) contacting the cDNA with forward and reverse primers carrying at least one nicking enzyme recognition sequence within their respective 5'-terminal regions which specifically bind the cDNA with their respective 3'-terminal regions in the presence of a nicking enzyme, dNTPs, and a strand-displacement polymerase under conditions permissive for the isothermal amplification of the cDNA, thereby generating amplicons; and

5

(d) detecting the amplicons, where the presence of an RNA viral amplicon diagnoses an RNA viral infection in the subject and failure to detect the amplicon diagnoses the absence of an RNA viral infection in the subject.

In various embodiments of any aspect delineated herein, no detectable signal is present in a control assay lacking a target polynucleotide at seven minutes, ten minutes, and/or fifteen minutes following initiation of the assay. In other embodiments of any aspect delineated herein, the primer used in step (a) has the same sequence or a different sequence than a primer used in step (b). In other embodiments of any of the above, steps (a)-(c) are carried out in a single reaction. In still other embodiments of the above aspects, the reverse transcriptase enzyme and the strand-displacement DNA polymerase are the same or different enzymes. In still other embodiments, the cDNA of step (a) is generated in a first reaction vessel, then transferred to a second reaction vessel where step (b) is carried out. In still other embodiments of any aspect delineated herein, the polynucleotide molecule is an Ebola polynucleotide. In still other embodiments of any aspect delineated herein, the sample is a bodily fluid (e.g., saliva, sweat, tears, fluids accumulating in a bodily cavity, urine, ejaculate, vaginal secretion, cerebrospinal fluid, lymph, feces, sputum, decomposition fluid, vomit, sweat, breast milk, blood, serum, and plasma). In still other embodiments of any aspect delineated herein, the bodily cavity is peritoneal cavity or pericardial cavity. In still other embodiments of any aspect delineated herein, the limit of detection is 10 or 20 copies per reaction. In still other embodiments of any aspect delineated herein, the method is carried out in about 5, 7, 10, 15, 20, 25 or thirty minutes. In still other embodiments of any aspect delineated herein, steps a-d are carried out in the context of the biological sample. In still other embodiments of any aspect delineated herein, Ebola or other viral RNA is not purified or isolated away from the biological sample (e.g, crude). In still other embodiments of any aspect delineated herein, the method is carried out at a point of care or diagnosis in a portable battery powered device. In still other embodiments of any aspect delineated herein, no separate reverse transcriptase primer is required, but the forward and/or reverse primers are used. In still other embodiments of any aspect delineated herein, the sample is a biological sample or an environmental sample. In still other embodiments of any aspect delineated herein, the biological sample is obtained from a subject, bat, bush meat, or a domestic animal. In still other embodiments of any aspect delineated herein, the biological sample is a swab of a mucosal membrane that is any one or more of buccal, nasal, eye, rectal, and vaginal or skin. In still other embodiments of any aspect delineated herein, the biological sample is a tissue

sample obtained from a subject, necropsy, or culture media. In still other embodiments of any aspect delineated herein, the necropsy is of a human, primate, bat, or other mammal. In still other embodiments of any aspect delineated herein, the environmental sample is a material that may be contaminated with a biological fluid of a subject having or having a propensity to develop an Ebola viral infection. In still other embodiments of any aspect delineated herein, the environmental sample is bedding, a seat cushion, a rug, an air condition filter or other material. In still other embodiments of any aspect delineated herein, the polymerase are 5'-exo⁻ derivatives of Bst DNA polymerase I, Gst DNA polymerase I, Gka DNA polymerase I, Gca DNA polymerase I, Gan DNA polymerase I, Gbo DNA polymerase I, Gsp70 DNA polymerase I, GspT3 DNA polymerase I, Gsp52 DNA polymerase I and/or fragments thereof. In still other embodiments of any aspect delineated herein, the nicking enzyme is one or more of Nt.BstNBI, Nt.BspD6I, Nt.BspQI, Nt.BsmAI, Nt.AlwI, N.Bst9I, or N.BstSEI. In still other embodiments of any aspect delineated herein, the reverse transcriptase is M-MLV RT, AMV RT, RSV RT, and/or mutants/derivates thereof. In still other embodiments of any aspect delineated herein, the detectable probe contains a molecular beacon. In various embodiments of any aspect delineated herein, an amplification primer (e.g., forward and/or reverse primer) comprises one or more 2' modified nucleotides (e.g., 2'-O-methyl ribonucleotides) in the 3' terminal region or recognition region. In particular embodiments, the amplification primer comprises one or more 2'-O-methyl modified nucleotides at the 3' end, including for example 2'-O-methyl, 2'-methoxyethoxy, 2'-fluoro, 2'-hydroxyl, 2'-alkyl, 2'-allyl, 2'-O-[2-(methylamino)-2-oxoethyl], 4'-thio, 4'-CH2-O-2'-bridge, 4'-(CH2)2-O-2'-bridge, 2'-LNA, and 2'-O-(N-methylcarbamate).

In still other embodiments of any aspect delineated herein, the forward and reverse primers for detection of Ebola virus contain the following sequences, respectively:

Forward primer:
GACTCGATATCGAGTCGCTTCCA[MeOC]AGTTATC[MeOU][MeOA][MeOC][MeOC][MeOG] (SEQ ID NO: 1)
Reverse Primer:
GACTCGATATCGAGTCGAAATGC[MeOA]ACGA[MeOC][MeOA][MeOC][MeOC][MeOU] (SEQ ID NO: 2).
In still other embodiments of any aspect delineated herein, amplification is detected using a probe having the following sequence: gctacACGACTTTYGCTGAAGgtagc (SEQ ID NO: 3). In still other embodiments of any aspect delineated herein, the probe has a fluorescent dye at 5'

7

end, and a quencher at 3' end or vice versa. In still other embodiments of any aspect delineated herein, the probe is

5'-CALRed₆₁₀ₙₘ- gctacACGACTTTYGCTGAAGgtagc BHQ2- 3' (SEQ ID NO: 4) or

5'-FAM or FITC - gctacACGACTTTYGCTGAAGgtagc-BHQ1-3' (SEQ ID NO: 5).

In still other embodiments of any aspect delineated herein, the 3' quencher is replaced by DABsyl.

In still other embodiments of any aspect delineated herein, the forward and reverse primers for detection of HIV virus contain one or more of the following sequences, respectively:

Forward primer:

GACTCGATATCGAGTCTGACTAGmCGGAGGmCmTmAmGmAmAmG (SEQ ID NO: 6),

GACTCGATATCGAGTCTGACTAGmCAGAGGmCmTmAmGmAmAmG (SEQ ID NO: 7); and

Reverse Primer:

GACTCGATATCGAGTCTATTGACmGCTCmTmCmGmCmAmC (SEQ ID NO: 8),

GACTCGATATCGAGTCTACTGACmGCTCmTmCmGmCmAmC (SEQ ID NO: 9).

In still other embodiments of any aspect delineated herein, amplification is detected using a probe having the following sequence: cgcaagGGAGAGAGATGGGTGcttgcg (SEQ ID NO: 10).

In still other embodiments of any aspect delineated herein, the forward and reverse primers for detection of Dengue virus contain one or more of the following sequences, respectively:

Forward primer:

GACTCGATATCGAGTCCAAAAACmAGCATATTmGmAmCmGmC (SEQ ID NO: 11); and

Reverse Primer:

GACTCGATATCGAGTCAGACAGCmAGGATCmTmCmTmGmG (SEQ ID NO: 12),

GACTCGATATCGAGTCAGACAGCmAGGATCmTmGmTmGmG (SEQ ID NO: 13).

In still other embodiments of any aspect delineated herein, amplification is detected using a probe having the following sequence: cgcatcTGGTCTTTCCCAGCgatgcg (SEQ ID NO: 14).

In still other embodiments of any aspect delineated herein, the forward and reverse primers for detection of influenza B virus contain one or more of the following sequences, respectively:

Forward primer:

GACTCGATATCGAGTCAAATGCAmGATGGTCTCmAmGmCmTmA (SEQ ID NO: 15),

8

GACTCGATATCGAGTCAAATGCAmAATGGTCTCmAmGmCmTmA (SEQ ID NO: 16),

GACTCGATATCGAGTCAAATGCAmGATGGTTTCmAmGmCmTmA (SEQ ID NO: 17); and

Reverse Primer:

GACTCGATATCGAGTCCTCCTTTmTCCCATTCCATmTmCmAmTmT (SEQ ID NO: 18),

GACTCGATATCGAGTCCTCCCTTmTCCCATTCCATmTmCmAmTmT (SEQ ID NO: 19),

GACTCGATATCGAGTCCTCCTTTmCCCCATTCCATmTmCmAmTmT (SEQ ID NO: 20).

In still other embodiments of any aspect delineated herein, amplification is detected using a probe having the following sequence: gccaaGCTATGAACACAGCAAActtggc (SEQ ID NO: 21).

In still other embodiments of any aspect delineated herein, the forward and reverse primers for detection of BVDV1 virus contain one or more of the following sequences, respectively:

Forward primer:

GACTCGATATCGAGTCGGCCCACmTGTATTGCTmAmCmTmGmAmAmA (SEQ ID NO: 22),

GACTCGATATCGAGTCGGCCCACmTGCACTGCTmAmCmTmAmAmAmA (SEQ ID NO: 23); and

Reverse Primer:

GACTCGATATCGAGTCTGTGATCmAACTCCmAmTmGmTmGmCmC (SEQ ID NO: 24).

In still other embodiments of any aspect delineated herein, amplification is detected using a probe having the following sequence: cgctacATCTCTGCTGTACATGgtagcg (SEQ ID NO: 25).

In still other embodiments of any aspect delineated herein, the probe has a fluorescent dye at the 5' end and a quencher at the 3' end, or a fluorescent dye at the 3' end and a quencher at the 5' end. In particular embodiments, the fluorescent dye is CALRed$_{610nm}$, and the quencher is BHQ2 or DABsyl. In certain embodiments, the fluorescent dye is FAM or FITC and the quencher is BHQ1 or DABsyl.

In still other embodiments of any aspect delineated herein, the RNA virus is an Ebola virus, human immunodeficiency virus (HIV), Dengue virus, influenza virus (e.g., influenza B), Bovine Viral Diarrhea virus (e.g., BVDV Genotype 1), Yellow Fever virus, West Nile virus, Hepatitis C, Lassa virus, Flavivirus, Arenavirus, or single-stranded RNA virus. In still other embodiments of any aspect delineated herein, the agent capable of extracting the virus is one of or a combination of sodium dodecyl sulfate, sodium lauryl sulfate, Guanidinium thiocyanate, and/or guanidine hydrochloride. In various embodiments, the Guanidinium thiocyanate or other agent capable of extracting the virus is used at a concentration of about 0.1, 0.5, 1.0, 2.5, 5.0, 7.5, 10, 15, 20, 25, 50, 100, 250, 500 mM or more. In still other embodiments of any aspect delineated herein, the method is used for daily screening of health

care workers. In still other embodiments of any aspect delineated herein, the samples are pooled and the screening is carried out on a human or animal population.

The present invention as claimed herein is described in the following items 1 to 12:

1.   A method of detecting a specific target polynucleotide in an isothermal amplification reaction coupled with reverse transcription, the method comprising:

(a) contacting a target polynucleotide molecule in a sample with a primer in the presence of a reverse transcriptase and dNTPs under conditions permissive for cDNA synthesis, thereby generating a cDNA;

(b) contacting the cDNA with

(i) forward and reverse primers each comprising a modified nucleotide (m);

wherein the polynucleotide molecule is Ebola virus (EBOV) and the forward and reverse primers for the detection of EBOV are selected from the group consisting of:

Forward primer:

GACTCGATATCGAGTCGCTTCCAmCAGTTATCmUmAmCmCmG (SEQ ID NO: 1), and

Reverse Primer:

GACTCGATATCGAGTCGAAATGCmAACGAmCmAmCmCmU (SEQ ID NO: 2); or

wherein the polynucleotide molecule is human immunodeficiency virus (HIV) and the forward and reverse primers for the detection of HIV are selected from the group consisting of:

Forward primers:

GACTCGATATCGAGTCTGACTAGmCGGAGGmCmTmAmGmAmAmG (SEQ ID NO: 6), and

GACTCGATATCGAGTCTGACTAGmCAGAGGmCmTmAmGmAmAmG (SEQ ID NO: 7), and

Reverse Primers:

GACTCGATATCGAGTCTATTGACmGCTCmTmCmGmCmAmC (SEQ ID NO: 8), and GACTCGATATCGAGTCTACTGACmGCTCmTmCmGmCmAmC (SEQ ID NO: 9); or

10

wherein the polynucleotide molecule is dengue virus and the forward and reverse primers for the detection of dengue virus are selected from the group consisting of:

Forward primer:

GACTCGATATCGAGTCCAAAAACmAGCATATTmGmAmCmGmC (SEQ ID NO: 11), and

Reverse Primer:

GACTCGATATCGAGTCAGACAGCmAGGATCmTmCmTmGmG (SEQ ID NO: 12), and

GACTCGATATCGAGTCAGACAGCmAGGATCmTmGmTmGmG (SEQ ID NO: 13); or

wherein the polynucleotide molecule is influenza B virus and the forward and reverse primers for the detection of influenza B virus are selected from the group consisting of:

Forward primers:

GACTCGATATCGAGTCAAATGCAmGATGGTCTCmAmGmCmTmA (SEQ ID NO: 15),

GACTCGATATCGAGTCAAATGCAmAATGGTCTCmAmGmCmTmA (SEQ ID NO: 16), and

GACTCGATATCGAGTCAAATGCAmGATGGTTTCmAmGmCmTmA (SEQ ID NO: 17), and

Reverse Primers:

GACTCGATATCGAGTCCTCCTTTmTCCCATTCCATmTmCmAmTmT (SEQ ID NO: 18),

GACTCGATATCGAGTCCTCCCTTmTCCCATTCCATmTmCmAmTmT (SEQ ID NO: 19), and

GACTCGATATCGAGTCCTCCTTTmCCCCATTCCATmTmCmAmTmT (SEQ ID NO: 20); or

wherein the polynucleotide molecule is bovine diarrhea virus and the forward and reverse primers for the detection of bovine diarrhea virus are selected from the group consisting of:

Forward primers:

11

GACTCGATATCGAGTCGGCCCACmTGTATTGCTmAmCmTmGmAmA mA (SEQ ID NO: 22), and

GACTCGATATCGAGTCGGCCCACmTGCACTGCTmAmCmTmAmAmAmA (SEQ ID NO: 23), and

Reverse Primer:

GACTCGATATCGAGTCTGTGATCmAACTCCmAmTmGmTmGmCmC (SEQ ID NO: 24),

(ii) dNTPs,

(iii) a detectable oligonucleotide probe, and

(iv) a strand-displacement polymerase

under conditions permissive for the isothermal amplification of the cDNA; and

(c) detecting a signal specific for detectable oligonucleotide probe hybridization to the amplicon, wherein detection of the signal indicates the presence or quantity of the target polynucleotide present in the sample and failure to detect the signal indicates the absence of target polynucleotide in the sample.

2.   A method of detecting an RNA virus in a sample, the method comprising

(a) contacting an RNA virus polynucleotide molecule in a sample with a primer in the presence of a reverse transcriptase and dNTPs under conditions permissive for cDNA synthesis, thereby generating a cDNA;

(b) contacting the cDNA with

(i) forward and reverse primers each comprising a modified nucleotide (m);

wherein the RNA virus polynucleotide is Ebola virus (EBOV) and the forward and reverse primers for the detection of EBOV are selected from the group consisting of:

Forward primer:

GACTCGATATCGAGTCGCTTCCAmCAGTTATCmUmAmCmCmG (SEQ ID NO: 1), and

Reverse Primer:

GACTCGATATCGAGTCGAAATGCmAACGAmCmAmCmCmU (SEQ ID NO: 2); or

wherein the RNA virus polynucleotide is human immunodeficiency virus (HIV) and the forward and reverse primers for the detection of HIV are selected from the group consisting of:

Forward primers:

GACTCGATATCGAGTCTGACTAGmCGGAGGmCmTmAmGmAmAmG (SEQ ID NO: 6), and

GACTCGATATCGAGTCTGACTAGmCAGAGGmCmTmAmGmAmAmG (SEQ ID NO: 7), and

Reverse Primers:

GACTCGATATCGAGTCTATTGACmGCTCmTmCmGmCmAmC (SEQ ID NO: 8), and GACTCGATATCGAGTCTACTGACmGCTCmTmCmGmCmAmC (SEQ ID NO: 9); or

wherein the RNA virus polynucleotide is dengue virus and the forward and reverse primers for the detection of dengue virus are selected from the group consisting of:

Forward primer: GACTCGATATCGAGTCCAAAAACmAGCATATTmGmAmCmGmC (SEQ ID NO: 11), and

Reverse Primer:

GACTCGATATCGAGTCAGACAGCmAGGATCmTmCmTmGmG (SEQ ID NO: 12), and

GACTCGATATCGAGTCAGACAGCmAGGATCmTmGmTmGmG (SEQ ID NO: 13); or

wherein the RNA virus polynucleotide is influenza B virus and the forward and reverse primers for the detection of influenza B virus are selected from the group consisting of:

Forward primers:

GACTCGATATCGAGTCAAATGCAmGATGGTCTCmAmGmCmTmA (SEQ ID NO: 15),

GACTCGATATCGAGTCAAATGCAmAATGGTCTCmAmGmCmTmA (SEQ ID NO: 16), and

GACTCGATATCGAGTCAAATGCAmGATGGTTTCmAmGmCmTmA (SEQ ID NO: 17), and

13

Reverse Primers:

GACTCGATATCGAGTCCTCCTTTmTCCCATTCCATmTmCmAmTmT (SEQ ID NO: 18),

GACTCGATATCGAGTCCTCCCTTmTCCCATTCCATmTmCmAmTmT (SEQ ID NO: 19), and

GACTCGATATCGAGTCCTCCTTTmCCCCATTCCATmTmCmAmTmT (SEQ ID NO: 20); or

wherein the RNA virus polynucleotide is bovine diarrhea virus and the forward and reverse primers for the detection of bovine diarrhea virus are selected from the group consisting of:

Forward primers:

GACTCGATATCGAGTCGGCCCACmTGTATTGCTmAmCmTmGmAmAmA (SEQ ID NO: 22), and

GACTCGATATCGAGTCGGCCCACmTGCACTGCTmAmCmTmAmAmAmA (SEQ ID NO: 23), and

Reverse Primer:

GACTCGATATCGAGTCTGTGATCmAACTCCmAmTmGmTmGmCmC (SEQ ID NO: 24),

(ii) dNTPs,

(iii) a detectable oligonucleotide probe, and

(iv) a strand-displacement polymerase

under conditions permissive for the isothermal amplification of the cDNA; and

(c) detecting a signal specific for detectable oligonucleotide probe hybridization to the amplicon, wherein detection of the signal indicates the presence or quantity of the RNA virus polynucleotide molecule present in the sample and failure to detect the amplicon indicates the absence of an RNA virus.

3.   A method of diagnosing a human or animal subject with an RNA virus, the method comprising

(a) contacting a sample of the subject with an agent capable of extracting an RNA virus present in the sample and an agent capable of stabilizing the extracted polynucleotide molecule against degradation;

14

(b) contacting the polynucleotide molecule with a reverse transcriptase primer in the presence of a reverse transcriptase and dNTPs under conditions permissive for cDNA synthesis, thereby generating a cDNA copy of the polynucleotide molecule;

(c) contacting the cDNA with

(i) forward and reverse primers each comprising a modified nucleotide (m);

wherein the polynucleotide molecule is Ebola virus (EBOV) and the forward and reverse primers are selected from the group consisting of:

Forward primer:

GACTCGATATCGAGTCGCTTCCAmCAGTTATCmUmAmCmCmG (SEQ ID NO: 1), and

Reverse Primer:

GACTCGATATCGAGTCGAAATGCmAACGAmCmAmCmCmU (SEQ ID NO: 2); or wherein the polynucleotide molecule is human immunodeficiency virus (HIV) and the forward and reverse primers are selected from the group consisting of:

Forward primers:

GACTCGATATCGAGTCTGACTAGmCGGAGGmCmTmAmGmAmAmG (SEQ ID NO: 6), and GACTCGATATCGAGTCTGACTAGmCAGAGGmCmTmAmGmAmAmG (SEQ ID NO: 7), and

Reverse Primers:

GACTCGATATCGAGTCTATTGACmGCTCmTmCmGmCmAmC (SEQ ID NO: 8), and GACTCGATATCGAGTCTACTGACmGCTCmTmCmGmCmAmC (SEQ ID NO: 9); or wherein the polynucleotide molecule is dengue virus and the forward and reverse primers are selected from the group consisting of:

Forward primer: GACTCGATATCGAGTCCAAAAACmAGCATATTmGmAmCmGmC (SEQ ID NO: 11), and

Reverse Primer:

GACTCGATATCGAGTCAGACAGCmAGGATCmTmCmTmGmG (SEQ ID NO: 12), and GACTCGATATCGAGTCAGACAGCmAGGATCmTmGmTmGmG (SEQ ID NO: 13); or wherein the polynucleotide molecule is influenza B virus and the forward and reverse primers are selected from the group consisting of:

Forward primers:

GACTCGATATCGAGTCAAATGCAmGATGGTCTCmAmGmCmTmA (SEQ ID NO: 15), GACTCGATATCGAGTCAAATGCAmAATGGTCTCmAmGmCmTmA (SEQ ID NO: 16),

15

and GACTCGATATCGAGTCAAATGCAmGATGGTTTCmAmGmCmTmA (SEQ ID NO: 17), and

Reverse Primers:

GACTCGATATCGAGTCCTCCTTTmTCCCATTCCATmTmCmAmTmT (SEQ ID NO: 18), GACTCGATATCGAGTCCTCCCTTmTCCCATTCCATmTmCmAmTmT (SEQ ID NO: 19), and GACTCGATATCGAGTCCTCCTTTmCCCCATTCCATmTmCmAmTmT (SEQ ID NO: 20); or

wherein the polynucleotide molecule is bovine diarrhea virus and the forward and reverse primers are selected from the group consisting of:

Forward primers:

GACTCGATATCGAGTCGGCCCACmTGTATTGCTmAmCmTmGmAmAmA (SEQ ID NO: 22), and

GACTCGATATCGAGTCGGCCCACmTGCACTGCTmAmCmTmAmAmAmA (SEQ ID NO: 23), and

Reverse Primer:

GACTCGATATCGAGTCTGTGATCmAACTCCmAmTmGmTmGmCmC (SEQ ID NO: 24),

ii) dNTPs,

iii) a detectable oligonucleotide probe, and

iv) a strand-displacement polymerase

under conditions permissive for the isothermal amplification of the cDNA, thereby generating amplicons; and

(d) detecting the amplicons, wherein the presence of an RNA viral amplicon diagnoses an RNA viral infection in the subject and failure to detect the amplicon diagnoses the absence of an RNA viral infection in the subject.

4.   The method of any one of items 1-3, wherein the polynucleotide molecule is obtained by contacting the sample with ne or more of an agent capable of extracting an RNA molecule present in the sample and an agent capable of stabilizing an RNA molecule against degradation, optionally wherein the agent capable of extraction is one or a combination of sodium dodecyl sulfate, sodium lauryl sulfate, Guanidinium thiocyanate, and/or guanidine hydrochloride; and/or

16

wherein no detectable signal is present in a control assay lacking a target polynucleotide at seven minutes, ten minutes, and/or fifteen minutes following initiation of the assay; and/or

wherein the primer used in step (a) has the same sequence or a different sequence than the forward or reverse primer used in step (b); and/or

wherein steps (a)-(c) are carried out in a single reaction; and/or

wherein the cDNA of step (a) is generated in a first reaction vessel, then transferred to a second reaction vessel where step (b) is carried out; and/or

wherein the reverse transcriptase enzyme used in step (a) and the strand-displacement DNA polymerase used in step (b) are the same or different enzyme; and/or

wherein the sample is a bodily fluid, optionally selected from the group consisting of saliva, sweat, tears, fluids accumulating in a bodily cavity, urine, ejaculate, vaginal secretion, cerebrospinal fluid, lymph, feces, sputum, decomposition fluid, vomit, sweat, breast milk, blood, serum, and plasma, optionally wherein the bodily cavity is peritoneal cavity or pericardial cavity; and/or

wherein the limit of detection is 10 or 20 copies per reaction; and/or

wherein the method is carried out in about 5, 7, 10, 15, 20, 25 or thirty minutes; and/or

wherein steps (a)-(d) are carried out in the context of the biological sample; and/or

wherein the polynucleotide molecule is not purified or isolated away from the biological sample.

5.   The method of any one of items 1-4, wherein the method is carried out at a point of care or diagnosis in a portable battery powered device; and/or

wherein no separate reverse transcriptase primer is required, but the forward and/or reverse primers are used; and/or

wherein the sample is a biological sample or an environmental sample, optionally wherein the biological sample is obtained from a subject, bat, bush meat, or a domestic animal; or wherein the biological sample is a swab of a mucosal membrane selected from the group consisting of buccal, nasal, eye, rectal, and vaginal or skin; or wherein the biological sample is a tissue sample obtained from a subject, necropsy, or culture media, optionally wherein the necropsy is of a human, primate, bat, or other mammal; or wherein the environmental sample is a material that may be contaminated with a biological fluid of a

17

subject having or having a propensity to develop an Ebola viral infection; or wherein the environmental sample is bedding, a seat cushion, a rug, an air condition filter or other material; and/or

wherein the polymerase are 5'-exo⁻ derivatives of Bst DNA polymerase I, Gst DNA polymerase I, Gka DNA polymerase I, Gca DNA polymerase I, Gan DNA polymerase I, Gbo DNA polymerase I, Gsp70 DNA polymerase I, GspT3 DNA polymerase I, Gsp52 DNA polymerase I and/or fragments thereof; and/or

wherein the nicking enzyme is one or more of Nt.BstNBI, Nt.BspD6I, Nt.BspQI, Nt.BsmAI, Nt.AlwI, N.Bst9I, or N.BstSEI; and/or

wherein the reverse transcriptase is M-MLV RT, AMV RT, RSV RT, and/or mutants/derivatives thereof.

6.   The method of any one of items 1-5, wherein the polynucleotide molecule is EBOV and the probe having the following sequence: gctacACGACTTTYGCTGAAGgtagc; optionally

wherein the probe is

5'-CALRed610nm- gctacACGACTTTYGCTGAAGgtagc BHQ2- 3' or

5'-FAM or FITC - gctacACGACTTTYGCTGAAGgtagc-BHQ1-3'; or

wherein the polynucleotide molecule is HIV and the probe comprises the following sequence:

cgcaagGGAGAGAGATGGGTGcttgcg; or

wherein the polynucleotide molecule is Dengue virus and the probe comprises the following sequence: cgcatcTGGTCTTTCCCAGCgatgcg; or

wherein the polynucleotide molecule is influenza B and the probe comprises the following sequence: gccaaGCTATGAACACAGCAAActtggc; or

wherein the polynucleotide molecule is bovine diarrhea virus and the probe comprises the following sequence: cgctacATCTCTGCTGTACATGgtagcg.

7.   The method of any one of items 1-6, wherein the detectable probe comprises a molecular beacon; or

wherein the detectable probe has a fluorescent dye at the 5' end, and a quencher at the 3' end or a fluorescent dye at the 3' end, and a quencher at 5' end; optionally,

wherein the quencher is BHQ1, BHQ2 or DABsyl; and/or

wherein the fluorescent dye is CALRed610nm, FAM or FITC.

18

8. The method of any one of items 1-7, wherein the one or more 2' modified nucleotide is one or more of 2'-O-methyl, 2'-methoxyethoxy, 2'-fluoro, 2'-hydroxyl, 2'-alkyl, 2'-allyl, 2'-O-[2-(methylamino)-2-oxoethyl], 4'-CH2-O-2'-bridge, 4'-(CH2)2-O-2'-bridge, 2'-LNA, and 2'-O-(N-methylcarbamate).

9. A kit for detecting an RNA virus polynucleotide molecule comprising:

(i) forward and reverse primers each comprising a modified nucleotide (m),wherein the RNA virus polynucleotide is Ebola virus (EBOV) and the forward and reverse primers are selected from the group consisting of:

Forward primer:

GACTCGATATCGAGTCGCTTCCAmCAGTTATCmUmAmCmCmG (SEQ ID NO: 1), and

Reverse Primer:

GACTCGATATCGAGTCGAAATGCmAACGAmCmAmCmCmU (SEQ ID NO: 2); or

wherein the RNA virus polynucleotide is human immunodeficiency virus (HIV) and the forward and reverse primers are selected from the group consisting of:

Forward primers:

GACTCGATATCGAGTCTGACTAGmCGGAGGmCmTmAmGmAmAmG (SEQ ID NO: 6), and GACTCGATATCGAGTCTGACTAGmCAGAGGmCmTmAmGmAmAmG (SEQ ID NO: 7), and

Reverse Primers:

GACTCGATATCGAGTCTATTGACmGCTCmTmCmGmCmAmC (SEQ ID NO: 8), and GACTCGATATCGAGTCTACTGACmGCTCmTmCmGmCmAmC (SEQ ID NO: 9); or

wherein the RNA virus polynucleotide is dengue virus and the forward and reverse primers are selected from the group consisting of:

Forward primer:

GACTCGATATCGAGTCCAAAAACmAGCATATTmGmAmCmGmC (SEQ ID NO: 11), and

Reverse Primer:

19

GACTCGATATCGAGTCAGACAGCmAGGATCmTmCmTmGmG (SEQ ID NO: 12), and GACTCGATATCGAGTCAGACAGCmAGGATCmTmGmTmGmG (SEQ ID NO: 13); or

wherein the RNA virus polynucleotide is influenza B virus and the forward and reverse primers are selected from the group consisting of:

Forward primers:

GACTCGATATCGAGTCAAATGCAmGATGGTCTCmAmGmCmTmA (SEQ ID NO: 15), GACTCGATATCGAGTCAAATGCAmAATGGTCTCmAmGmCmTmA (SEQ ID NO: 16), and GACTCGATATCGAGTCAAATGCAmGATGGTTTCmAmGmCmTmA (SEQ ID NO: 17), and

Reverse Primers:

GACTCGATATCGAGTCCTCCTTTmTCCCATTCCATmTmCmAmTmT (SEQ ID NO: 18), GACTCGATATCGAGTCCTCCCTTmTCCCATTCCATmTmCmAmTmT (SEQ ID NO: 19), and GACTCGATATCGAGTCCTCCTTTmCCCCATTCCATmTmCmAmTmT (SEQ ID NO: 20); or

wherein the RNA virus polynucleotide is bovine diarrhea virus and the forward and reverse primers are selected from the group consisting of:

Forward primers:

GACTCGATATCGAGTCGGCCCACmTGTATTGCTmAmCmTmGmAmAmA (SEQ ID NO: 22), and GACTCGATATCGAGTCGGCCCACmTGCACTGCTmAmCmTmAmAmAmA (SEQ ID NO: 23), and

Reverse Primer:

GACTCGATATCGAGTCTGTGATCmAACTCCmAmTmGmTmGmCmC (SEQ ID NO: 24),

(ii) a detectable probe that specifically binds an RNA virus amplicon,

(iii) a reverse transcriptase enzyme,

(iv) a nicking enzyme, and

(v) a strand-displacement polymerase.

10.   The kit of item 9,

wherein the RNA virus polynucleotide is EBOV and the probe comprises the following sequence: gctacACGACTTTYGCTGAAGgtagc; optionally wherein the probe is

20

5'-CALRed610nm- gctacACGACTTTYGCTGAAGgtagc BHQ2- 3' or

5'-FAM or FITC - gctacACGACTTTYGCTGAAGgtagc-BHQ1-3', optionally wherein the 3' quencher is replaced by DABsyl; or

wherein the RNA virus polynucleotide is HIV and the probe comprises the following sequence: cgcaagGGAGAGAGATGGGTGcttgcg; or

wherein the RNA virus polynucleotide is Dengue virus and the probe comprises the following sequence: cgcatcTGGTCTTTCCCAGCgatgcg; or

wherein the RNA virus polynucleotide is influenza B virus and the probe comprises the following sequence: gccaaGCTATGAACACAGCAAActtggc; or

wherein the RNA virus polynucleotide is bovine diarrhea virus and the probe comprises the following sequence: cgctacATCTCTGCTGTACATGgtagcg.

11.   The kit of item 9 or item 10, wherein the probe has a fluorescent dye at the 5' end and a quencher at the 3' end or fluorescent dye at the 3' end and a quencher at the 5' end; optionally,

wherein the quencher is BHQ1, BHQ2 or DABsyl; and/or

wherein the fluorescent dye is CALRed610nm, FAM or FITC.

12.   The kit of any one of items 9-11, wherein the kit further comprises a capillary tube that may or may not comprise lyophilized lysis or RNA stabilization reagents for viral polynucleotide extraction; and/or

wherein the kit further comprises one or more vessels comprising a buffer suitable for carrying out a reverse transcriptase and/or amplification reaction; and/or

wherein the kit further comprises vessels comprising the reverse transcriptase enzyme, nicking enzyme, and strand-displacement polymerase in lyophilized form.

Definitions

By "Ebola virus (EBOV)" is meant a Filoviridae virus having at least about 85% amino acid sequence identity to an Ebola virus. Exemplary Ebola viruses include, but are not limited to, Ebola-Zaire virus, Ebola-Sudan virus, Ebola-Ivory Coast virus, and Ebola-Bundibugyo, which cause disease in humans, or Ebola-Reston virus, which affects non-human primates.

The sequence of an exemplary Ebola Zaire genome is provided at NCBI Accession
No. KC242800.1 (SEQ ID NO: 26), which is reproduced below:

```
   1 cggacacaca aaaagaaaga agaatttttta ggatctttttg tgtgcgaata actatgagga
  61 agattaataa ttttcctctc attgaaattt atatcggaat ttaaattgaa attgttactg
 121 taatcacacc tggtttgttt cagagccaca tcacaaagat agagaacagc ctaggtctcc
 181 gaagggaaca agggcaccag tgtgctcagt tgaaaatccc ttgtcaacat ctaggtctta
 241 tcacatcaca agttccacct cagactctgc agggtgatcc aacaacccta atagaaaaat
 301 tattgttaac ggacagcatt agttcacagt caaacaagca agattgagaa ttaaccttga
 361 ttttgaactt caacacctag aggattggag attcaacaac cctaaaactt ggggtaaaac
 421 attggaaata gttgaaagac aaattgctcg gaatcacaaa attccgagta tggattctcg
 481 tcctcagaaa gtctggatga cgccgagtct tactgaatct gacatggatt accacaagat
 541 cttgacagca ggtctgtccg ttcaacaggg gattgttcgg caaagagtca tcccagtgta
 601 tcaagtaaac aatcttgagg aaatttgcca acttatcata caggcctttg aagcaggtgt
 661 tgattttcaa gagagtgcgg acagtttcct tctcatgctt tgtcttcatc atgcgtacca
 721 aggagatcac aaacttttct tggaaagtgg tgcagtcaag tatttggaag ggcacgggtt
 781 ccgtttttgaa gtcaagaaac gtgatggggt gaagcgcctt gaggaattgc tgccagcagt
 841 atctagtgga aaaaacatta agagaacact tgctgccatg ccggaagagg agacgactga
 901 agctaatgcc ggtcagtttc tctcttttgc aagtctattc cttccgaaat tggtagtagg
 961 agaaaaggct tgccttgaga aagttcaaag gcaaattcaa gtacatgcag agcaaggact
1021 gatacaatat ccaacagctt ggcaatcagt aggacacatg atggtgattt tccgtttgat
1081 gcgaacaaat tttttgatca aatttctcct aatacaccaa gggatgcaca tggttgccgg
1141 gcatgatgcc aacgatgctg tgatttcaaa ttcagtggct caagctcgtt tttcaggttt
1201 attgattgtc aaaacagtcc ttgatcatat cctacaaaag acagaacgag gagttcgtct
1261 ccatcctctt gcaaggactg ccaaggtaaa aaatgaggtg aactccttta aggctgcact
1321 cagctccctg gccaagcatg gagagtatgc tcctttcgcc cgacttttga acctttctgg
1381 agtaaataat cttgagcatg gtcttttccc tcaactatcg gcaattgcac tcggagtcgc
1441 cacagcacac gggagcaccc tcgcaggagt aaatgttgga gaacagtatc aacagctcag
1501 agaggctgcc actgaagctg agaagcaact ccaacaatat gcagaatctc gcgaacttga
1561 ccatcttgga cttgatgatc aggaaaagaa aattcttatg aacttccatc agaaaaagaa
1621 cgaaatcagc ttccagcaaa caaacgctat ggtaactcta agaaaagagc gcctggccaa
```

```
1681 gctgacagaa gctatcactg ctgcatcact gcccaaaaca agtggacctt acgatgatga
1741 tgacgacatt ccctttccag gacccatcaa tgatgacgac aatcctggcc atcaagatga
1801 tgatccgact gactcacagg atacgaccat tcccgatgtg gtggttgatc ccgatgatgg
1861 aagctacggc gaataccaga gttactcgga aaacggcatg aatgcaccag atgacttggt
1921 cctattcgat ctagacgagg acgacgagga cactaagcca gtgcctaaca gattgaccaa
1981 gggtggacaa cagaaaaaca gtcaaaaggg ccagcataca gagggcagac agacacaatc
2041 caggccaact caaaatgtcc caggccctcg cagaacaatc caccacgcca gtgctccact
2101 cacggacaac gacagaggaa atgaaccctc cggctcaacc agccctcgca tgctgacacc
2161 aattaacgaa gaggcagacc cactggacga tgccgacgac gagacgtcta gtcttccgcc
2221 cttggagtca gacgatgaag aacaggacag ggacgaaact tccaaccgca cacccactgt
2281 cgccccaccg gctcccgtat acagagatca ctctgaaaag aaagaactcc cgcaagatga
2341 gcagcaagat caggaccaca ctcaagaggc caggaaccag gacagtgaca cacccagcc
2401 agaacactct tttgaggaga tgtatcgcca cattctaaga tcacagggac catttgatgc
2461 tgttttgtat tatcatatga tgaaggatga gcctgtagtt ttcagtacta gtgatggcaa
2521 agagtacacg tatccggact cccttgaaga ggaatatcca ccatggctca ctgaaaaaga
2581 ggccatgaat gaagagaata gatttgttac attggatggt caacaatttt attggccggt
2641 aatgaatcac aagaataaat tcatggcaat cctgcaacat catcagtgaa tgagaatgga
2701 ataatgggat gatttaaccg acaaatagct aacattaaat agtcaagaaa cgcaaacagg
2761 aagaattttt gatgtctaag gtgtgaatta ttatcacaat aaaagtgatt cttatttttg
2821 aatttaaagc tagcttatta ttactagccg tttttcaaag ttcaatttga gtcttaatgc
2881 aaataggcgt taagccacag ttatagccat aattgtaact caatatctta gctagcgatt
2941 tatctaaatt aaattacatt atgctttat aacttaccta ctagcctgcc caacatttac
3001 acgatcgttt tataattaag aaaaaactaa tgatgaagat taaaaccttc atcatcctta
3061 cgtcaattga attctctagc actcgaagct tattgtcttc aatgtaaaag aaaagctggt
3121 ccaacaagat gacaactaga acaaagggca ggggccatac tgtggccacg actcaaaacg
3181 acagaatgcc aggccctgag ctttcgggct ggatctccga gcagctaatg accggaagaa
3241 ttcctgtaag cgacatcttc tgtgatattg agaacaatcc aggattatgt tacgcatccc
3301 aaatgcaaca aacaaagcca aacccgaaga tgcgcaacag tcaaacccaa acggacccaa
3361 tttgcaatca tagttttgag gaggtagtac aaacattggc ttcattggct actgttgtgc
3421 aacaacaaac tatcgcatca gaatcattag aacaacgtat tacgagtctt gagaatggtc
3481 taaagccagt ttatgatatg gcaaaaacaa tctcctcatt gaacagggtt gtgctgaga
3541 tggttgcaaa atatgatctt ctggtgatga caaccggtcg ggcaacagca accactgcgg
3601 caactgaggc ttattgggct gaacatggtc aaccaccacc tggaccatca ctttatgaag
3661 aaagtgcaat tcggggtaag attgaatcta gagatgagac cgtccctcaa agtgttaggg
3721 aggcattcaa caatctagac agtaccactt cactaactga ggaaaatttt gggaaacctg
3781 acatttcagc aaaggatttg agaaacatta tgtatgatca cttgcctggt tttggaactg
3841 ctttccacca attagtacaa gtgatttgta aattgggaaa agatagcaac tcattggata
3901 tcattcatgc tgagttccag gccagcctgg ctgaaggaga ctctcctcaa gtgtgccctaa
3961 ttcaaattac aaaaagagtt ccaatcttcc aagatgctgc tccacctgtc atccacatcc
4021 gctctcgagg tgacattccc cgagcttgcc agaaaagctt gcgtccagtc ccgccatcac
4081 ccaagattga tcgaggttgg gtatgtgttt ccagcttca agatggtaaa acacttggac
4141 tcaaaatttg agccaatctc ccttccctcc gaaagaggcg accaatagca gaggcttcaa
4201 ctgctgaact acagggtacg ttacattaat gatacacttg tgagtatcag ccctagataa
4261 tataagtcaa ttaaacgacc aagccaaaat tgttcatatc ccgctagcag cttaaaatat
```

21

```
4321  aaatgaaata ggagctatat ctctgacagt attataatca attgttatta agtaacccaa
4381  accaaaaatg atgaagatta agaaaaacct acctcgactg agagagtgtt tttccattaa
4441  ccttcatctt gtaaacgttg agcaaaattg ttacgaatat gaggcgggtt atattgccta
4501  ctgctcctcc tgaatatatg gaggccatat accctgtcag gtcaaattca acaattgcta
4561  ggggtggcaa caacaataca ggcttcctga caccggagtc agtcaatgga gacactccat
4621  cgaatccact caggccaatt gctgatgaca ccatcgacca tgctagccac acaccaggca
4681  gtgtgtcatc agcattcatc cttgaagcta tggtgaatgt catatcgggc cccaaagtgc
4741  taatgaagca aattccaatt tggcttcctc taggtgtcgc tgatcaaaag acctacagct
4801  ttgactcaac tacggccgcc atcatgcttg cttcatatac tatcacccat ttcggcaagg
4861  caaccaatcc acttgtcaga gtcaatcggc tgggtcctgg aatcccggat caccccctca
4921  ggctcctgcg aattggaaac caggccttcc tccaggagtt cgttcttccg ccagtccaac
4981  taccccagta tttcaccttt gatttgacag cactcaaact gatcacccaa ccactgcctg
5041  ctgcaacatg gaccgatgac actccaacag gatcaaatgg agcgctgcgt ccaggaattt
5101  cgtttcatcc aaaacttcgc cccattcttt tacctaacaa aagtgggaag aaggggaaca
5161  gtgccgatct aacatctcca gagaaaatcc aagcaataat gacttcactc caggacttta
5221  agatcgttcc aattgatcca accaaaaata tcatgggtat cgaagtgcca gaaactctgg
5281  tccacaagct gaccggtaag aaggtgactt ctaaaaatgg acaaccaatc atccctgttc
5341  ttttgccaaa gtacattggg ttggacccgg tggctccagg agacctcacc atggtaatca
5401  cacaggattg tgacacgtgt cattctcctg caagtcttcc agctgtgatt gagaagtaat
5461  tgcaataatt gactcagatc cagtttttaca gaatcttctc agggatagtg ataacatcta
5521  tttagtaatc cgtctattag aggagatact tttaattgat caatatacta aaggtgcttt
5581  acaccattgt ctttttctc tcctaaatgt agaacttaac aaaagactca caatatactt
5641  gtcttaaaga gattgattga tgaaagatca tgactaataa cattacaaat aatcctacta
5701  taatcaatac ggtgattcaa atattaatct ttctaattgc acatactctc tgcccctatc
5761  ctcaaattgc ctacatgcct acatctgagg atagccagtg tgacttggat tggagatgta
5821  gggaagaaat cggaacccat ctccaggttg ttcacaatcc aagcacagac atcgcccttc
5881  taattaagaa aaaatcggcg atgaagatta agccgacagt gagcgcaatc ttcatctctc
5941  ttagattatt tgttttccag agtagggtc atcaggtcct ttccaatcat ataaccaaaa
6001  taaacttcac tagaaggata ttgtgaggca acaacacaat gggtattaca ggaatattgc
6061  agttacctcg tgatcgattc aagaggacat cattctttct ttgggtaatt atcctttttcc
6121  aaagaacatt ttccatccca cttggagtca tccacaatag cacattacaa gttagtgatg
6181  tcgacaaact agtttgtcgt gacaaactgt catccacaaa tcaattgaga tcagttggac
6241  tgaatctcga agggaatgga gtggcaactg acgtgccatc tgcaactaaa agatggggct
6301  tcaggtccgg tgtccctcca aaggtggtca attatgaagc tggtgaatgg gctgaaaact
6361  gctacaatct tgaaatcaaa aaacctgacg ggagtgagtg tctaccagca gcgccagacg
6421  ggattcgggg cttcccccgg tgccggtatg tgcacaaagt atcaggaacg ggaccgtgtg
6481  ccggagactt tgccttccac aaagagggtg ctttcttcct gtatgatcga cttgcttcca
6541  cagttatcta ccgaggaacg actttcgctg aaggtgtcgt tgcatttctg atactgcccc
6601  aagctaagaa ggacttcttc agctcacacc ccttgagaga gccggtcaat gcaacggagg
6661  acccgtccag tggctactat tctaccacaa ttagatatca ggctaccggt tttggaacca
6721  atgagacgga gtacttgttc gaggttgaca atttgaccta cgtccaactt gaatcaagat
6781  tcacgccaca gttttttgctc cagctgaatg agacaatata tgcaagtggg aaaaggagca
6841  acaccacggg aaaactaatt tggaaggtca accccgaaat tgatacaaca atcgggggagt
6901  gggccttctg ggaaactaaa aaaacctcac tagaaaaatt cgcagtgaag agttgtcttt
```

22

```
6961  cacagctgta  tcaaacggag  ccaaagacat  cagtggtcag  agtccggcgc  gaacttcttc
7021  cgacccagag  acctacacaa  caactgaaga  ccacaaaatc  atggcttcag  aaaattcctc
7081  tgcaatggtt  caagtgcaca  atcaaggaag  ggaagctgca  gtgtcgcatc  tgataaccct
7141  tgccacaatc  tccacgagtc  ctcaatcccc  tacaaccaaa  ccaggtcagg  acaacagcac
7201  ccataataca  cccgtgtata  aacttgacat  ctctgaggca  actcaagttg  aacaacatca
7261  tcgcagaaca  gacaacgaca  gcacagcctc  cgacactccc  cccgccacga  ccgcagccgg
7321  accccaaaa  gcagagaaca  tcaacacgag  caagagcgct  gactccctgg  accccgccac
7381  cacgacaagt  ccccaaaact  acagcgagac  cgctggcaac  aacaacactc  atcaccaaga
7441  taccggagaa  gagagtgccg  gcagcgggaa  gctgggcttg  attgccaata  ctattgctgg
7501  agtcgcaggg  ctgatcacag  gcgggagaag  aactcgaaga  gaagcaattg  tcaatgctca
7561  acccaaatgc  aaccccaatc  tacattactg  gactactcag  gatgaaggtg  ctgcaatcgg
7621  attggcctgg  ataccatatt  tcgggccagc  agccgaggga  atttacacag  aggggctaat
7681  gcacaatcaa  gatggtttaa  tctgtggatt  gaggcagctg  gccaatgaga  cgactcaagc
7741  tcttcaactg  ttcctgagag  ccacaactga  gctacgcacc  ttttcaatcc  tcaaccgtaa
7801  ggcaattgat  ttcttgctgc  agcgatgggg  cggcacatgc  cacattttgg  gaccggactg
7861  ctgtatcgaa  ccacatgatt  ggaccaagaa  cataacagac  aaaattgatc  agattattca
7921  tgattttgtt  gataaaaccc  ttccggacca  ggggggacaat  gacaattggt  ggactggatg
7981  gagacaatgg  ataccggcag  gtattggagt  tacaggcgtt  ataattgcag  ttattgcttt
8041  attctgtata  tgcaaatttg  tctttttagtt  tttcttcaga  ttgcttcatg  gcaaagctca
8101  gcctcaaatc  aatgagatta  ggatttaatt  atatggatca  cttgaatcta  agattacttg
8161  acaaatgata  atataataca  ctggagcttt  aaatatagcc  aatgtgattc  taactccttt
8221  aaactcacaa  ttaatcataa  acaaggtttg  acatcaatct  agttatatct  ttgagaatga
8281  taaacttgat  gaagattaag  aaaaaggtaa  tctttcgatt  atctttagtc  ttcatccttg
8341  attctacaat  catgacagtt  gtctttagtg  acaagggaaa  gaagcctttt  tagtaagttg
8401  taataatcag  atctgcgaac  cggtagagtt  taattgcaac  ctaacacaca  taaagcattg
8461  gtcaaaaagt  caatagaaat  ttaaacagtg  agtggagaca  actttcaaat  ggaagctcca
8521  tacgagagag  gacgcccccg  agctgccaga  cagcattcaa  gggatggaca  cgaccatcat
8581  gttcgagcac  gatcatcatc  cagagagaat  tatcgaggtg  agtaccgtca  atcaaggagc
8641  gcctcacaag  tgcgcgttcc  tactgtattt  cataagagga  gagttgaacc  attaacagtt
8701  cctccagcac  ctaaagacat  atgtccgacc  ttgaaaaaag  gattttttgtg  tgacagtagt
8761  ttttgcaaaa  aagatcacca  gttggaaagt  ttaactgata  gggaattact  cctactaatc
8821  gcccgtaaga  cttgtggatc  agtagaacaa  caattaaata  taactgcacc  caaggactcg
8881  cgcttagcaa  atccaacggc  tgatgatttc  cagcaagagg  aaggtccaaa  aattaccttg
8941  ttgacactga  tcaagacggc  agaacactgg  gcgagacaag  acatcaggac  cacagaggat
9001  tcaaaattaa  gagcattgtt  gactctatgt  gctgtgatga  cgaggaaatt  ctcaaaatcc
9061  cagctgagtc  ttttatgtga  gacacacctg  aggcgcgagg  ggcttgggca  agatcaggca
9121  gaacccgttc  tcgaagtata  tcaacgatta  cacagtgata  aaggaggcag  tttcgaagct
9181  gcactatggc  aacaatggga  tcgacaatcc  ctaattatgt  ttatcactgc  attcttgaat
9241  atcgctctcc  agttaccgtg  tgaaagttct  gctgtcgttg  tttcagggtt  aagaacattg
9301  gttcctcaat  cagataatga  ggaagcttca  accaacccgg  ggacatgctc  atggtctgat
9361  gatggtaccc  cttaataagg  ctgactaaaa  cactatataa  ccttctactt  gatcacaata
9421  ctccgtatac  ctatcatcat  atattcaatc  aagacggtat  cctttaaaac  ttattcagta
9481  ctataatcac  tctcgtttca  aattaataag  atatgcataa  ttgctttaat  atatgaagag
9541  gtatgataca  accctaacag  tgatcaaaga  aaatcataat  ctcttatcgc  tcgtaatata
```

23

```
 9601 acctgccaag catacctctt gcacaaagtg attcttgtac acaaataatg ttttactcta
 9661 caggaggtag caacgatcca tcccatcaaa aaataagtat tttatgactt actaatgatc
 9721 tcttaaaata ttaagaaaaa ctgacggaac acaaattctt tctgcttcaa gttgtggagg
 9781 aggtctttgg tattggctat tgttatatta caatcaataa caagcttgta aaaatattgt
 9841 tcttgtttca agaggtagat tgtgaccgga aacgctaaac taatgatgaa gattaatgcg
 9901 gaggtctgat aagaataaac cttattattc agattaggcc ccaagaggca ttcttcatct
 9961 ccttttagca aagtactatt tcagggtagt ccaattagtg acacgtcttt tagctgtata
10021 tcagtcgccc ctgagatacg ccacaaaagt gtctctaagc taaattggtc tgtacacatc
10081 tcatacattg tattaggggc aataatatct aattgaactt agccgtttaa aatttagtgc
10141 ataaacctgg gctaactcca ccaggtcaac tccattggct gaaaagaagc ccacctacaa
10201 cgaacatcac tttgagcgcc cttacaatta aaaaatagga acgtcgttcc aacaattgag
10261 cgcaaggttt caaggttgaa ctgagagtgc ctaaacacca aaatatcgat aattcagaca
10321 ccaagcaaga cctgagaagg aaccatggct aaagctacgg gacgatacaa tctaatatcg
10381 cccaaaaagg acctggagaa aggggttgtc ttaagcgacc tctgtaactt cctagttagt
10441 caaactattc aagggtggaa ggtctattgg gctggtattg agtttgatgt gactcacaaa
10501 ggaatggccc tattgcatag actgaaaact aatgactttg cccctgcatg gtcaatgaca
10561 aggaatctat ttcctcattt atttcaaaat ccgaattcca caattgagtc accactgtgg
10621 gcattgagag tcatccttgc agcaggggta caggaccagc tgattgacca gtctttgatt
10681 gaacccttag caggagccct tggtctgatc tctgattggc tgctaacaac caacactaac
10741 catttcaaca tgcgaacaca acgtgttaag gaacaattga gcctaaaaat gctgtcgttg
10801 attcgatcca atattctcaa gtttattaac caattggatg ctctacatgt cgtgaactac
10861 aacgggttgt tgagcagtat tgaaattgga actcaaaatc atacaatcat tataactcga
10921 actaacatgg gttttctggt ggagctccaa gaacccgaca aatcggcaat gaaccgcaag
10981 aagcctgggc cggcgaaatt ttccctcctt catgagtcca cactgaaagc atttacacaa
11041 gggtcctcga cacgaatgca aagtttgatt cttgaattta atagctctct tgctatctaa
11101 ttaagatgga atacttcata ttgagctaac tcatatatgc tgactcaata gttatcttga
11161 catctctgct ttcataatca gatatataag cataataaat aaatactcat atttcttgat
11221 aatttgttta accacagata aatcctaact gtaagccagc ttccaagttg acacccttac
11281 aaaaaccagg actcagaatc cctcaaataa gagattccaa gacaacatca tagaattgct
11341 ttattatatg aataagcatg ttatcaccag aaatccaata tactaaatag ttaattgtaa
11401 ctgaacccgc aggtcacgtg tgttaggttt cacagattat atatattact aactccatac
11461 ccgtaattaa cattagataa gtagattaag aaaaacgctt gaggaagatt aagaaaaact
11521 gcttattggg tctttccgtg ttttagatga agcagttgac attcttcctc ttgatattaa
11581 atggctacac aacatacccа atacccagac gccaggttat catcaccaat tgtattggac
11641 caatgtgacc tagtcactag agcttgcggg ttatattcat catactccct taatccgcaa
11701 ctacgcaact gtaaactccc gaaacatatc taccgtttaa aatatgatgt aactgttacc
11761 aagttcttaa gtgatgtacc agtggcgaca ttgccaatag atttcatagt cccaattctt
11821 ctcaaggcac tgtcaggcaa tgggttctgt cctgttgagc cgcggtgtca acagttctta
11881 gatgaaatca ttaagtacac aatgcaagat gctctcttcc tgaaatatta tctcaaaaat
11941 gtgggtgctc aagaggactg tgttgatgac cactttcaag agaaaatctt atcttcaatt
12001 cagggcaatg aatttttaca tcaaatgttc ttctggtatg acctggctat tttgactcga
12061 aggggtagat taaatcgagg aaactctaga tcaacatggt ttgttcatga tgatttaata
12121 gacatcttag gctatgggga ctatgttttt tggaagatcc caatttcaat gttacccctg
12181 aacacacaag gaatccccca tgctgctatg gattggtatc aggcatcagt attcaaagaa
```

24

```
12241  gcggttcaag  ggcatacaca  cattgtttct  gtttctactg  ccgacgtctt  gataatgtgc
12301  aaagatttaa  ttacatgtcg  attcaacaca  actctaatct  caaagatagc  agaggttgag
12361  gatccagttt  gttctgatta  tcccgatttt  aagattgtgt  ctatgcttta  ccagagcgga
12421  gattacttac  tctccatatt  agggtctgat  gggtataaaa  ttattaagtt  cctcgaacca
12481  ttgtgcttgg  ccaaaattca  attatgctca  aagtacaccg  agaggaaggg  ccgattctta
12541  acacaaatgc  atttagctgt  aaatcacacc  ctggaagaaa  ttacagaaat  gcgtgcacta
12601  aagccttcac  aggatcaaaa  gatccgtgaa  ttccatagaa  cattgataag  gctggagatg
12661  acgccacaac  aactttgtga  gctattttcc  attcaaaaac  actgggggca  tcctgtgcta
12721  catagtgaaa  cagcaatcca  aaaagttaaa  aaacatgcca  cggtgctaaa  agcattacgc
12781  cctatagtga  ttttcgagac  atattgtgtt  tttaaatata  gtattgcaaa  acattatttt
12841  gatagtcaag  gatcttggta  cagtgttact  tcagatagga  atttaacgcc  aggtcttaat
12901  tcttatatca  aaagaaatca  attccccccg  ttgccaatga  ttaaagaact  actatgggaa
12961  ttttaccacc  ttgaccatcc  tccacttttc  tcaaccaaaa  ttattagtga  cttaagtatt
13021  tttataaaag  acagagctac  cgcagtggaa  aggacatgct  gggatgcagt  attcgagcct
13081  aatgttctag  gatataatcc  acctcacaaa  ttcagtacta  aacgtgtacc  agaacaattt
13141  ttagagcaag  aaaacttttc  tattgagaat  gttctttcct  acgcgcaaaa  actcgagtat
13201  ctactaccac  aataccggaa  tttttctttc  tcattgaaag  agaaagagtt  gaatgtaggt
13261  agaactttcg  gaaaattgcc  ttatccgact  cgcaatgttc  aaacactttg  tgaagctctg
13321  ttagctgatg  gtcttgctaa  agcatttcct  agcaatatga  tggtagtcac  agagcgtgag
13381  caaaaagaaa  gcttattgca  tcaagcatca  tggcaccaca  caagtgatga  ttttggtgag
13441  catgccacag  ttagagggag  tagctttgta  actgatttag  agaaatacaa  tcttgcattt
13501  agatatgagt  ttacagcacc  ttttatagaa  tattgtaacc  gttgctatgg  tgttaagaat
13561  gtttttaatt  ggatgcatta  tacaatcccc  cagtgttata  tgcatgtcag  tgattattat
13621  aatccaccgc  ataacctcac  tctggaaaat  cgagacaacc  cccccgaagg  gcccagttca
13681  tacagaggtc  atatgggagg  gattgaagga  ctgcaacaaa  aactctggac  aagtatttca
13741  tgtgctcaaa  tttctttagt  tgaaataaag  actggttttta  agttacgctc  agctgtgatg
13801  ggtgacaatc  agtgcattac  cgttttatca  gtcttcccct  tagagactga  cgcagacgag
13861  caggaacaga  gcgccgaaga  caatgcagcg  agggtggccg  ccagcctagc  aaaagttaca
13921  agtgcctgtg  gaatcttttt  aaaacctgat  gaaacatttg  tacattcagg  ttttatctat
13981  tttggaaaaa  aacaatattt  gaatggggtc  caattgcctc  agtcccttaa  aacggctaca
14041  agaatggcac  cattgtctga  tgcaatttttt  gatgatcttc  aagggaccct  ggctagtata
14101  ggcactgctt  ttgaacgatc  catctctgag  acacgacata  tctttccttg  caggataacc
14161  gcagctttcc  atacgttttt  ttcggtgaga  atcttgcaac  atcatcacct  cgggttcaat
14221  aagggttttg  accttggaca  gttgacactt  ggcaaacctc  tggatttcgg  aacaatatca
14281  ttggcactag  cggtaccgca  ggtgcttgga  gggttatcct  tcttgaatcc  tgagaaatgt
14341  ttctaccgga  atttaggaga  tccagttacc  tcaggcttat  tccagttaaa  aacttatctc
14401  cgaatgattg  agatggatga  tttattctta  cctttaattg  cgaagaaccc  tgggaactgc
14461  actgccattg  actttgtgct  aaatcctagc  ggattaaatg  tccccgggtc  gcaagactta
14521  acttcatttc  tgcgccagat  tgtgcgtagg  actatcaccc  taagtgcgaa  aaacaaactt
14581  attaatactt  tatttcatgc  gtcagctgac  ttcgaagacg  aaatggtttg  taaatggcta
14641  ttatcatcaa  ctcctgttat  gagtcgtttt  gcggccgata  tcttttcacg  cacgcccagt
14701  gggaagcgat  tgcaaattct  aggatacctg  gaaggaacac  gcacattatt  agcctctaag
14761  atcatcaaca  ataatacaga  aacaccggtt  ttggacagac  tgaggaaaat  aacattgcaa
14821  aggtggagtc  tatggtttag  ttatcttgat  cattgtgata  atatcctggc  agaggcttta
```

25

```
14881  acccaaataa cttgcacagt tgatttagca cagatcctga gggaatattc atgggcacat
14941  attttagagg ggagacctct tattggagcc acacttccat gtatgattga gcaattcaaa
15001  gtggtttggc tgaaacccta cgaacaatgt ccgcagtgtt caaatgcaaa gcaacctggt
15061  gggaaaccat tcgtgtcagt ggcagtcaag aaacatattg ttagtgcatg gccgaacgca
15121  tcccgaataa gctggactat cggggatgga atcccataca ttggatcaag gacagaagat
15181  aagataggac aacctgctat taaaccaaaa tgtccttccg cagccttaag agaggccatt
15241  gaactggcgt cccgtttaac atgggtaact caaggcagtt cgaacagtga tttgctaata
15301  aaaccatttt tggaagcacg agtaaattta agtgttcaag aaatacttca aatgaccccт
15361  tcacattact caggaaatat tgttcacagg tacaacgatc aatatagtcc tcattctttc
15421  atggccaatc gtatgagtaa ttcagcgacg cgattgattg tttctactaa cactttaggt
15481  gagttttcag gaggtggcca gtctgcacgc gacagcaata ttattttcca gaatgttata
15541  aattatgcag ttgcactgtt cgatattaaa tttagaaaca ctgaggctac agatatccaa
15601  tataatcgtg ctcaccttca tctaactaag tgttgcaccc gggaagtacc agctcagtat
15661  ttaacataca catctacatt ggatttagat ttaacaagat accgagaaaa cgaattgatt
15721  tatgacaata atcctctaaa aggaggactc aattgcaata tctcattcga taacccatтт
15781  ttccaaggta aacggctaaa cattatagaa gatgatctta ttcgactgcc tcacttatct
15841  ggatgggagc tagccaagac catcatgcaa tcaattattt cagatagcaa caattcgtct
15901  acagacccaa ttagcagtgg agaaacaaga tcattcacta cccatttctt aacttatccc
15961  aagataggac ttctgtacag ttttgggggcc tttataagtt attatcttgg caatacaatt
16021  cttcggacta agaaattaac acttgacaat ttтttatatt acttaactac ccaaattcat
16081  aatctaccac atcgctcatt gcgaatactt aagccaacat tcaaacatgc aagcgttatg
16141  tcacggttaa tgagtattga tcctcatttt tctatttaca taggcggtgc ggcaggtgac
16201  agaggactct cagatgcggc caggttattt ttgagaacgt ccatttcatc ttttcttgca
16261  tttataaaag agtggataat taatcgcgga acaattgtcc ctttatggat agtatatccg
16321  ctagagggtc aaaacccaac acctgttaat aatttcctcc atcagatcgt agaactgctg
16381  gtgcatgatt catcaagaca acaggctttt aaaactacca taagtgatca tgtacatcct
16441  cacgacaatc ttgtttacac atgtaagagt acagccagca atttcttcca tgcgtcattg
16501  gcgtactgga gaagcaggca cagaaacagc aatcgaaaat acttggcaag agactcttca
16561  actggatcaa gcacaaacaa cagtgatggt catattgaga gaagtcaaga acaaaccacc
16621  agagatccac atgatggcac tgaacggaat ctagtcctac aaatgagcca tgaaataaaa
16681  agaacgacaa ttccacaaga aagcacgcac cagggtccgt cgttccagtc atttctaagt
16741  gactctgctt gtggtacagc aaatccaaaa ctaaatttcg atagatcgag acataatgtg
16801  aaatctcagg atcataactc ggcatccaag agggaaggtc atcaaataat ctcacaccgt
16861  ctagtcctac ctttctttac attgtctcaa gggacgcgcc aattaacgtc atccaatgag
16921  tcacaaaccc aagacgagat atcaaagtac ttacggcaat tgagatccgt cattgatacc
16981  acagtttatt gtaggtttac cggtatagtc tcgtccatgc attacaaact tgatgaggtc
17041  ctttgggaaa tagagagttt taagtcggct gtgacgctag cagagggaga aggtgctggt
17101  gccttactat tgattcagaa ataccaagtt aagaccttat tttтcaacac gctagctact
17161  gagtccagta tagagtcaga aatagtatca ggaacgacta ctcctaggat gcttctacct
17221  gttatgtcaa aattccataa tgaccaaatt gagattattc ttaacaattc ggcaagccaa
17281  ataacagaca taacaaatcc tacttggttc aaagaccaaa gagcaaggct acctaggcaa
17341  gtcgaggtta taaccatgga tgcagagacg acagaaaata taaacagatc gaaattgtac
17401  gaagctgtat ataaattgat cttacaccat attgatccca gcgtattgaa agcagtggtc
17461  cttaaagtct ttctaagtga tactgagggt atgttatggc taaatgataa tttagccccg
```

26

```
17521 tttttttgcca ctggttattt aattaagcca ataacgtcaa gtgctagatc tagtgagtgg
17581 tatctttgtc tgacgaactt cttatcaact acacgtaaga tgccacacca aaaccatctc
17641 agttgtaaac aggtaatact tacggcattg caactgcaaa ttcaacggag cccatactgg
17701 ctaagtcatt taactcagta tgctgactgc gatttacatt taagttatat ccgccttggt
17761 tttccatcat tagagaaagt actataccac aggtataacc tcgtcgattc aaaaagaggt
17821 ccactagtct ctatcactca gcacttggca catcttagag cagagattcg agaattgact
17881 aatgattata atcaacagcg acaaagtcgg actcaaacat atcactttat tcgtactgca
17941 aaaggacgaa tcacaaaact agtcaatgat tatttaaaat tctttcttat tgtgcaagca
18001 ttaaaacata atgggacatg gcaagctgag tttaagaaat taccagagtt gattagtgtg
18061 tgcaataggt tctatcatat tagagattgc aattgtgaag aacgtttctt agttcaaacc
18121 ttatatctac atagaatgca ggattctgaa gttaagctta tcgaaaggct gacagggctt
18181 ctgagtttat tcccggatgg tctctacagg tttgattgaa ttaccgtgca tagtatcctg
18241 atacttgtga aggttgatta tcaacgtaca gattataaaa aactcacaaa ttgctctcat
18301 acatcatatt gatcgaattt caataaataa ctatttaaat aacgaaagaa gtccttatat
18361 tatacactat atttagcctc tctccctgcg tgataatcaa aaaattcaca atgcagcatg
18421 tgtgacatat tacttccgcg atgaatctaa cgcaacataa taaactctgc actctttata
18481 attaagcttt aacaaaaggt ctgggctcat attgttattg atataataat gttgtatcaa
18541 tatcctgtca gatggaatag tgttttggtt gataacacga cttcttaaaa caaaattgat
18601 cttcaagatt aagttttttta taattatcat tactttaatt tgtcgattta aaaatggtga
18661 tagccttaat ctttgtgtaa aataagagat taggtgtaat aactttaaca ttttgtctag
18721 taagctacta tttcatacag aatgataaaa ttaaaagaaa aggcatgact gtaaaatcag
18781 aaataccttc tttacaatat agcagactag ataataatct tcgtgttaat gataattaag
18841 acattgacca cgctcatcag gaggctcgcc aggataaacg ttgcaaaaag gattcctgga
18901 aaaatggtcg cacacaaaaa tttaaaaata aatctatttc ttcttttttg tgtgtcca
```

The invention further provides polynucleotides having at least about 85, 90, 95, 96, 97, 98, 99, or 100% identity to this sequence. Other Ebola Zaire genomes are known in the art and described, for example, by Baize et al., N Engl J Med 2014;371:1418-25., which is incorporated herein by reference.

By "Ribonuclease P RNA component H1 (RPPH1) is meant the RNA component of the RNase P ribonucleoprotein, an endoribonuclease that cleaves tRNA precursor molecules to form the mature 5-prime termini of their tRNA sequences. An exemplary nucleic acid sequence is provided at NCBI Accession No. NR_002312 (SEQ ID NO: 27).

```
  1 atagggcgga gggaagctca tcagtggggc cacgagctga gtgcgtcctg tcactccact
 61 cccatgtccc ttgggaaggt ctgagactag ggccagaggc ggccctaaca gggctctccc
121 tgagcttcgg ggaggtgagt tcccagagaa cggggctccg cgcgaggtca gactgggcag
181 gagatgccgt ggacccgcc cttcggggag gggcccggcg gatgcctcct ttgccggagc
241 ttggaacaga ctcacggcca gcgaagtgag ttcaatggct gaggtgaggt accccgcagg
301 ggacctcata acccaattca gactactctc ctccgcccat t
```

By "amplicon" is meant a polynucleotide generated during the amplification of a polynucleotide of interest. In one example, an amplicon is generated during a polymerase chain reaction.

By "amplification rate modifiers" is meant an agent capable of affecting the rate of polymerase extension.

By "base substitution" is meant a substituent of a nucleobase polymer that does not cause significant disruption of the hybridization between complementary nucleotide strands.

In this disclosure, "comprises," "comprising," "containing" and "having" and the like can have the meaning ascribed to them in U.S. Patent law and can mean " includes," "including," and the like; "consisting essentially of" or "consists essentially" likewise has the meaning ascribed in U.S. Patent law and the term is open-ended, allowing for the presence of more than that which is recited so long as basic or novel characteristics of that which is recited is not changed by the presence of more than that which is recited, but excludes prior art embodiments.

By "complementary" or "complementarity" is meant that a nucleic acid can form hydrogen bond(s) with another nucleic acid sequence by either traditional Watson-Crick or Hoogsteen base pairing. Complementary base pairing includes not only G-C and A-T base pairing, but also includes base pairing involving universal bases, such as inosine. A percent complementarity indicates the percentage of contiguous residues in a nucleic acid molecule that can form hydrogen bonds (e.g., Watson-Crick base pairing) with a second nucleic acid sequence (e.g., 5, 6, 7, 8, 9, or 10 nucleotides out of a total of 10 nucleotides in the first oligonucleotide being based paired to a second nucleic acid sequence having 10 nucleotides represents 50%, 60%, 70%, 80%, 90%, and 100% complementary respectively). To determine that a percent complementarity is of at least a certain percentage, the percentage of contiguous residues in a nucleic acid molecule that can form hydrogen bonds (e.g., Watson-Crick base pairing) with a second nucleic acid sequence is calculated and rounded to the nearest whole number (e.g., 12, 13, 14, 15, 16, or 17 nucleotides out of a total of 23 nucleotides in the first oligonucleotide being based paired to a second nucleic acid sequence having 23 nucleotides represents 52%, 57%, 61%, 65%, 70%, and 74%, respectively; and has at least 50%, 50%, 60%, 60%, 70%, and 70% complementarity, respectively). As used herein, "substantially complementary" refers to complementarity between the strands such that they are capable of hybridizing under biological conditions. Substantially complementary sequences have 60%, 70%, 80%, 90%, 95%, or even 100% complementarity.

28

Additionally, techniques to determine if two strands are capable of hybridizing under biological conditions by examining their nucleotide sequences are well known in the art.

As used herein, "duplex" refers to a double helical structure formed by the interaction of two single stranded nucleic acids. A duplex is typically formed by the pairwise hydrogen bonding of bases, i.e., "base pairing", between two single stranded nucleic acids which are oriented antiparallel with respect to each other. Base pairing in duplexes generally occurs by Watson-Crick base pairing, e.g., guanine (G) forms a base pair with cytosine (C) in DNA and RNA, adenine (A) forms a base pair with thymine (T) in DNA, and adenine (A) forms a base pair with uracil (U) in RNA. Conditions under which base pairs can form include physiological or biologically relevant conditions (e.g., intracellular: pH 7.2, 140 mM potassium ion; extracellular pH 7.4, 145 mM sodium ion). Furthermore, duplexes are stabilized by stacking interactions between adjacent nucleotides. As used herein, a duplex may be established or maintained by base pairing or by stacking interactions. A duplex is formed by two complementary nucleic acid strands, which may be substantially complementary or fully complementary. Single-stranded nucleic acids that base pair over a number of bases are said to "hybridize."

"Detect" refers to identifying the presence, absence or amount of the analyte to be detected. In one embodiment, the analyte is an Ebola polynucleotide or other RNA viral polynucleotide.

By "detectable moiety" is meant a composition that when linked to a molecule of interest renders the latter detectable, via spectroscopic, photochemical, biochemical, immunochemical, or chemical means. For example, useful labels include radioactive isotopes, magnetic beads, metallic beads, colloidal particles, fluorescent dyes, electron-dense reagents, enzymes (for example, as commonly used in an ELISA), biotin, digoxigenin, or haptens.

By "fragment" is meant a portion of a nucleic acid molecule. This portion contains, preferably, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the entire length of the reference nucleic acid molecule or polypeptide. A fragment may contain 5, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, or 100 nucleotides. In one embodiment, the fragment comprises at least about 50, 75, 80, 85, 89, 90, or 100 nucleotides of an Ebola polynucleotide or other RNA viral polynucleotide.

By "free energy (ΔG)" is meant the net exchange of energy between the system and its environment at a constant temperature and pressure described by the formula: $\Delta G = \Delta H -$

29

TΔS. Free energy represents how thermodynamically stable a structure is, with formation of structures having a negative ΔG (e.g., expressed in kcal/mole) being thermodynamically stable (i.e., a structure having a lower ΔG is more stable than one having a higher ΔG). The thermodynamic potential is minimized when a system reaches equilibrium at constant pressure and temperature.

By "hybridize" is meant to form a double-stranded molecule between complementary polynucleotide sequences (e.g., a gene described herein), or portions thereof, under various conditions of stringency. (See, e.g., Wahl, G. M. and S. L. Berger (1987) Methods Enzymol. 152:399; Kimmel, A. R. (1987) Methods Enzymol. 152:507). Hybridization occurs by hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleobases. For example, adenine and thymine are complementary nucleobases that pair through the formation of hydrogen bonds.

By "isolated polynucleotide" is meant a nucleic acid (e.g., a DNA, RNA) that is free of the genes which, in the naturally-occurring genome of the organism from which the nucleic acid molecule of the invention is derived, flank the gene. The term therefore includes, for example, a recombinant DNA that is incorporated into a vector; into an autonomously replicating plasmid or virus; or into the genomic DNA of a prokaryote or eukaryote; or that exists as a separate molecule (for example, a cDNA or a genomic or cDNA fragment produced by PCR or restriction endonuclease digestion) independent of other sequences. In addition, the term includes an RNA molecule that is transcribed from a DNA molecule, as well as a recombinant DNA that is part of a hybrid gene encoding additional polypeptide sequence.

The terms "isolated," "purified," or "biologically pure" refer to material that is free to varying degrees from components which normally accompany it as found in its native state. "Isolate" denotes a degree of separation from original source or surroundings. "Purify" denotes a degree of separation that is higher than isolation. A "purified" or "biologically pure" protein is sufficiently free of other materials such that any impurities do not materially affect the biological properties of the protein or cause other adverse consequences. That is, a nucleic acid or peptide of this invention is purified if it is substantially free of cellular material, viral material, or culture medium when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized. Purity and homogeneity are typically determined using analytical chemistry techniques, for example, polyacrylamide gel electrophoresis or high performance liquid chromatography. The term

"purified" can denote that a nucleic acid or protein gives rise to essentially one band in an electrophoretic gel. For a protein that can be subjected to modifications, for example, phosphorylation or glycosylation, different modifications may give rise to different isolated proteins, which can be separately purified.

By "melting temperature (Tm)" is meant the temperature of a system in equilibrium where 50% of the molecular population is in one state and 50% of the population is in another state. With regard to the nucleic acids of the invention, Tm is the temperature at which 50% of the population is single-stranded and 50% is double-stranded (e.g., intramolecularly or intermolecularly).

By "monitoring a reaction" is meant detecting the progress of a reaction. In one embodiment, monitoring reaction progression involves detecting polymerase extension and/or detecting the completion of an amplification reaction.

As used herein, "obtaining" as in "obtaining an agent" includes synthesizing, purchasing, or otherwise acquiring the agent.

As used herein, the term "nucleic acid" refers to deoxyribonucleotides, ribonucleotides, or modified nucleotides, and polymers thereof in single- or double-stranded form. The term encompasses nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non-naturally occurring, which have similar binding properties as the reference nucleic acid, and which are metabolized in a manner similar to the reference nucleotides. Examples of such analogs include, without limitation, 2' modified nucleotides (e.g., 2'-O-methyl ribonucleotides, 2'-F nucleotides).

As used herein, "modified nucleotide" refers to a nucleotide that has one or more modifications to the nucleoside, the nucleobase, pentose ring, or phosphate group. For example, modified nucleotides exclude ribonucleotides containing adenosine monophosphate, guanosine monophosphate, uridine monophosphate, and cytidine monophosphate and deoxyribonucleotides containing deoxyadenosine monophosphate, deoxyguanosine monophosphate, deoxythymidine monophosphate, and deoxycytidine monophosphate. Modifications include those naturally occurring that result from modification by enzymes that modify nucleotides, such as methyltransferases. Modified nucleotides also include synthetic or non-naturally occurring nucleotides. Synthetic or non-naturally occurring modifications in nucleotides include those with 2' modifications, e.g., 2'-O-methyl, 2'-methoxyethoxy, 2'-fluoro, 2'-hydroxyl (RNA), 2'-allyl, 2'-O-[2-(methylamino)-

2-oxoethyl], 4'-thio, 4'-CH2-O-2'-bridge, 4'-(CH2) 2-O-2'-bridge, and 2'-O-(N-methylcarbamate) or those comprising base analogs.

By "nucleotide adduct" is meant a moiety that is bound covalently or otherwise fixed to a standard nucleotide base.

By "nicking agent" is meant a chemical entity capable of recognizing and binding to a specific structure in double stranded nucleic acid molecules and breaking a phosphodiester bond between adjoining nucleotides on a single strand upon binding to its recognized specific structure, thereby creating a free 3'-hydroxyl group on the terminal nucleotide preceding the nick site. In preferred embodiments, the 3' end can be extended by an exonuclease deficient polymerase. Exemplary nicking agents include nicking enzymes, RNAzymes, DNAzymes, and transition metal chelators.

By "palindromic" is meant nucleic acid sequences that are identical or substantially identical when read from 5' to 3' on one strand or 5' to 3' on the complementary strand. A perfect palindrome refers to a sequence having two adjacent subsequences, such that when one subsequence is read from the 5' to 3' direction, it is identical to the other subsequence read from the 3' to 5' direction.

By "polymerase-arresting molecule" is meant a moiety associated with a polynucleotide template/primer that prevents or significantly reduces the progression of a polymerase on the polynucleotide template. Preferably, the moiety is incorporated into the polynucleotide. In one preferred embodiment, the moiety prevents the polymerase from progressing on the template.

By "polymerase extension" is meant the forward progression of a polymerase that matches incoming monomers to their binding partners on a template polynucleotide.

As used herein, "primer-dimer" is meant a dimer of two monomer oligonucleotide primers. In the oligonucleotide primers of the invention, the 5' tail regions of monomer primers dimerize.

By "semi-quantitative" is meant providing an estimate of relative quantity based on an internal control.

By "specific product" is meant a polynucleotide product resulting from the hybridization of primer oligonucleotides to a complementary target sequence and subsequent polymerase mediated extension of the target sequence.

By "substantially isothermal condition" is meant at a single temperature or within a narrow range of temperatures that does not vary significantly. In one embodiment, a reaction

32

carried out under substantially isothermal conditions is carried out at a temperature that varies by only about 1-5°C (e.g., varying by 1, 2, 3, 4, or 5 degrees). In another embodiment, the reaction is carried out at a single temperature within the operating parameters of the instrument utilized.

5   By "quantity threshold method" is meant providing an estimate of quantity based on either exceeding or not exceeding in quantity a comparative standard.

By "reference" is meant a standard or control condition. As is apparent to one skilled in the art, an appropriate reference is where an element is changed in order to determine the effect of the element.

0   By "reverse transcriptase" is meant an enzyme that replicates a primed single-stranded RNA template strand into a complementary DNA strand in the presence of deoxyribonucleotides and permissive reaction medium comprising, but not limited to, a buffer (pH 7.0 – 9.0), sodium and/or potassium ions and magnesium ions. As is apparent to one skilled in the art, concentration and pH ranges of a permissive reaction media may vary

5   in regard to a particular reverse transcriptase enzyme. Examples of suitable "reverse transcriptases" well known in the art, but not limited to, are MmLV reverse transcriptase and its commercial derivatives "Superscript I, II and III" (Life Technologies), "MaxiScript" (Fermentas), RSV reverse transcriptase and its commercial derivative "OmniScript" (Qiagen), AMV reverse transcriptase and its commercial derivative "Thermoscript" (Sigma-

0   Aldrich).

By "subject" is meant a mammal, including, but not limited to, a human or non-human mammal, such as a bovine, equine, canine, ovine, or feline.

By "target nucleic acid molecule" is meant a polynucleotide to be analyzed. Such polynucleotide may be a sense or antisense strand of the target sequence. The term "target

25   nucleic acid molecule" also refers to amplicons of the original target sequence.

Ranges provided herein are understood to be shorthand for all of the values within the range. For example, a range of 1 to 50 is understood to include any number, combination of numbers, or sub-range from the group consisting 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40,

30   41, 42, 43, 44, 45, 46, 47, 48, 49, or 50.

Unless specifically stated or obvious from context, as used herein, the term "or" is understood to be inclusive. Unless specifically stated or obvious from context, as used herein, the terms "a", "an", and "the" are understood to be singular or plural.

Unless specifically stated or obvious from context, as used herein, the term "about" is understood as within a range of normal tolerance in the art, for example within 2 standard deviations of the mean. About can be understood as within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the stated value. Unless otherwise clear from context, all numerical values provided herein are modified by the term about.

The recitation of a listing of chemical groups in any definition of a variable herein includes definitions of that variable as any single group or combination of listed groups. The recitation of an embodiment for a variable or aspect herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof.

Any compositions or methods provided herein can be combined with one or more of any of the other compositions and methods provided herein.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic diagram illustrating the design of candidate assays for *Ebola* virus (EBOV). Assays 1 and 2 were tested for their ability to detect an EBOV polynucleotide (SEQ ID NO: 51).

Figure 2 shows the various probes and primers tested (SEQ ID NOs: 52-65, respectively, in order of appearance), as well as the Ebola gBlock sequence used in assay development (SEQ ID NO: 66). A gBlock is a synthetic, double-stranded fragment of DNA ranging in size from 100 bp to 1000 bp that is entirely assembled *in-vitro* from synthetic single-stranded oligonucleotides and which represents a sequence-verified synthetic block of genomic DNA. Unless specifically stated or obvious from context, as used herein, the "gBlock®" is used as a synthetic target nucleic acid whenever a native target sequence or target genome is not available and/or not useful. Sequence-verified blocks of genomic DNA for any target sequence can be procured as a custom-order service from IDT Technologies Inc. (1710 Commercial Park, Coralville, Iowa 52241, USA) and the term "gBlock®" is a registered trademark of that company.

Figures 3A-3X show amplification results obtained with Assay 1 and Assay 2.

Figure 4 shows detection of *Ebola* virus in a background of total human RNA in a one-step assay.

Figure 5 shows detection of synthetic *Ebola* virus RNA in a background of total human RNA in a one-step assay.

Figures 6A-6C provide flow charts illustrating sample processing for use in an amplification and detection instrument, including, for example, a hand-held device. Figure 6A indicates that a stabilization/lysis reagent (e.g., Guanidine isothiocyanate (GITC)) is lyophilized onto the inside of the capillary tube. Figure 6B illustrates use of a paper impregnated with lyophilized GITC and buffer (e.g., Whatman™ FTA™ Elute Cards). Figure 6C depicts a lyophilized assay procedure in multiplex (e.g., an 8-well strip) or single tube.

Figures 7A and 7B show sample preparation methods. Figure 7A depicts sample preparation from swab samples. Figure 7B depicts sample preparation from a blood sample.

Figure 8 is a graph showing results obtained in a one-step reaction process where the reverse transcriptase and polymerase are included in a single reaction.

Figure 9 is a graph showing results obtained in a two-step reaction process where the reverse transcriptase reaction is carried out at room temp or 56°C and the cDNA is transferred to a second tube where the amplification reaction is carried out at 56°C.

Figure 10 is a graph showing RT at 56°C, DNAble at 56°C on $1 \times 10e^4$ copies.

Figures 11A and 11B show the detection of a target RNA in a sample containing total cellular RNA. Figure 11A is a graph showing detection of RPPH1 (RNase P RNA Component) in a 2-step reaction. Figure 11B is a graph showing detection of RPPH1 in a 1-step reaction.

Figure 12 is a graph showing the detection of Zaire Ebola in a crude blood preparation in a 1-step reaction.

Figure 13 is a graph depicting that the Zaire Ebola assay specifically detects Zaire Ebola Mayinga but not Sudan Ebola Boniface.

Figure 14 are graphs depicting instrument comparison for the detection of various dilutions of Zaire Ebolavirus Mayinga.

Figures 15A-15D depict the limit of detection of the *Ebola* virus assay. Figure 15A is a graph depicting detection in samples containing 100 copies of *Ebola* virus target RNA. Figure 15B is a graph depicting detection in samples containing 50 copies of *Ebola* virus target RNA. Figure 15C is a graph depicting detection in samples containing 25 copies of *Ebola* virus target RNA. Figure 15D is a graph depicting detection in samples containing 12 copies of *Ebola* virus target RNA.

Figures 16A and 16B show detection of human immunodeficiency virus (HIV) in a one-step assay. Figure 16A is an amplicon map showing sequences used in the design of

35

assay primers and probes (SEQ ID NOs: 67-68, respectively, in order of appearance). Population sequence variations in forward and reverse primers are indicated (SEQ ID NOs: 6-9, 43 and 10, respectively, in order of appearance). External primer sequence is specific to HIV subtype C (for the purified RNA sample used). Figure 16B shows real-time target specific amplification of HIV in a one-step assay. Cp values are shown across 5 technical replicates for each copy number (10µL reactions). Copies of purified HIV RNA (subtype C) (SeraCare) are indicated, as quantified by COBAS TaqMan HIV-1 v2.0 test

Figures 17A and 17B show detection of dengue virus type 4 (DENV-4) in a one-step assay. Figure 17A is an amplicon map showing sequences used in the design of assay primers and probes (SEQ ID NOs: 69-70, respectively, in order of appearance). Population sequence variations in reverse primers are indicated (SEQ ID NOs: 11-13, 44 and 14, respectively, in order of appearance). Figure 17B shows real-time target specific amplification of DENV-4 in a one-step assay. Cp values are shown across 4 technical replicates (10uL reactions). Isolated total RNA (20pg) from cell culture included both viral and host cell RNA and total copy number of viral RNA was unknown.

Figures 18A and 18B show detection of influenza B in a one-step assay. Figure 18A is an amplicon map showing sequences used in the design of assay primers and probes (SEQ ID NOs: 71-73, respectively, in order of appearance). Population sequence variations in forward and reverse primers and external primers are indicated (SEQ ID NOs: 15-20, 45, 46 and 21, respectively, in order of appearance). Figure 18B shows real-time target specific amplification of influenza B in a one-step assay. Cp values are shown across 4 technical replicates (10uL reactions). Isolated total RNA (20pg) from cell culture included both viral and host cell RNA and total copy number of viral RNA was unknown. Samples 1 and 2 are different viral isolates.

Figures 19A and 19B show detection of Bovine Viral Diarrhea Virus Genotype 1 (BVDV1) in a one-step assay. Figure 19A is an amplicon map showing sequences used in the design of assay primers and probes (SEQ ID NOs: 74-75, respectively, in order of appearance). Population sequence variations in forward primers are indicated (SEQ ID NOs: 22-24, 47 and 25, respectively, in order of appearance). Figure 19B shows real-time target specific amplification of Bovine Viral Diarrhea Virus Genotype 1 (BVDV1) in a one-step assay. Technical replicates (10uL reactions) are shown. Isolated total RNA (20pg) from cell culture included both viral and host cell RNA and total copy number of viral RNA was unknown. Cell culture crude lysate was used undiluted and at 1:100 dilution.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides methods for rapidly identifying an RNA viral infection (e.g., *Ebola* virus) using an isothermal nucleic acid amplification reaction that can be carried out on extracted RNA in the context of a crude biological sample.

Ebola is clinically difficult to diagnose and to distinguish. A rapid and reliable laboratory diagnosis is required in suspected cases of Ebola. The present invention provides such an assay. The invention is based, at least in part, on the discovery that an Ebola viral polynucleotide (e.g., RNA) can be detected in a one-step or two-step real-time reverse transcription-isothermal amplification assay for an Ebola viral polynucleotide.

Ebola Virus

The Ebola viruses are filamentous viruses with a negative-sense RNA genome. Virions are cylindrical/tubular containing a viral envelope, matrix, and nucleocapsid components, approximately 80 nm in diameter and 800–1000 nm in length. Ebola is classified as a biosafety level 4 agent. The period of incubation for the Ebola virus hemorrhagic fever is usually 5–18 days, but may extend from 2–21 days depending on the viral strain contracted and the condition of the infected individual. The Ebola virus acts quickly. Initial symptoms of Ebola resemble symptoms of malaria, influenza, or various bacterial infections. Therefore, days or weeks may pass before Ebola is diagnosed. Secondary symptoms include diarrhea, red eyes, vomiting blood, bleeding from the nose, mouth or rectum, and even bleeding in the brain. About 50%–90% of those infected with the virus go on to systemic multi-organ failure and death.

Patient Diagnosis and Monitoring

The condition of a patient as having or not having Ebola can be diagnosed by detecting an Ebola viral polynucleotide in a biological sample and correlating this detection with the existence of an Ebola infection. In one embodiment, a disease state of a patient having *Ebola* virus can be detected using the methods and compositions of the invention to detect *Ebola* virus in a biological sample of the patient. Exemplary biological samples include body fluids (e.g. saliva, sweat, tears, fluids accumulating in a bodily cavity, urine, ejaculate, vaginal secretion, cerebrospinal fluid, lymph, feces, sputum, decomposition fluid, vomit, sweat, breast milk, blood, serum, and plasma), tissue extracts, culture media (e.g., a

37

liquid in which a cell, such as a pathogen cell, has been grown), or environmental samples obtained, for example, from a material that may be contaminated with a biological fluid of a subject.

In one embodiment, the invention provides a method of amplifying a target polynucleotide in a reverse transcriptase and nicking amplification reaction involving:

(a) contacting a target RNA molecule (e.g., *Ebola* virus genome) with a reverse transcriptase (RT) primer in the presence of a reverse transcriptase and dNTPs under conditions permissive for cDNA synthesis, thereby generating a cDNA; and

(b) contacting the cDNA with forward and reverse primers carrying at least one nicking enzyme recognition sequence within their respective 5'-terminal regions which specifically bind the cDNA with their respective 3'-terminal regions in the presence of a nicking enzyme, dNTPs, and a strand-displacement polymerase under conditions permissive for the isothermal amplification of the cDNA, thereby generating amplicons.

In one particular embodiment, the invention provides a method of detecting an Ebola virus in a biological sample involving:

(a) contacting a sample with an agent capable of extracting an Ebola RNA present in the sample (e.g., SDS, sodium lauryl sulfate, guanidium isothio-cyanate, guanidium hydrochloride) and an agent capable of stabilizing Ebola RNA against degradation (e.g., SDS, RNAase inhibitors, antibodies against RNAse, competitive RNAse inhibitor, or an agent capable of reversibly chemically modifying RNA in situ (e.g., acetic anhydride);

(b) contacting the Ebola RNA with a RT primer in the presence of a reverse transcriptase and dNTPs under conditions permissive for cDNA synthesis, thereby generating a cDNA copy of the Ebola RNA;

(c) contacting the Ebola cDNA with forward and reverse primers carrying at least one nicking enzyme recognition sequence within their respective 5'-terminal regions which specifically binds the Ebola cDNA with their respective 3'-terminal regions in the presence of a nicking enzyme, dNTPs, and a strand-displacement polymerase under conditions permissive for the isothermal amplification of the cDNA, thereby generating amplicons; and

(d) detecting the amplicons, wherein the presence of an *Ebola* virus amplicon detects an *Ebola* virus infection in the sample and failure to detect the amplicon indicates the absence of an *Ebola* virus infection.

In one embodiment, the methods of the invention described herein provide results in no longer than 5, 7, 10, 15, 20, 25 or 30 minutes. Advantageously, the methods of the

invention can be applied to RNAs extracted—but not purified or isolated from—a crude biological sample (e.g., saliva, sweat, tears, fluids accumulating in a bodily cavity, urine, ejaculate, vaginal secretion, cerebrospinal fluid, lymph, feces, sputum, decomposition fluid, vomit, sweat, breast milk, blood, serum, and plasma). Because the test is carried out on-site (e.g., in a hospital, clinic, physician's office, urgent care center, home, community center, airport, ship (e.g., cruise ship or other vessel used for transporting humans or animals), train or train station, or point of entry into a nation (e.g., border crossing). Advantageously, in one embodiment, the testing is carried out in a portable battery powered device (e.g., Amplifire).

In one embodiment, the RNA is extracted from the biological sample using a chaotropic salt (e.g., GITC, GHCL) or a detergent (e.g., SDS, Tween and triton). If desired, an RNAse inhibitor is added before, during, or after the extraction step.

In another embodiment, the reverse transcriptase enzyme and the strand-displacement DNA polymerase are one and the same.

In another embodiment, no separate primer is required or the RT primer same as forward and/or reverse primers.

In another embodiment, the invention provides for detection of an EBOV or other viral amplicon using a Dual FRET molecular beacon for mRNA detection (e.g., as described by Santagelo, Nucleic Acids Res. 2004; 32(6): e57), turbidity release of pyrophosphate from DNTPs and precipitation with magnesium or calcium.

In another embodiment, the invention provides for detection of an Ebola viral amplicon using a lateral flow device where the Ebola virus amplicon comprises one member of a pair of binding partners (e.g., biotin and streptavidin) and the lateral flow device comprises the other member of the pair, and provides a means of detection (e.g., colorimetric) for the amplicon.

Reverse transcriptases used in the methods of the invention include, but are not limited to, a Maloney murine leukemia virus reverse transcriptase enzyme (MMLV RT) and derivatives or variants thereof comprising a mutation relative to wild-type MMLV RT; avian myeloblastosis virus (AMV RT) and derivatives or variants thereof comprising a mutation relative to that render them thermostable, Rous sarcoma virus (RSV) RT (e.g., Omniscript, Qiagen) and derivatives or variants thereof, and a pyroreverse transcriptase (e.g., Pyroscript luceigen) and derivatives or variants thereof, an RT described in US Patent No. 7,094,539, which is incorporated herein by reference in its entirety, or a commercially available High-

fidelity Thermostable Reverse Transcriptase for RT PCR and Transcriptome analysis (e.g., Lucigen).

In one embodiment, at 56 degrees the primer and RNA or amplicon forms a stable complex. In one embodiment, more than 50% of primer sequence must be complementary to the target nucleic acid molecule. In one embodiment, the rT primer is about 18 bases in length. In one embodiment, the reverse transcriptase (RT) primer is a random primer (e.g., in each sequence position any one of four bases is possible, any of these primers hybridize with the target). In one embodiment, the rT primer is a hexamer, heptamer, octamer, or nonamer.

In one embodiment, the RT is derived from Geobacillus stearothermophilus, is M-MLV RT (i.e. Superscript/LifeTech, Maxima/Thermo-Fisher) and/or mutants/derivatives thereof, AMV RT (i.e. Thermoscript/LifeTech) and/or mutants/ derivatives thereof, RSV RT (i.e. OmniScript/Qiagen) and/or mutants/ derivatives thereof.

Methods of the invention provide a high degree of sensitivity. In one embodiment, EBOV is detected at $1 \times 10^{3,}$ 1×10^4, 1×10^5, 1×10^6, 1×10^7, or 1×10^9 copies of EBOV RNA per ml in blood. In another embodiment, the invention provides for the detection of between about 1-10 (e.g, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10) copies of RNA per reaction.

EBOV (or other virus) is detected by obtaining a sample (e.g., biological sample) from a subject having or suspected of having an EBOV infection or by obtaining an environmental sample from a home, hospital room, means of transportation that is or is suspected of being contaminated with an Ebola virus or EBOV-containing biological fluid. In one embodiment, a biological sample is obtained by obtaining a blood sample, mucous sample, feces, or by swabbing an affected tissue. Swabs can be taken from the nose, throat, eyes, or other mucosal membrane. At necropsy, samples can be collected from blood or tissues of the deceased.

Advantageously, the diagnostic methods of the invention are suitable for use in virtually any setting. EBOV is endemic in much of west Africa including Liberia, Nigeria, Guinea, and Sierra Leone. Many areas within west Africa lack access to basic medical facilities and diagnostic laboratories. The present invention can be used in a battery powered hand held device that is well-suited to testing of biological samples in areas where access to electricity is non-existent. Moreover, the present methods are simple enough that they can easily be carried out by health workers who have limited training in the use of diagnostic technologies.

40

The present invention provides methods for rapidly identifying an EBOV or other viral infection using an isothermal nucleic acid amplification reaction that can be carried out on extracted RNA in the context of a crude biological sample.

Early in the disease process, only low levels of virus are present in a biological sample of the subject, such as a blood sample. If desired, the virions present in the sample are enriched using methods known in the art, for example, by precipitating the virions from the sample by adding PEG and NaCl then filtering virions out of the sample using a nanopore filter, thereby providing for early detection of a viral polynucleotide.

The disease state or treatment of a subject that may have been exposed to *Ebola* virus (or other virus) can be monitored using the methods and compositions of the invention. In one embodiment, the detection of an *Ebola* virus polynucleotide (or other virus polynucleotide) is present in a bodily fluid, such as saliva, sweat, tears, fluids accumulating in a bodily cavity, urine, ejaculate, vaginal secretion, cerebrospinal fluid, lymph, feces, sputum, decomposition fluid, vomit, sweat, breast milk, blood, serum, and plasma, is monitored. Such monitoring may be useful, for example, in diagnosing the subject as having Ebola (or other virus), or determining the efficacy of a particular drug in a subject or in assessing disease progression.

Nucleic Acid Amplification Methods

Nucleic acid amplification technologies have provided a means of understanding complex biological processes, detection, identification, and quantification of pathogenic organisms, such as EBOV or other RNA viruses. The present invention provides for the detection of an EBOV negative-sense RNA genome in a biological sample by using reverse transcriptase to synthesize an EBOV DNA molecule from the RNA genome and then amplifying the DNA in an isothermal nicking amplification reaction.

The polymerase chain reaction (PCR) is a common thermal cycling dependent nucleic acid amplification technology used to amplify DNA consisting of cycles of repeated heating and cooling of the reaction for DNA melting and enzymatic replication of the DNA using a DNA polymerase. Real-Time quantitative PCR (qPCR) is a technique used to quantify the number of copies of a given nucleic acid sequence in a biological sample. Currently, qPCR utilizes the detection of reaction products in real-time throughout the reaction and compares the amplification profile to the amplification of controls which contain a known quantity of nucleic acids at the beginning of each reaction (or a known relative ratio of nucleic acids to

41

the unknown tested nucleic acid). The results of the controls are used to construct standard curves, typically based on the logarithmic portion of the standard reaction amplification curves. These values are used to interpolate the quantity of the unknowns based on where their amplification curves compared to the standard control quantities.

5   In addition to PCR, non-thermal cycling dependent amplification systems or isothermal nucleic acid amplification technologies exist including, without limitation: Nicking Amplification Reaction, Rolling Circle Amplification (RCA), Helicase-Dependent Amplification (HDA), Loop-Mediated Amplification (LAMP), Strand Displacement Amplification (SDA), Transcription-Mediated Amplification (TMA), Self-Sustained Sequence Replication (3SR), Nucleic Acid Sequence Based Amplification (NASBA), Single Primer Isothermal Amplification (SPIA), Q-β Replicase System, and Recombinase Polymerase Amplification (RPA).

        Isothermal nicking amplification reactions have similarities to PCR thermocycling. Like PCR, nicking amplification reactions employ oligonucleotide sequences which are complementary to a target sequences referred to as primers. In addition, nicking amplification reactions of target sequences results in a logarithmic increase in the target sequence, just as it does in standard PCR. Unlike standard PCR, the nicking amplification reactions progress isothermally. In standard PCR, the temperature is increased to allow the two strands of DNA to separate. In nicking amplification reactions, the target nucleic acid sequence is nicked at specific nicking sites present in a test sample. The polymerase infiltrates the nick site and begins complementary strand synthesis of the nicked target nucleotide sequence (the added exogenous DNA) along with displacement of the existing complimentary DNA strand. The strand displacement replication process obviates the need for increased temperature. At this point, primer molecules anneal to the displaced complementary sequence from the added exogenous DNA. The polymerase now extends from the 3' end of the template, creating a complementary strand to the previously displaced strand. The second oligonucleotide primer then anneals to the newly synthesized complementary strand and extends making a duplex of DNA which includes the nicking enzyme recognition sequence. This strand is then liable to be nicked with subsequent strand displacement extension by the polymerase, which leads to the production of a duplex of DNA which has nick sites on either side of the original target DNA. Once this is synthesized, the molecule continues to be amplified exponentially through replication of the displaced strands with new template molecules. In addition, amplification also proceeds linearly from each

42

product molecule through the repeated action of the nick translation synthesis at the template introduced nick sites. The result is a very rapid increase in target signal amplification; much more rapid than PCR thermocycling, with amplification results in less than ten minutes.

Nicking Amplification Assays

The invention provides for the detection of EBOV target nucleic acid molecules amplified in an isothermal nicking amplification assay.

Polymerases useful in the methods described herein are capable of catalyzing the incorporation of nucleotides to extend a 3' hydroxyl terminus of an oligonucleotide (e.g., a primer) bound to a target nucleic acid molecule and/or a 3' hydroxyl terminus at a nick site in a double-stranded DNA molecule in conjunction with strand displacement activity. Such polymerases also lack or have substantially reduced 5'-3' exonuclease activity and may include those that are thermophilic. DNA polymerases useful in methods involving primers having 2'-modified nucleotides in the primer region comprising the six 3'-terminal nucleotides include derivatives and variants of the DNA polymerase I isolated from *Bacillus stearothermophilus*, also classified as *Geobacillus stearothermophilus*, and from closely related bacterial strains, isolates and species comprising the genus *Geobacillus*, which lack or have substantially reduced 5'-3' exonuclease activity and have strand-displacement activity. Exemplary polymerases include, but are not limited to, the large fragments of Bst DNA polymerase I, Gst DNA polymerase I, and Gka DNA polymerase I.

A nicking agent useful in methods described herein is a chemical entity capable of recognizing and binding to a specific structure in double stranded nucleic acid molecules and breaking a phosphodiester bond between adjoining nucleotides on the top strand with a substantially higher rate than breaking the phosphodiester bond between adjoining nucleotides on the bottom strand upon binding to its recognized specific structure, thereby creating a free 3'-hydroxyl group on the terminal nucleotide preceding the nick site that can be extended by a 5'-3'-exonuclease deficient strand displacement polymerase. In a preferred embodiment of the methods disclosed herein, the top strand phosphodiester bond cleavage rate of the "nicking agent" approaches 100%, while the cleavage rate of the bottom strand phosphodiester bond approaches 0%. Nicking agents useful in methods described herein, can either be enzymes, i.e. self-regenerating catalysts turning over multiple substrate molecules, or non-regenerating catalysts turning over just a single substrate molecule at an equimolar ratio fashion.

43

A nicking enzyme binds double-stranded DNA and cleaves one strand of a double-stranded duplex. In the methods of the invention, the nicking enzyme cleaves the top stand (the strand comprising the 5'-3' sequence of the nicking agent recognition site). In a particular embodiment of the invention disclosed herein, the nicking enzyme cleaves the top strand only and 3' downstream of the recognition site. In exemplary embodiments, the reaction comprises the use of a nicking enzyme that cleaves or nicks downstream of the binding site such that the product sequence does not contain the nicking site. Using an enzyme that cleaves downstream of the binding site allows the polymerase to more easily extend without having to displace the nicking enzyme. Ideally, the nicking enzyme is functional under the same reaction conditions as the polymerase. Exemplary nicking enzymes include, but are not limited to, N.Bst9I, N.BstSEI, Nb.BbvCI(NEB), Nb.Bpu10I(Fermantas), Nb.BsmI(NEB), Nb.BsrDI(NEB), Nb.BtsI(NEB), Nt.AlwI(NEB), Nt.BbvCI(NEB), Nt.Bpu10I(Fermentas), Nt.BsmAI, Nt.BspD6I, Nt.BspQI(NEB), Nt.BstNBI(NEB), and Nt.CviPII(NEB). Sequences of nicking enzyme recognition sites are provided at Table 1.

Table 1. Nicking enzyme recognition sequences

N.Bst9I	5'-GAGTCNNNNN↓NN-3' (Seq ID No: 28) |||||||||| || 3'-CTCAGNNNNN•NN-5'
N.BstSEI	5'-GAGTCNNNNN↓NN-3' (Seq ID No: 28) |||||||||| || 3'-CTCAGNNNNN•NN-5'
Nb.BbvCI(NEB)	5'-CCTCA•GC-3' ||||| || 3'-GGAGT↑CG-5'
Nb.Bpu10I(Fermantas)	5'-CCTNA•GC-3' ||||| || 3'-GGANT↑CG-5'
Nb.BsmI(NEB)	5'-GAATG•CN-3' ||||| || 3'-CTTAC↑GN-5'
Nb.BsrDI(NEB)	5'-GCAATG•NN-3' |||||| || 3'-CGTTAC↑NN-5'
Nb.BtsI(NEB)	5'-GCAGTG•NN-3' |||||| || 3'-CGTCAC↑NN-5'
Nt.AlwI(NEB)	5'-GGATCNNNN↓N-3' (Seq ID No: 29) ||||||||| | 3'-CCTAGNNNN•N-5'

44

16745492_1 (GHMatters) P105727.AU

Nt.BbvCI(NEB)	5'-CC↓TCAGC-3' || ||||| 3'-GG•AGTCG-5'
Nt.Bpu10I(Fermentas)	5'-CC↓TNAGC-3' || ||||| 3'-GG•ANTCG-5'
Nt.BsmAI	5'-GTCTCN↓N-3' |||||| | 3'-CAGAGN•N-5'
Nt.BspD6I	5'-GAGTCNNNN↓N-3' (Seq ID No: 30) ||||||||| | 3'-CTCAGNNNN•N-5'
Nt.BspQI(NEB)	5'-GCTCTTCN↓-3' |||||||| 3'-CGAGAAGN -5'
Nt.BstNBI(NEB)	5'-GAGTCNNNN↓N-3' (Seq ID No: 30) ||||||||| | 3'-CTCAGNNNN•N-5'
Nt.CviPII(NEB)	5'-↓CCD-3' ||| 3'- GGH-5'

Nicking enzymes also include engineered nicking enzymes created by modifying the cleavage activity of restriction endonucleases (NEB expressions July 2006, vol 1.2). when restriction endonucleases bind to their recognition sequences in DNA, two catalytic sites

5   within each enzyme for hydrolyzing each strand drive two independent hydrolytic reactions which proceed in parallel. Altered restriction enzymes can be engineered that hydrolyze only one strand of the duplex, to produce DNA molecules that are "nicked" (3′-hydroxyl, 5′-phosphate), rather than cleaved. Nicking enzymes may also include modified CRISPR/Cas proteins, Transcription activator-like effector nucleases (TALENs), and Zinc-finger nucleases

10   having nickase activity.

A nicking amplification reaction typically comprises nucleotides, such as, for example, dideoxyribonucleoside triphosphates (dNTPs). The reaction may also be carried out in the presence of dNTPs that comprise a detectable moiety including but not limited to a radiolabel (e.g., ^{32}P, ^{33}P, ^{125}I, ^{35}S) an enzyme (e.g., alkaline phosphatase), a fluorescent label

15   (e.g., fluorescein isothiocyanate (FITC)), biotin, avidin, digoxigenin, antigens, haptens, or fluorochromes. The reaction further comprises certain salts and buffers that provide for the activity of the nicking enzyme and polymerase.

Advantageously, the nicking amplification reaction is carried out under substantially isothermal conditions where the temperature of the reaction is more or less constant during

45

the course of the amplification reaction. Because the temperature does not need to be cycled between an upper temperature and a lower temperature, the nicking amplification reaction can be carried out under conditions where it would be difficult to carry out conventional PCR. Typically, the reaction is carried out at about between 35 C and 90 C (e.g., about 35, 37, 42, 55, 60, 65, 70, 75, 80, or 85 °C). Advantageously, it is not essential that the temperature be maintained with a great degree of precision. Some variability in temperature is acceptable.

Sets of primers for amplification reactions are selected as having $\Delta\Delta G$'s $\leq$ -15, -16, 17, -18, -19, -20, -25, -30 kcal/mole or more. The performance characteristics of amplification reactions may be altered by increasing the concentration of one or more oligonucleotides (e.g., one or more primers and/or probes) and/or their ratios. High concentrations of primers also favor primer-dimer formation. In various embodiments, concentration of a primers is 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 nM or more. Melt temperature (Tm) and reaction rate modifiers may also be used to lower the melting temperature of the oligonucleotides, such as (but not limited to) ethylene glycol and glycerol. In addition, DNA polymerase reaction rate modifiers (such as dNTP and magnesium concentration) may be used to alter the reaction rate to lead to a greater quantification precision. In particular embodiments, the 5' tail sequences of the forward and reverse primers have the same nucleic acid sequence.

This invention provides methods of monitoring a nicking amplification reaction in real time, including for example utilizing the amplification strategy as described herein. In one embodiment, quantitative nucleic acid amplification utilizes target nucleic acids amplification alongside a control amplification of known quantity. The amount of target nucleic acid can be calculated as an absolute quantification or a relative quantification (semi-quantitative) based on the source of the control (exogenous or endogenous control).

Quantification of the unknown nucleotide sequence can be achieved either through comparison of logarithmic threshold amplification of the unknown to a series of known target sequences in either a separate set of reactions or in the same reaction; or as an internal endogenous or exogenous co-amplification product, which produces a threshold value, indicative of either a positive result (if the unknown exceeds the threshold) or negative result (if the unknown does not exceed the threshold).

The invention also provides a method of designing a nicking agent-dependent isothermal strand-displacement amplification assay without experimental screening of a

multitude of combinations of candidate forward primers and/or candidate reverse primers. A 35 to 70 bp long region within the target sequence is identified having a 12 to 20 bp sequence in the central portion with a Tm ≥ the assay temperature (e.g., ~55° C). Adjacent sequences 12 bp to 20 bp long immediately downstream and upstream of the 15 to 20 bp long central region are identified, according to the above criteria. The Tm of the chosen double stranded downstream and upstream adjacent sequences deviate from each other by less than ± 3°C. A target-specific pair of forward and reverse primers are created by attaching a 5'-tail region for a stable dimer-forming primer to the 5'-terminus of the 12-20 base upstream adjacent sequence and to the 5'-terminus of the complementary strand of the 12-20 base downstream adjacent sequence. When combining the forward primer, reverse primer, and a probe, the primer driving the synthesis of the strand complementary to the probe is in excess over the other primer at a molar ratio of about 1.1:1 to 10:1. The combined concentration of a primer in the assay is no higher than 1000 nM. The assay design method can also be used to convert a pre-validated PCR assay for an amplicon ≤ 70 bp to a nicking agent-dependent isothermal strand-displacement amplification assay.

Primer Design

Conventional methods for primer design have focused on primer melting temperature, primer annealing temperature, GC (guaninine and cytosine) content, primer length, and minimizing interactions of the primer with all but the target nucleic acid (see e.g., www.premierbiosoft.com/tech_notes/PCR_Primer_Design.html). Contrary to these methods, it has been found that primers that form stable primer/dimers, expressed in terms of free energy of formation (ΔG), function predictably in nucleic acid amplification reactions. While Free Energy (ΔG) and Melting Temperature (Tm) share primary components Enthalpy (ΔH) and Entropy (ΔS), ΔG and Tm values are derived differently and have no correlative relationship, and the only way to relate a given ΔG with a given Tm value is to explicitly know the value of ΔH and ΔS from which they are derived (Manthey, "mFold, Delta G, and Melting Temperature" ©2005 and 2011 Integrated DNA Technologies). Figures 1-11 relate to the design of optimal primers.

The free energy of formation (ΔG) for intermolecular primer structures may be calculated using formulas known in the art. A number of programs are available for determining the formation of various intramolecular and intermolecular primer structures and calculating their ΔG's, including for example mfold and UNAfold prediction algorithms (see

47

e.g., Markham and Zuker. UNAFold: Software for Nucleic Acid Folding and Hybridization. Bioinformatics: Volume 2, Chapter 1, pp 3-31, Humana Press Inc., 2008; Zuker et al. Algorithms and Thermodynamics for RNA Secondary Structure Prediction: A Practical Guide In RNA Biochemistry and Biotechnology, 11-43, NATO ASI Series, Kluwer Academic Publishers, 1999; M. Zuker. Prediction of RNA Secondary Structure by Energy Minimization. Methods in Molecular Biology, 267-294, 1994; Jaeger et al. Predicting Optimal and Suboptimal Secondary Structure for RNA. In Molecular Evolution: Computer Analysis of Protein and Nucleic Acid Sequences, Methods in Enzymology 183, 281-306, 1990; Zuker. On Finding All Suboptimal Foldings of an RNA Molecule. Science 244, 48-52, 1989). OligoAnalyzer 3.1 is one such implementation of mfold for primer design (www.idtdna.com/analyzer/Applications/OligoAnalyzer/). For example, with reference to OligoAnalyzer 3.1, ΔG calculations may be performed using the following parameters: Target Type: DNA; Oligo Concentration 0.25 μM; Na^+ Concentration: 60mM; Mg^{++} Concentration: 15mM; and dNTPs Concentration: 0.3 mM.

3' Recognition region

The invention provides a primer having a 3' recognition sequence whose primer-target formation is stable ($\Delta G \leq$ about -20 kcal/mol or more) and has the potential to enhance nucleic acid amplification reaction performance. The 3' recognition region specifically binds to the nucleic acid molecule, for example a complementary sequence of the nucleic acid molecule. In certain embodiments, the 3' recognition region has a sequence that is complementary to 12, 13, 14, 15, 16, 17, 18, 19, or 20 bases or more of a nucleic acid sequence. In particular embodiments, the 3' recognition region comprises one or more inosine bases. In specific embodiments, the 3' recognition region comprises no more than 2/12 inosines. In various embodiments, the primer-target melting temperature is equal to or greater than 8° or 6 °C below the reaction or extension temperature of the assay (Tm $\geq$ assay temperature - 8°). In particular embodiments, the 3' recognition sequence comprises 12-20, 12-17, or 12-14 bases. In particular embodiments, the primer-target formation is more stable than self dimer formation (e.g., $\Delta\Delta G \leq$ about -15, -16, -17, -18, -19, -20 kcal/mol or more). Preferably, the 3' recognition sequence does not contain self-complementary sequences, short inverted repeats (e.g., >4 bases/repeat), or sequences that otherwise promote intramolecular interactions, which have the potential to interfere with primer-target annealing.

In one embodiment, a primer is designed having a Tm of 56°C with 4 sequence specific bases at the end of the primer that may not contribute to annealing. In one embodiment, the primer is a 16, 17, 18, 19, 20 or 21-mer.

In particular, a primer of the invention having a 3' recognition sequence is useful in nicking amplification assays. Additionally, the EBOV or other viral target specific 3' recognition region comprises one or more 2' modified nucleotides (e.g., 2'-O-methyl, 2'-methoxyethoxy, 2'-fluoro, 2'-alkyl, 2'-allyl, 2'-O-[2-(methylamino)-2-oxoethyl], 2'-hydroxyl (RNA), 4'-thio, 4'-CH$_2$-O-2'-bridge, 4'-(CH$_2$)$_2$-O-2'-bridge, and 2'-O-(N-methylcarbamate)). Without being bound to theory, it is hypothesized that incorporating one or more 2' modified nucleotides in the recognition regions reduces or eliminates intermolecular and/or intramolecular interactions of primers/templates (e.g., primer-dimer formation), and, thereby, reduces or eliminates the background signal in isothermal amplification. The 2' modified nucleotide preferably has a base that base pairs with the target sequence. In particular embodiments, two or more 2' modified nucleotides (e.g., 2, 3, 4, 5 or more 2' modified nucleotides) in the EBOV or other viral target specific recognition region are contiguous (e.g., a block of modified nucleotides). In some embodiments, the block of 2' modified nucleotides is positioned at the 3' end of the target specific recognition region. In other embodiments, the block of 2' modified nucleotides is positioned at the 5' end of the EBOV or other viral target specific recognition region. When the block of 2' modified nucleotides is positioned at the 5' end of the target specific recognition region, the 2' modified nucleotides may be separated from the nick site by one or more non-modified nucleotides (e.g., 2, 3, 4, 5 or more 2' unmodified nucleotides). Applicants have found that positioning of one or more 2' modified nucleotides or of a block of 2' modified nucleotides alters the kinetics of amplification. When the one or more 2' modified nucleotides or block of 2' modified nucleotides are positioned at or near the 5' end of the recognition region or proximal to the nick site, real-time amplification reactions showed decreased time to detection. Additionally, the signal curve is contracted and the slope of the curve shifted.

In a related embodiment, ratios of a primer having one or more 2' modified nucleotides can be used to alter the time-to-detection and/or the efficiency of the reaction for the 'tuning' of reactions, resulting in a predictable control over reaction kinetics. Increasing the ratio of primer having one or more 2' modified nucleotides at the 3' end of the recognition sequence to primer having one or more 2' modified nucleotides at the 5' end of the recognition sequence contracted the signal curve and shifted the slope of the curve. It is

49

advantageous to be able to "tune" a reaction providing a means to manipulate both the time-to-detection as well as the efficiency of the reaction. Relative quantification using an internal control requires that two important conditions be met. First, it is beneficial to be able to modify a reaction's time-to-detection creating a non-competitive reaction condition. Thus,

5   by affecting the control reaction to be detectable at a later time-point (relative to the target of interest) the control reaction does not out-compete the specific target of interest even when the target of interest is in low initial abundance. Second, to ensure a true relative abundance calculation, it is required that the control and specific target reactions have matched efficiencies. By controlling the efficiency of each reaction using a "tuning" condition enables

0   reactions to be matched allowing for satisfactory relative quantification calculations. Tuning the reactions can be used to match efficiencies of target nucleic acid amplification and reference nucleic amplification (e.g., internal standard) in quantitative PCR (qPCR). Additionally, amplification curves of the target nucleic acid and the internal standard may be altered so time of detection of their amplification products are separated, while providing the

5   same efficiency for target nucleic acid amplification and internal standard amplification. Through the use of specific combinations and ratios of oligonucleotide structures within a reaction it is possible to create conditions which enable tuned reaction performance.

5' Tail Dimerization Region

:0   The invention provides a primer having a 5' tail region capable of self-dimerization that enhances EBOV or other viral nucleic acid amplification reaction performance. Without being bound to theory, in a nucleic acid amplification reaction the primer anneals to the target nucleic acid as a primer-dimer. For example, nicking amplification primers have a nicking agent recognition site present at the 5' end that is unrelated to the binding specificity of the

25   primer for the target recognition sequence. Non-specific background products from non-specific primer interactions have the potential to sequester reaction components that would otherwise have been utilized for the amplification of the specific product. In various embodiments, homodimer formation is stable (e.g., $\Delta G \leq$ about -30, -35, -40, -45, -50, -55, -60 kcal/mol or more). In various embodiments, the homodimer has a melting temperature

30   higher than the extension reaction temperature. In particular embodiments, the 5' tail region has a sequence that is a palindrome. In further embodiments, the 5' tail region is at least 12 bases (e.g., 12, 13, 14,15, 16, 17, 18, 19, 20, 21, 22, 23, 24 bases) in length. In additional embodiments, the 5' tail region has a GC content of 80-90%. In certain embodiments,

50

homodimer formation is more stable than formation of other less stable primer dimer conformations formation (e.g., $\Delta\Delta G \leq$ about -12, -13, -14, -15, -16, -17, -18, -19, -20, -25, -30, -35, -40 kcal/mol or more).

In particular, a primer of the invention having a 5' tail sequence is useful in nicking amplification reactions. For use in nicking amplification reactions, the 5' tail region comprises one or more nicking agent recognition sites and the 5' tail region has a symmetrically inverted sequence. In particular embodiments, the 5' tail region contains an even number of nucleotides (e.g., 22, 24 nucleotides). The nick site is designed to be positioned between the nucleotide at the 3' end of the 5' tail region and the nucleotide at the 5' end of the 3' recognition region. Without being bound to theory, the nicking enzyme does not cleave at the nick site when the 3' recognition is single-stranded. However, cleavage at the nick site occurs when the 3' recognition region is double stranded (e.g., when the primer is incorporated into a double-stranded target nucleic acid molecule during the course of the nucleic acid amplification reaction).

In various embodiments, the 5' tail sequence comprises from 5' to 3' an inverted nicking enzyme recognition sequence that is operatively linked to a palindromic sequence (or self-complementary sequence) that is operatively linked to a nicking enzyme recognition sequence. In certain embodiments, the spacer region is an even number of nucleotides (e.g., 2, 4, 6, etc.). Exemplary 5' tails based on the Nt.BstNBI nicking enzyme recognition sequence (5'-GAGTC-3') having a 2, 4, and 6 nucleotide spacers comprise a nucleic acid sequences according to the formula below:

5'- **GACTC**$N_1 N_{1'}$**GAGTC** -3' (SEQ ID NO: 31)

5'- **GACTC**$N_2 N_1 N_{1'} N_{2'}$**GAGTC** -3' (SEQ ID NO: 32)

5'- **GACTC**$N_3 N_2 N_1 N_{1'} N_{2'} N_{3'}$**GAGTC** -3' (SEQ ID NO: 33)

where "N" is any nucleotide (e.g., having an adenine (A), thymine (T), cytosine (C), or guanine (G) nucleobase), and N_1 is complementary to $N_{1'}$, N_2 is complementary to $N_{2'}$, and N_3 is complementary to $N_{3'}$, etc.

Exemplary 5' tail region sequences 24 nucleotides in length having a Nt.BstNBI recognition sequence can be generated based on the following template 5'-NNNNGACTCNNNNNNGAGTCNNNN-3' (SEQ ID NO: 34). Based on this template, there are 537,824 5' tail sequences having the following properties: ΔG = -48 Kcal/mole to -62 kcal/mole; $\Delta\Delta G < $ -40 kcal/mole; and GC content 68% to 84%. Of these, 1050

51

selected sequences are provided, representing 0.2% of the entire sequence space (248,832). Exemplary 5' tail region sequences 22 nucleotides in length having a Nt.BstNBI recognition sequence and based on the following template 5'- NNNNGACTCNNNNGAGTCNNNN -3' (SEQ ID NO: 35). Based on this template, there are 248,832 5' tail sequences having the following properties: ΔG = -47 Kcal/mole to -55 kcal/mole; $\Delta\Delta G$ < -40 kcal/mole; and GC content 72% to 82%. Of these, 200 selected sequences are provided, representing 0.08% of the entire sequence space (248,832).

Target Nucleic Acid Molecules

Methods and compositions of the invention are useful for the amplification and/or identification of an EBOV or other viral nucleic acid molecule in a test sample. The target sequences are amplified from virtually any samples that comprises a viral nucleic acid molecule, including a EBOV nucleic acid molecule. In particular, the methods and compositions of the invention are useful for the amplification and/or identification of RNA viruses. In addition to EBOV, exemplary RNA viruses that can be detected using the methods and compositions of the invention include, without limitation, Human Immunodeficiency Virus (HIV), Dengue virus, influenza virus (e.g., influenza B), Bovine Viral Diarrhea virus (e.g., BVDV Genotype 1), Yellow Fever virus, West Nile Virus, Hepatitis C, Lassa virus, Flaviviridae, Arenaviridae, and single-stranded RNA viruses.

Exemplary test samples include body fluids (e.g. bsaliva, sweat, tears, fluids accumulating in a bodily cavity, urine, ejaculate, vaginal secretion, cerebrospinal fluid, lymph, feces, sputum, decomposition fluid, vomit, sweat, breast milk, blood, serum, and plasma), tissue extracts, culture media (e.g., a liquid in which a cell, such as a pathogen cell, has been grown), environmental samples, agricultural products or other foodstuffs, and their extracts, and DNA identification tags. If desired, the sample is purified prior to inclusion in a nicking amplification reaction using any standard method typically used for isolating a nucleic acid molecule from a biological sample.

In one embodiment, primers amplify a target nucleic acid of a pathogen to detect the presence of EBOV or other virus in a sample. For environmental applications, test samples may include water, liquid extracts of building materials (e.g., drywall, ceiling tiles, wall board, fabrics, wall paper, and floor coverings) that may have been exposed to a subject infected with EBOV, environmental swabs, or any other sample.

52

Methods of the invention provide for the detection of 1 x 10^3, 1 x 10^4, 1 x 10^5, 1 x 10^6, 1 x 10^7, or 1 x 10^9 copies of EBOV RNA per ml in blood.

Applications

Target nucleic acid amplification using primers of the invention have characteristics useful for rapid detection of viral (e.g., EBOV) nucleic acid molecules. Compositions and methods of the invention are useful in human diagnostics, where a rapid diagnostic answer is desired (e.g., detectable amplification in under 20, 15, 10, 9, 8, 7, 6, 5 minutes or less). In particular embodiments, the invention provides for the use of an EBOV nicking amplification reaction assay in human or veterinary diagnostics in clinical settings or in the field. In other embodiments, the invention provides for the use of nicking amplification reaction assays in diagnostic field work, where access to thermocycling equipment is unavailable or would be prohibitively expensive. In still other embodiments, the invention provides for the use of nicking amplification reaction assays in a clinical setting where rapid quantitative answers are desired.

Detectable Oligonucleotide Probes

The present invention provides for the detection of target nucleic acid molecules or amplicons thereof in a nicking amplification reaction using non-amplifiable detectable polynucleotide probes comprising at least one polymerase-arresting molecule (e.g., nucleotide modification or other moiety that renders the oligonucleotide capable of binding a target nucleic acid molecule, but incapable of supporting polymerase extension utilizing the detectable oligonucleotide probe as a target). Without wishing to be bound by theory, the presence of one or more moieties which does not allow polymerase progression likely causes polymerase arrest in non-nucleic acid backbone additions to the oligonucleotide or through stalling of a replicative polymerase (i.e. C3-spacer, damaged DNA bases, other spacer moiety, O-2-Me bases). These constructs thus prevent or reduce illegitimate amplification of the probe during the course of a nicking amplification reaction. This distinguishes them from conventional detection probes, which must be added at the end of the nicking amplification reaction to prevent their amplification.

Conventional detection probes have proven impractical for detecting a nicking amplification reaction in real time. If conventional detection probes are incorporated into the nicking amplification reaction, these conventional detection probes are amplified

concurrently with the target. The amplification of these detection molecules masks the detection of legitimate target amplicons due to the number of starting molecules of the detection probe at the start of the reaction.

The invention provides non-amplifiable detectable polynucleotide probe that comprise least one polymerase-arresting molecule. A polymerase-arresting molecule of the invention includes, but is not limited to, a nucleotide modification or other moiety that blocks extension by replicative DNA polymerases, thereby preventing the amplification of detection molecules; but can allow proper hybridization or nucleotide spacing to the target molecule or amplified copies of the target molecule. In one embodiment, a detectable oligonucleotide probe of the invention comprises a 3 carbon spacer (C3-spacer) that prevents or reduces the illegitimate amplification of a detection molecule.

In one embodiment, a detectable oligonucleotide probe comprises one or more modified nucleotide bases having enhanced binding affinity to a complementary nucleotide. Examples of modified bases include, but are not limited to 2' Fluoro amidites, and 2'OMe RNA amidites (also functioning as a polymerase arresting molecule). Detectable oligonucleotide probes of the invention can be synthesized with different colored fluorophores and may be designed to hybridize with virtually any target sequence. In view of their remarkable specificity, a non-amplifiable detectable polynucleotide probe of the invention is used to detect a single target nucleic acid molecule in a sample, or is used in combination with detectable oligonucleotide probes each of which binds a different target nucleic acid molecule. Accordingly, the non-amplifiable detectable polynucleotide probes of the invention may be used to detect one or more target nucleic acid molecules in the same reaction, allowing these targets to be detected simultaneously. The present invention encompasses the use of such fluorophores in conjunction with the detectable oligonucleotide probes described herein.

Implementation in Hardware and/or Software

The methods described herein can be implemented on general-purpose or specially programmed hardware or software. For example, the methods can be implemented by a computer readable medium. Accordingly, the present invention also provides a software and/or a computer program product configured to perform the algorithms and/or methods according to any embodiment of the present invention. It is well-known to a skilled person in the art how to configure software which can perform the algorithms and/or methods provided

54

in the present invention. The computer-readable medium can be non-transitory and/or tangible. For example, the computer readable medium can be volatile memory *(e.g.,* random access memory and the like) or non-volatile memory *(e.g.,* read-only memory, hard disks, floppy discs, magnetic tape, optical discs, paper table, punch cards, and the like). The computer executable instructions may be written in a suitable computer language or combination of several languages. Basic computational biology methods are described in, for example Setubal and Meidanis et al., Introduction to Computational Biology Methods (PWS Publishing Company, Boston, 1997); Salzberg, Searles, Kasif, (Ed.), Computational Methods in Molecular Biology, (Elsevier, Amsterdam, 1998); Rashidi and Buehler, Bioinformatics Basics: Application in Biological Science and Medicine (CRC Press, London, 2000) and Ouelette and Bzevanis Bioinformatics: A Practical Guide for Analysis of Gene and Proteins (Wiley & Sons, Inc., 2nd ed., 2001).

The present invention may also make use of various computer program products and software for a variety of purposes, such as probe design, management of data, analysis, and instrument operation. (See, US Patent Nos 5,593,839, 5,795,716, 5,733,729, 5,974,164, 6,066,454, 6,090,555, 6,185,561, 6,188,783, 6,223,127, 6,229,911 and 6,308,170.) Additionally, the present invention may have preferred embodiments that include methods for providing genetic information over networks such as the Internet as shown in US Ser Nos 10/197,621, 10/063,559 (US Pub No 20020183936), 10/065,856, 10/065,868, 10/328,818, 10/328,872, 10/423,403, and 60/482,389.

Kits

The invention also provides kits for the amplification of an EBOV or other RNA virus nucleic acid molecule. Such kits are useful for the detection or quantitation of an EBOV or other RNA nucleic acid in a biological sample obtained from a subject. Kits of the present invention may comprise, for example, one or more of reverse transcriptase, DNA polymerases, forward and reverse primers, and one or more nicking enzymes, as described herein, and a detectable probe. Where EBOV or other RNA is to be amplified, one or two nicking enzymes may be included in the kit. Where multiple pathogen sequences are to be amplified, and the templates designed for those target sequences comprise the nicking enzyme sites for the same nicking enzyme, then one or two nicking enzymes may be included. Where the templates are recognized by different nicking enzymes, more nicking enzymes may be included in the kit, such as, for example, 3 or more.

55

In one aspect, the invention provides a kit for nucleic acid amplification comprising a reverse transcriptase, DNA polymerase; a primary primer, a secondary primer, a nicking enzyme with specificity to a nicking enzyme binding site within the primers, and deoxynucleotide triphosphates (dNTP's) (e.g., in a buffered solution containing components sufficient for amplification. In various embodiments, the primary primer and secondary primer, each have a 3'-end specific recognition region sequence complementary or substantially complementary to the target sequence, where the end specific recognition region comprises one or more 2' modified nucleotides; a 5'-end tail region containing a nicking enzyme binding site upstream of the 3'-end specific recognition region sequences that is able to dimerize with itself (e.g., self-complementary). In particular embodiments, one or more primers are in a primer-dimer configuration (e.g., produced by heating about Tm and slow cooling).

The kits of the present invention may also comprise one or more of the components in any number of separate containers, packets, tubes (e.g., <0.2 ml, 0.2 ml, 0.6 ml, 1.5 ml, 5.0 ml, >5.0 ml), vials, microtiter plates (e.g., <96-well, 96-well, 384-well, 1536-well, >1536-well), ArrayTape, and the like, or the components may be combined in various combinations in such containers. In various embodiments, the kit further comprises a pair of primers capable of binding to and amplifying a reference sequence. In particular embodiments, the kit comprises one or more primers in a primer-dimer configuration (e.g., produced by heating about Tm and slow cooling). In yet other embodiments, the kit comprises a sterile container which contains the primers; such containers can be boxes, ampules, bottles, vials, tubes, bags, pouches, blister-packs, or other suitable container form known in the art. Such containers can be made of plastic, glass, laminated paper, metal foil, or other materials suitable for holding nucleic acids.

The components of the kit may, for example, be present in one or more containers, for example, all of the components may be in one container, or, for example, the enzymes may be in a separate container from the primers. The components may, for example, be dried (e.g., powder) or in a stable buffer (e.g., chemically stabilized, thermally stabilized). Dry components may, for example, be prepared by lyophilization, vacuum and centrifugal assisted drying and/or ambient drying. In various embodiments, the polymerase and nicking enzymes are in lyophilized form in a single container, and the primers are either lyophilized, freeze dried, or in buffer, in a different container. In some embodiments, the polymerase, nicking enzymes, and the primers are, in lyophilized form, in a single container. In other

56

embodiments, the polymerase and the nicking enzyme may be separated into different containers.

Kits may further comprise, for example, dNTPs used in the reaction, or modified nucleotides, cuvettes or other containers used for the reaction, or a vial of water or buffer for re-hydrating lyophilized components. The buffer used may, for example, be appropriate for both polymerase and nicking enzyme activity.

The kits of the present invention may also comprise instructions for performing one or more methods described herein and/or a description of one or more compositions or reagents described herein. Instructions and/or descriptions may be in printed form and may be included in a kit insert. A kit also may include a written description of an Internet location that provides such instructions or descriptions.

The practice of the present invention employs, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry and immunology, which are well within the purview of the skilled artisan. Such techniques are explained fully in the literature, such as, "Molecular Cloning: A Laboratory Manual", second edition (Sambrook, 1989); "Oligonucleotide Synthesis" (Gait, 1984); "Animal Cell Culture" (Freshney, 1987); "Methods in Enzymology" "Handbook of Experimental Immunology" (Weir, 1996); "Gene Transfer Vectors for Mammalian Cells" (Miller and Calos, 1987); "Current Protocols in Molecular Biology" (Ausubel, 1987); "PCR: The Polymerase Chain Reaction", (Mullis, 1994); "Current Protocols in Immunology" (Coligan, 1991). These techniques are applicable to the production of the polynucleotides and polypeptides of the invention, and, as such, may be considered in making and practicing the invention. Particularly useful techniques for particular embodiments will be discussed in the sections that follow.

The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the assay, screening, and therapeutic methods of the invention, and are not intended to limit the scope of what the inventors regard as their invention.

EXAMPLES

Example 1. One-step and Two-step Real-time Reverse Transcription-Isothermal Amplification Assays for EBOV

A one-step reaction refers to a reverse transcriptase (RT) reaction in which reverse transcription and amplification occur in a single reaction protocol. A two-step reaction refers to a reverse transcriptase reaction in which the reverse transcription is carried out first; followed by a transfer to a second amplification reaction.

Assays 1 and 2 were tested for their ability to detect an EBOV polynucleotide EBOV (Figure 1). Primers for these assays are shown at Figure 2.

Figures 3A-3X show amplification results obtained with Assay 1 and Assay 2. The assays were used to detect copies of EBOV gBlock in a background of human cDNA. Reaction conditions are specified.

Figure 4 shows detection of EBOV in a background of total human RNA in a one-step assay.

Figure 5 shows detection of synthetic EBOV RNA in a background of total human RNA in a one-step assay.

Figures 6A-6C provide flow charts illustrating sample processing for use in an amplification and detection instrument.

Figures 7A and 7B show sample preparation methods from swabs and blood, respectively.

In one working example, *Ebola* virus was detected using the following primers and probe sequences:

Forward Primer	GACTCGATATCGAGTCGCTTCCA[MeOC]AGTTATC[MeOU][MeOA][MeOC][MeOC][MeOG]	SEQ ID NO: 1
Reverse Primer	GACTCGATATCGAGTCGAAATGC[MeOA]ACGA[MeOC][MeOA][MeOC][MeOC][MeOU]	SEQ ID NO: 2
Probe	gctacACGACTTTYGCTGAAGgtagc	SEQ ID NO: 3
External Primer	CTTCTTAGCTTGGGGCAGTATCA	SEQ ID NO: 36

Primers: [MeON] indicates methoxy base
Probe sequence: lowercase = stems, uppercase = recognition
1:5 1000nM 0.3U/μl nicking enzyme

In the sequences above, GAGTC is the nicking enzyme recognition site. Pyrimidine provides for degeneracy detection of Ebola strains including Zaire.

Synthetic DNA target (SEQ ID NO: 37):

58

AAGATGACTGCAGGAGTCAATGCGCAGTTGGTCCCGGCAGACCAGGCGAACATTACCGAATT

TTACAACAAGTCCCTTTCATCCTACAAGGAGAATGAGGAGAACATCCAGTGTGGGGAGAACT

TCATGGACATGGAGTGCTTCATGATTCTGAACCCCAGTCAGCAGCTGGCAATTGCCGTCTTG

TCTCTCACACTGGGCACCTTCACAGTTCTGGAGAACTTGCTGGTGCTGTGTGTCACCACAGT

TATCTACCGAGGAACGACTTTCGCTGAAGGTGTCGTTGCATTTCTGATTCCTTCACTCCCGC

AGCCTCCGCTGCCGGCCCTCTTACCACTTCATCATTAGCCTGGCCGTGGCCGACCTTCTGGG

GAGTGTCATTTTTGTCTACAGCTTTGTTGACTTTCATGTGTTCCACCGCAAGGACAGCCCCA

ACGTCTTTCTCTTCAAATTGGGTGGGGTCACCGCCTCCTTCACGGCCTCTGTAGGCAGCCTC

TTCC

Synthetic RNA target (SEQ ID NO: 38):

rGrArCrUrGrCrArGrGrArGrUrCrUrGrCrUrGrCrUrUrCrCrArCrArGrUrUrArU

rCrUrArCrCrGrArGrGrArArCrGrArCrUrUrUrCrGrCrUrGrArArGrGrUrGrUrC

rGrUrUrGrCrArUrUrUrCrUrGrArUrUrCrCrUrUrCrArCrUrCrCrG

Both 1-step and 2-step reactions contained a final concentration of 166.7nM forward primer and a final concentration of 833.3nM reverse primer with 200nM concentration of Probe and 0.1X SYBR green (final concentration). In addition both 1 and 2 step reactions contained a final concentration of 1x Extract Buffer 2, comprising Tris pH 8.0, NH_4^+, Na^+, and Mg^{2+}; dNTPs; 0.4 U/µl BST polymerase; and 0.3 U/ µl Nt.BSTnbi nicking enzyme. In addition to these components; the 1 step reactions contained 10U/ul of Maxima Reverse Transcriptase enzyme; 1.0 U/ µl of an RNAse inhibitor (SUBERase IN by life technologies). Synthetic RNA had 1.0U/ µl of RNAse inhibitor added as well to prevent degradation. All water used was purchased nuclease free.

Reactions were mixed on ice and kept cold until run on the Roche LC480. The Roche LC480 was run under a two color detection to detect the calfluor red 610 beacon signal (Abs 590nm/ Em 610nm) and the SYBR green signal (Abs 495nm/ Em 520nm).

1-Step reactions were carried out at 56°C for 20 minutes. Results are shown at Figure 8.

2-step reactions were carried out with the reverse transcriptase step at 56°C for 5 minutes (in a heat block) or at room temperature for 5 minutes following the setup condition outlined by New England Biolabs (www.neb.com/protocols/2012/10/03/first-strand-cdna-synthesis-kit-using-protoscript-ii-reverse-transcriptase-m0368) (Figure 9). Both these RT temperatures produced signal for $1x10^5$ copies of target per reaction. The reverse transcriptase step was followed by an amplification step at 56°C for 15 minutes on the

59

LC480. Results of this assay are shown at Figure 10. The copy number indicated per reaction was determined using the suppliers' calculations.

Example 2. Detection of a target RNA in a complex RNA mixture

To determine whether the 1-step and 2-step reactions could detect a target RNA in complex mixtures of RNA molecules, assays were designed for the detection of RPPH1 (RNase P RNA Component) in total human RNA. In one working example, RPPH1 was detected using the following primers and probe sequences:

Forward Primer	RPPH1.Fc	GACTCGATATCGAGTCCACGAGCmUGAGTGCmGmUmCmCmUmG	SEQ ID NO: 39
Reverse Primer	RPPH1.Rc	GACTCGATATCGAGTCAGACCTTmCCCAAGGmGmAmCmAmU	SEQ ID NO: 40
Probe	RPPH1.Probe.T	CCACGCCTGTCACTCCACTCCGCGTGG	SEQ ID NO: 41
External Primer	rpph1extprimR	CCTCTGGCCCTAGTCTCAG	SEQ ID NO: 42

Primers: **mN** indicates methoxy base

In a 2-step reaction, human RNA (10 ng) was converted to cDNA with random hexamer primer and RPPH1 was detected by amplification of a target specific sequence (Figure 11A). In a 1-step reaction, human RNA (20 ng) was detected by amplification of a target specific sequence using specific reverse transcription primers (Figure 11B).

Example 3: Detection of *Ebola* virus in a biological sample

In another working example, a synthetic *Ebola* virus RNA target was detected when mixed with a crude blood preparation using the 1-step assay. The crude blood preparation was prepared by mixing whole blood (20 μl) and sodium dodecyl sulfate (0.5% SDS; 20 μl) and incubating the mixture at room temperature (3 min.). After incubation, bovine serum albumin was added (2% BSA; 20 μl) and the resulting mixture was incubated at room temperature (1 min.). The crude blood preparation (1 μl) was spiked with a synthetic *Ebola* virus RNA target (1000 copies). Reactions were run in triplicate at 56°C on a Roche LC480. Results are shown at Figure 12.

60

In an additional experiment, the 1-step assay was able to distinguish between Zaire Ebolavirus Mayinga and Sudan Ebolavirus Boniface RNA molecules. Vero E6 cells were infected with Zaire Ebolavirus Mayinga or Sudan Ebolavirus Boniface virus and viral RNAs were purified. Sets of reactions were run using purified RNA Zaire Ebolavirus Mayinga (683 copies) or Sudan Ebolavirus Boniface virus (650 copies). For each set, quadruplicate reactions (10 μl) were run on a Roche LC480. The assay detected Zaire Ebolavirus Mayinga RNA (Figure 13; set of curves denoted A) and did not detect Sudan Ebolavirus Boniface RNA (Figure 13; set of curves denoted B). Thus, the Zaire Ebola assay was specific for the detection of Zaire Ebola Mayinga.

An instrument comparison was run using various dilutions of Zaire Ebolavirus Mayinga RNA from about 10^1-10^7 copies of target RNA, including a no target control (NTC) sample. Instruments tested included the Roche Lightcycler 480 II, Axxin Detector, and Douglas Scientific Amplifire amplification and detection instruments. While some instrument variability was observed, all instruments could detect copies of EBOV RNA over a wide range (Figure 14).

To determine a lower limit of detection for the 1-step EBOV assay, serially diluted samples containing 100, 50, 25, and 12 copies of Zaire Ebolavirus Mayinga RNA were tested. The 1-step reactions (10 μl) were run on the Roche LightCycler 480 using at least 10 technical replicates for each dilution. Twenty (20) technical replicates were run for the 100 and 50 copy reactions. Forty (40) technical replicates were run for the 25 copy reactions. A 100% (20/20) detection rate was observed for the detection of 100 and 50 copies per reaction (Figures 15A and 15B). A 95% (38/40) detection rate was observed for the detection of 25 copies per reaction (Figure 15C). Thus, these results show the sensitivity and specificity of the EBOV assay, even when performed as a 1-step assay.

Example 4: Detection of human immunodeficiency virus (HIV) in a biological sample

In one working example, human immunodeficiency virus (HIV) was detected in a 1-step RNAble® assay targeting a gag protein sequence. Purified HIV RNA (subtype C) was obtained (SeraCare), and known quantities of the HIV RNA, as quantified by COBAS TaqMan HIV-1 v2.0 test, were tested in the 1-step HIV RNAble® assay. The following primers and probe sequences were used:

61

Hgag (HIV gag target)

Primer	Sequence	SEQ ID NO
Hgag.F2a	GACTCGATATCGAGTCTGACTAGmCGGAGGmCmT mAmGmAmAmG	SEQ ID NO: 6
Hgag.F2b	GACTCGATATCGAGTCTGACTAGmCAGAGGmCmT mAmGmAmAmG	SEQ ID NO: 7
Hgag.R1a	GACTCGATATCGAGTCTATTGACmGCTCmTmCmG mCmAmC	SEQ ID NO: 8
Hgag.R1b	GACTCGATATCGAGTCTACTGACmGCTCmTmCmG mCmAmC	SEQ ID NO: 9
Hgag.rt3.subC*	GCATCTAATTTTTCGCC (external primer)	SEQ ID NO: 43
Hgag.probe.T	cgcaagGGAGAGAGATGGGTGcttgcg	SEQ ID NO: 10

Primers: **mN** indicates methoxy base

Probe sequence: lowercase = stems, uppercase = recognition

*External primer sequence is specific to HIV subtype C (for the purified RNA sample used)

Figure 16A is a map of the amplicon showing the locations of the sequences used. The sequence of the external primer was specific to HIV subtype C (for the purified RNA sample used). The 1-step HIV RNAble® assay was designed with two sets of forward and reverse primers to account for sequence variations in the population. In the sequences above, GAGTC is the nicking enzyme recognition site.

The 1-step reactions contained a final concentration of 9 nM forward primer (1:1 mix of Hgag.F2a+Hgag.F2b) and a final concentration of 91 nM reverse primer (1:1 mix of Hgag.R1a+Hgag.R1b) in a primer ratio of about 1:10 forward to reverse primers. Final concentrations of 200nM probe and 100nM external primer were used. In addition, the 1 step reactions contained a final concentration of 1x Run Buffer, comprising Tris, K^+, and Mg^{2+}; Guanidinium thiocyanate (GITC); dNTPs; 0.4 U/ µl BST polymerase; and 0.3 U/ µl Nt.BSTnbi nicking enzyme. In addition to these components; the 1 step reactions contained 0.2U/ µl of AMV Reverse Transcriptase High Spec Activity XL (Life Sciences Advanced Technologies) and 0.5 U/ µl of an RNAse inhibitor (Superasin; Thermo Fisher). All water used was nuclease free.

Reactions were run using real-time detection of calfluor red 610 beacon signal (Abs 590nm/ Em 610nm). 1-Step reactions were carried out at 56°C for 20 minutes using 125, 250, 500, and 1000 copies of HIV RNA. Specific detection of HIV RNA at all copy numbers was demonstrated in the 1-step HIV RNAble® assay (Figure 16B).

Example 5: Detection of Dengue Virus type 4 (DENV-4) in a biological sample

In one working example, dengue virus type 4 (DENV-4) was detected in a 1-step RNAble® assay targeting a 3' UTR sequence. Total RNA was isolated from cell culture, which included both viral and host cell RNA, and used in the 1-step DENV-4 RNAble® assay. Thus, total copy number was unknown. The following primers and probe sequences were used:

Den4 (Dengue type 4)

Primer	Sequence	SEQ ID NO
Den4.F2	GACTCGATATCGAGTCCAAAAACmAGCATATTmGmAmCmGmC	SEQ ID NO: 11
Den4.R1a	GACTCGATATCGAGTCAGACAGCmAGGATCmTmCmTmGmG	SEQ ID NO: 12
Den4.R1b	GACTCGATATCGAGTCAGACAGCmAGGATCmTmGmTmGmG	SEQ ID NO: 13
Den4.extRT1	TCTGTGCCTGGATTGAT (external primer)	SEQ ID NO: 44
Den4.probe.B	cgcatcTGGTCTTTCCCAGCgatgcg	SEQ ID NO: 14

Primers: **mN** indicates methoxy base

Probe sequence: lowercase = stems, uppercase = recognition

Figure 17A is a map of the amplicon showing the locations of the sequences used. The 1-step DENV-4 RNAble® assay was designed with two sets of reverse primers to account for sequence variations in the population. In the sequences above, GAGTC is the nicking enzyme recognition site.

The 1-step reactions contained a final concentration of 83 nM forward primer and a final concentration of 17 nM reverse primer (1:1 mix of Den4.R1a+Den4.R1b) in a primer ratio of about 5:1 forward to reverse primers. Final concentrations of 200nM probe and 100nM external primer were used. In addition, the 1 step reactions contained a final concentration of 1x Run Buffer, comprising Tris, K^+, and Mg^{2+}; dNTPs; 0.4 U/ μl BST polymerase; and 0.3 U/ μl Nt.BSTnbi nicking enzyme. In addition to these components; the 1 step reactions contained 0.2U/ μl of AMV Reverse Transcriptase High Spec Activity XL (Life Sciences Advanced Technologies) and 0.5 U/ μl of an RNAse inhibitor (Superasin; Thermo Fisher). All water used was nuclease free.

Reactions were run using real-time detection of calfluor red 610 beacon signal (Abs 590nm/ Em 610nm). 1-Step reactions were carried out at 56°C for 20 minutes using 20pg

total RNA. Specific detection of Dengue 4 RNA was demonstrated in the 1-step DENV-4 RNAble® assay (Figure 17B).

Example 6: Detection of Influenza B in a biological sample

In one working example, influenza B was detected in a 1-step RNAble® assay targeting an influenza Segment 7 sequence. Total RNA was isolated from cell culture, which included both viral and host cell RNA, and used in the 1-step influenza B RNAble® assay. Thus, total copy number was unknown. The following primers and probe sequences were used:

FluB (influenza B)

Primer	Sequence	SEQ ID NO
FluB.F2a	GACTCGATATCGAGTCAAATGCAmGATGGTCTCmAmGmCmTmA	SEQ ID NO: 15
FluB.F2b	GACTCGATATCGAGTCAAATGCAmAATGGTCTCmAmGmCmTmA	SEQ ID NO: 16
FluB.F2c	GACTCGATATCGAGTCAAATGCAmGATGGTTTCmAmGmCmTmA	SEQ ID NO: 17
FluB.R3a	GACTCGATATCGAGTCCTCCTTTmTCCCATTCCATmTmCmAmTmT	SEQ ID NO: 18
FluB.R3b	GACTCGATATCGAGTCCTCCCTTmTCCCATTCCATmTmCmAmTmT	SEQ ID NO: 19
FluB.R3c	GACTCGATATCGAGTCCTCCTTTmCCCCATTCCATmTmCmAmTmT	SEQ ID NO: 20
FluB.extRT1a	TTTTGGACGTCTTCTCC (external primer)	SEQ ID NO: 45
FluB.extRT1b	TTTTGAACGTCTTCTCC (external primer)	SEQ ID NO: 46
FluB.probe.T	gccaaGCTATGAACACAGCAAActtggc	SEQ ID NO: 21

Primers: **mN** indicates methoxy base

Probe sequence: lowercase = stems, uppercase = recognition

Figure 18A is a map of the amplicon showing the locations of the sequences used. The 1-step Influenza B RNAble® assay was designed with three sets of forward and reverse primers and two external primers to account for sequence variations in the population. In the sequences above, GAGTC is the nicking enzyme recognition site.

The 1-step reactions contained a final concentration of 9 nM forward primer (1:1:1 mix of FluB.F2a+FluB.F2b+FluB.F2c) and a final concentration of 91 nM reverse primer (1:1:1 mix of FluB.R3a+FluB.R3b+FluB.R3c) in a primer ratio of about 1:10 forward to reverse primers. Final concentrations of 200nM probe and 100nM external primer were used. In addition, the 1 step reactions contained a final concentration of 1x Run Buffer, comprising Tris, K⁺, and Mg²⁺; dNTPs; 0.4 U/ μl BST polymerase; and 0.3 U/ μl Nt.BSTnbi nicking enzyme. In addition to these components; the 1 step reactions contained 0.2U/ μl of AMV

64

Reverse Transcriptase High Spec Activity XL (Life Sciences Advanced Technologies) and 0.5 U/ μl of an RNAse inhibitor (Superasin; Thermo Fisher). All water used was nuclease free.

Reactions were run using real-time detection of calfluor red 610 beacon signal (Abs 590nm/ Em 610nm). 1-Step reactions were carried out at 56°C for 20 minutes using total RNA from different isolates. Specific detection of influenza B in all isolates was demonstrated in the 1-step influenza B RNAble® assay (Figure 18B).

Example 7: Detection of Bovine Viral Diarrhea Virus Genotype 1 (BVDV1) in a biological sample

In one working example, Bovine Viral Diarrhea Virus Genotype 1 (BVDV1) was detected in a 1-step RNAble® assay targeting an influenza Segment 7 sequence. Total RNA was isolated from cell culture, which included both viral and host cell RNA, and used in the 1-step BVDV1 RNAble® assay. Thus, total copy number was unknown. The following primers and probe sequences were used:

Bovine Viral Diarrhea Virus Type 1 (BVDV1)

Primer	Sequence	SEQ ID NO
BVDV1.F1a	GACTCGATATCGAGTCGGCCCACmTGTATTGCTmAmCmTmGmAmAmA	SEQ ID NO: 22
BVDV1.F1b	GACTCGATATCGAGTCGGCCCACmTGCACTGCTmAmCmTmAmAmAmA	SEQ ID NO: 23
BVDV1.R1	GACTCGATATCGAGTCTGTGATCmAACTCCmAmTmGmTmGmCmC	SEQ ID NO: 24
BVDV1.RT1v	TATGTTTTGTATAAAAGTTCATTTG (external primer)	SEQ ID NO: 47
BVDV1.ProbeT	**cgctacATCTCTGCTGTACATGgtagcg**	SEQ ID NO: 25

Primers: **mN** indicates methoxy base

Probe sequence: lowercase = stems, uppercase = recognition

Figure 19A is a map of the amplicon showing the locations of the sequences used. The 1-step BVDV1 RNAble® assay was designed with two sets of forward primers to account for sequence variations in the population. In the sequences above, GAGTC is the nicking enzyme recognition site.

The 1-step reactions contained a final concentration of 9 nM forward primer (1:1 mix of BVDV1.F1a+BVDV1.F1b) and a final concentration of 91 nM reverse primer in a primer ratio of about 1:10 forward to reverse primers. Final concentrations of 200nM probe and

65

100nM external primer were used. In addition, the 1 step reactions contained a final concentration of 1x Run Buffer, comprising Tris, K$^+$, and Mg^{2+}; dNTPs; 0.4 U/ µl BST polymerase; and 0.3 U/ µl Nt.BSTnbi nicking enzyme. In addition to these components; the 1 step reactions contained 0.2U/ µl of AMV Reverse Transcriptase High Spec Activity XL (Life Sciences Advanced Technologies) and 0.5 U/ µl of an RNAse inhibitor (Superasin; Thermo Fisher). All water used was nuclease free.

Reactions were run using real-time detection of calfluor red 610 beacon signal (Abs 590nm/ Em 610nm). 1-Step reactions were carried out at 56°C for 20 minutes using purified RNA (20pg/technical replicate) from BVDV1 virus culture (mixed bovine host cell RNA and virus) and cell culture crude lysate (undiluted and 1:100 dilution). Specific detection of BVDV1 virus in all samples was demonstrated in the 1-step BVDV1 RNAble® assay (Figure 19B).

Example 8: Molecular beacon recognition of Ebola Strains

Exemplary Beacon BLAST Alignment Output and strains list:

Zaire ebolavirus isolate H.sapiens-tc/COD/1976/Yambuku-Ecran, complete genome
Sequence ID: gb|KM655246.1| Length: 18797 Number of Matches: 5

Range 1: 6513 to 6528 GenBank Graphics   ▼ Next Match ▲ Previous Match

Score	Expect	Identities	Gaps	Strand
29.4 bits(14)	0.017	15/16(94%)	0/16(0%)	Plus/Plus

```
Query   1     ACGACTTTYGCTGAAG  16
              ||||||||| |||||||
Sbjct   6513  ACGACTTTCGCTGAAG  6528
```

Query 1 (SEQ ID NO: 48)
Subject (SEQ ID NO: 49)

Beacon Alone Strains List:
Zaire ebolavirus isolate H.sapiens-tc/COD/1976/Yambuku-Ecran, complete genome
        29.4   89.2   100%   0.017   94%   KM655246.1

Zaire ebolavirus isolate H.sapiens-wt/GIN/2014/Gueckedou-C05, complete genome
        29.4   104   100% 0.017   94%   KJ660348.2

Zaire ebolavirus isolate H.sapiens-wt/GIN/2014/Gueckedou-C07, complete genome
        29.4   104   100% 0.017   94%   KJ660347.2

Zaire ebolavirus isolate H.sapiens-wt/GIN/2014/Kissidougou-C15, complete genome
        29.4   104   100% 0.017   94%   KJ660346.2

66

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-NM042.3, partial genome

      29.4   104   100% 0.017 94%   KM233118.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-NM042.2, partial genome

      29.4   104   100% 0.017 94%   KM233117.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-NM042.1, partial genome

      29.4   104   100% 0.017 94%   KM233116.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3857, partial genome

      29.4   104   100% 0.017 94%   KM233115.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3856.3, partial genome

      29.4   104   100% 0.017 94%   KM233114.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3856.1, partial genome

      29.4   104   100% 0.017 94%   KM233113.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3851, partial genome

      29.4   104   100% 0.017 94%   KM233112.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3850, partial genome

      29.4   104   100% 0.017 94%   KM233111.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3848, partial genome

      29.4   104   100% 0.017 94%   KM233110.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3846, partial genome

      29.4   104   100% 0.017 94%   KM233109.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3841, partial genome

29.4   104   100% 0.017 94%   KM233107.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3840, partial genome
29.4   104   100% 0.017 94%   KM233106.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3838, partial genome
29.4   104   100% 0.017 94%   KM233105.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3834, partial genome
29.4   104   100% 0.017 94%   KM233104.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3831, partial genome
29.4   104   100% 0.017 94%   KM233103.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3829, partial genome
29.4   104   100% 0.017 94%   KM233102.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3827, partial genome
29.4   104   100% 0.017 94%   KM233101.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3826, partial genome
29.4   104   100% 0.017 94%   KM233100.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3825.2, partial genome
29.4   104   100% 0.017 94%   KM233099.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3825.1, partial genome
29.4   104   100% 0.017 94%   KM233098.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3823, partial genome
29.4   104   100% 0.017 94%   KM233097.1

68

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3822, partial genome

        29.4   104   100% 0.017 94%   KM233096.1

5   Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3821, partial genome

        29.4   104   100% 0.017 94%   KM233095.1

0   Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3819, partial genome

        29.4   104   100% 0.017 94%   KM233093.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3818, partial genome

5   29.4   104   100% 0.017 94%   KM233092.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3817, partial genome

        29.4   104   100% 0.017 94%   KM233091.1

0   Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3816, partial genome

        29.4   104   100% 0.017 94%   KM233090.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3814, partial

5   genome

        29.4   104   100% 0.017 94%   KM233089.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3810.2, partial genome

30   29.4   104   100% 0.017 94%   KM233088.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3810.1, partial genome

        29.4   104   100% 0.017 94%   KM233087.1

35

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3809, partial genome

        29.4   104   100% 0.017 94%   KM233086.1

40   Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3808, partial genome

        29.4   104   100% 0.017 94%   KM233085.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3807, partial genome

29.4   104   100% 0.017 94%   KM233084.1

5   Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3805.2, partial genome

29.4   104   100% 0.017 94%   KM233083.1

0   Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3805.1, partial genome

29.4   104   100% 0.017 94%   KM233082.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3800, partial genome

29.4   104   100% 0.017 94%   KM233081.1

5

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3799, partial genome

29.4   104   100% 0.017 94%   KM233080.1

0   Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3798, partial genome

29.4   104   100% 0.017 94%   KM233079.1

5   Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3795, partial genome

29.4   104   100% 0.017 94%   KM233077.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3789.1, partial genome

30   29.4   104   100% 0.017 94%   KM233076.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3788, partial genome

29.4   104   100% 0.017 94%   KM233075.1

35

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3787, partial genome

29.4   104   100% 0.017 94%   KM233074.1

40   Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3786, partial genome

29.4   104   100% 0.017 94%   KM233073.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3782, partial genome

      29.4   104   100% 0.017 94%   KM233072.1

5   Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3771, partial genome

      29.4   104   100% 0.017 94%   KM233071.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3770.2, partial genome

0   29.4   104   100% 0.017 94%   KM233070.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3770.1, partial genome

      29.4   104   100% 0.017 94%   KM233069.1

5

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3769.3, partial genome

      29.4   104   100% 0.017 94%   KM233067.1

0   Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3769.2, partial genome

      29.4   104   100% 0.017 94%   KM233066.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3769.1, partial

5   genome

      29.4   104   100% 0.017 94%   KM233065.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3765.2, partial genome

30   29.4   104   100% 0.017 94%   KM233064.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3764, partial genome

      29.4   104   100% 0.017 94%   KM233063.1

35

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3758, partial genome

      29.4   104   100% 0.017 94%   KM233062.1

40   Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3752, partial genome

      29.4   104   100% 0.017 94%   KM233061.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3750.3, partial genome

29.4   104   100% 0.017 94%   KM233060.1

5   Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3750.2, partial genome

29.4   104   100% 0.017 94%   KM233059.1

0   Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3750.1, partial genome

29.4   104   100% 0.017 94%   KM233058.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3735.2, partial genome

5   29.4   104   100% 0.017 94%   KM233057.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3735.1, partial genome

29.4   104   100% 0.017 94%   KM233056.1

0

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3734.1, partial genome

29.4   104   100% 0.017 94%   KM233055.1

5   Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3729, partial genome

29.4   104   100% 0.017 94%   KM233054.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3724, partial

30   genome

29.4   104   100% 0.017 94%   KM233053.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3713.4, partial genome

35   29.4   104   100% 0.017 94%   KM233052.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3713.3, partial genome

29.4   104   100% 0.017 94%   KM233051.1

40

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3713.2, partial genome

29.4   104   100% 0.017 94%   KM233050.1

72

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3707, partial genome

        29.4   104   100% 0.017 94%   KM233049.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-EM124.4, partial genome

        29.4   104   100% 0.017 94%   KM233048.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-EM124.3, partial genome

        29.4   104   100% 0.017 94%   KM233047.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-EM124.2, partial genome

        29.4   104   100% 0.017 94%   KM233046.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-EM124.1, partial genome

        29.4   104   100% 0.017 94%   KM233045.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-EM121, partial genome

        29.4   104   100% 0.017 94%   KM233044.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-EM120, partial genome

        29.4   104   100% 0.017 94%   KM233043.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-EM119, partial genome

        29.4   104   100% 0.017 94%   KM233042.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-EM115, partial genome

        29.4   104   100% 0.017 94%   KM233041.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-EM113, partial genome

        29.4   104   100% 0.017 94%   KM233040.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-EM112, partial genome

29.4   104   100%   0.017   94%   KM233039.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-EM111, partial genome

5   29.4   104   100%   0.017   94%   KM233038.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-EM110, partial genome

0   29.4   104   100%   0.017   94%   KM233037.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-EM106, partial genome

5   29.4   104   100%   0.017   94%   KM233036.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-EM104, partial genome

           29.4   104   100%   0.017   94%   KM233035.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3687.1, partial

0   genome
           29.4   104   100%   0.017   94%   KM034563.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3686.1, partial genome

5   29.4   104   100%   0.017   94%   KM034562.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3683.1, partial genome

           29.4   104   100%   0.017   94%   KM034561.1

30

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3682.1, partial genome

           29.4   104   100%   0.017   94%   KM034560.1

35   Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3680.1, partial genome

           29.4   104   100%   0.017   94%   KM034559.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3679.1, partial

40   genome
           29.4   104   100%   0.017   94%   KM034558.1

74

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3677.2, partial genome

29.4   104   100% 0.017 94%   KM034557.1

5   Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3677.1, partial genome

29.4   104   100% 0.017 94%   KM034556.1

0   Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3676.2, partial genome

29.4   104   100% 0.017 94%   KM034555.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3676.1, partial genome

5   29.4   104   100% 0.017 94%   KM034554.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3670.1, partial genome

29.4   104   100% 0.017 94%   KM034553.1

0

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-EM098, partial genome

29.4   104   100% 0.017 94%   KM034552.1

5   Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-EM096, partial genome

29.4   104   100% 0.017 94%   KM034551.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-EM095, partial

30   genome

29.4   104   100% 0.017 94%   KM034550.1

Zaire ebolavirus isolate H.sapiens-wt/SLE/2014/ManoRiver-EM095B, partial genome

29.4   104   100% 0.017 94%   KM034549.1

35

Mutant Zaire ebolavirus, complete sequence

29.4   89.2   100% 0.017 94%   KF827427.1

Amplicon Similarity Analysis Across Ebola Strains

40

Exemplary BLAST Alignment Output and strains list:

75

Zaire ebolavirus isolate H.sapiens-tc/COD/1976/Yambuku-Ecran, complete genome
Sequence ID: gb|KM655246.1| Length: 18797 Number of Matches: 1

Range 1: 6492 to 6547 GenBank Graphics			▼ Next Match ▲ Previous Match	
Score	**Expect**	**Identities**	**Gaps**	**Strand**
102 bits(112)	1e-23	56/56(100%)	0/56(0%)	Plus/Plus

```
Query  1     TCCACAGTTATCTACCGAGGAACGACTTTCGCTGAAGGTGTCGTTGCATTTCTGAT    56
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  6492  TCCACAGTTATCTACCGAGGAACGACTTTCGCTGAAGGTGTCGTTGCATTTCTGAT    6547
```

(SEQ ID NO: 50)

Strains List:

Zaire ebolavirus isolate H.sapiens-tc/COD/1976/Yambuku-Ecran, complete genome
        102   102   100% 1e-23 100% KM655246.1

Zaire ebolavirus isolate H.sapiens-wt/GIN/2014/Gueckedou-C05, complete genome
        102   102   100% 1e-23 100% KJ660348.2

Zaire ebolavirus isolate H.sapiens-wt/GIN/2014/Gueckedou-C07, complete genome
        102   102   100% 1e-23 100% KJ660347.2

Zaire ebolavirus isolate H.sapiens-wt/GIN/2014/Kissidougou-C15, complete genome
        102   102   100% 1e-23 100% KJ660346.2

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-NM042.3, partial genome
        102   102   100% 1e-23 100% KM233118.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-NM042.2, partial genome
        102   102   100% 1e-23 100% KM233117.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-NM042.1, partial genome
        102   102   100% 1e-23 100% KM233116.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3857, partial genome
        102   102   100% 1e-23 100% KM233115.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3856.3, partial genome
        102   102   100% 1e-23 100% KM233114.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3856.1, partial genome
102   102   100%   1e-23   100% KM233113.1

5   Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3851, partial genome
102   102   100%   1e-23   100% KM233112.1

0   Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3850, partial genome
102   102   100%   1e-23   100% KM233111.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3848, partial genome
5   102   102   100%   1e-23   100% KM233110.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3846, partial genome
102   102   100%   1e-23   100% KM233109.1
:0

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3841, partial genome
102   102   100%   1e-23   100% KM233107.1

:5   Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3840, partial genome
102   102   100%   1e-23   100% KM233106.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3838, partial genome
30   102   102   100%   1e-23   100% KM233105.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3834, partial genome
35   102   102   100%   1e-23   100% KM233104.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3831, partial genome
102   102   100%   1e-23   100% KM233103.1
40

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3829, partial genome
102   102   100%   1e-23   100% KM233102.1

77

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3827, partial genome

       102   102   100%   1e-23   100% KM233101.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3826, partial genome

       102   102   100%   1e-23   100% KM233100.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3825.2, partial genome

       102   102   100%   1e-23   100% KM233099.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3825.1, partial genome

       102   102   100%   1e-23   100% KM233098.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3823, partial genome

       102   102   100%   1e-23   100% KM233097.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3822, partial genome

       102   102   100%   1e-23   100% KM233096.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3821, partial genome

       102   102   100%   1e-23   100% KM233095.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3819, partial genome

       102   102   100%   1e-23   100% KM233093.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3818, partial genome

       102   102   100%   1e-23   100% KM233092.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3817, partial genome

       102   102   100%   1e-23   100% KM233091.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3816, partial genome

102   102   100% 1e-23 100% KM233090.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3814, partial genome

102   102   100% 1e-23 100% KM233089.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3810.2, partial genome

102   102   100% 1e-23 100% KM233088.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3810.1, partial genome

102   102   100% 1e-23 100% KM233087.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3809, partial genome

102   102   100% 1e-23 100% KM233086.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3808, partial genome

102   102   100% 1e-23 100% KM233085.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3807, partial genome

102   102   100% 1e-23 100% KM233084.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3805.2, partial genome

102   102   100% 1e-23 100% KM233083.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3805.1, partial genome

102   102   100% 1e-23 100% KM233082.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3800, partial genome

102   102   100% 1e-23 100% KM233081.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3799, partial genome

102   102   100% 1e-23 100% KM233080.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3798, partial genome

    102   102   100%   1e-23   100%   KM233079.1

5   Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3795, partial genome

    102   102   100%   1e-23   100%   KM233077.1

0   Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3789.1, partial genome

    102   102   100%   1e-23   100%   KM233076.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3788, partial genome

5   102   102   100%   1e-23   100%   KM233075.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3787, partial genome

    102   102   100%   1e-23   100%   KM233074.1

:0

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3786, partial genome

    102   102   100%   1e-23   100%   KM233073.1

:5   Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3782, partial genome

    102   102   100%   1e-23   100%   KM233072.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3771, partial genome

30   102   102   100%   1e-23   100%   KM233071.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3770.2, partial genome

35   102   102   100%   1e-23   100%   KM233070.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3770.1, partial genome

    102   102   100%   1e-23   100%   KM233069.1

40

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3769.3, partial genome

    102   102   100%   1e-23   100%   KM233067.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3769.2, partial genome
        102   102   100%   1e-23   100%   KM233066.1

5

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3769.1, partial genome
        102   102   100%   1e-23   100%   KM233065.1

0   Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3765.2, partial genome
        102   102   100%   1e-23   100%   KM233064.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3764, partial
5   genome
        102   102   100%   1e-23   100%   KM233063.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3758, partial genome
:0   102   102   100%   1e-23   100%   KM233062.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3752, partial genome
        102   102   100%   1e-23   100%   KM233061.1

:5

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3750.3, partial genome
        102   102   100%   1e-23   100%   KM233060.1

30   Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3750.2, partial genome
        102   102   100%   1e-23   100%   KM233059.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3750.1, partial
35   genome
        102   102   100%   1e-23   100%   KM233058.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3735.2, partial genome
40   102   102   100%   1e-23   100%   KM233057.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3735.1, partial genome

102   102   100%   1e-23   100%   KM233056.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3734.1, partial genome
5   102   102   100%   1e-23   100%   KM233055.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3729, partial genome
0   102   102   100%   1e-23   100%   KM233054.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3724, partial genome
             102   102   100%   1e-23   100%   KM233053.1

5   Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3713.4, partial genome
             102   102   100%   1e-23   100%   KM233052.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3713.3, partial
0   genome
             102   102   100%   1e-23   100%   KM233051.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3713.2, partial genome
5   102   102   100%   1e-23   100%   KM233050.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3707, partial genome
             102   102   100%   1e-23   100%   KM233049.1
30
Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-EM124.4, partial genome
             102   102   100%   1e-23   100%   KM233048.1

35   Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-EM124.3, partial genome
             102   102   100%   1e-23   100%   KM233047.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-EM124.2, partial
40   genome
             102   102   100%   1e-23   100%   KM233046.1

82

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-EM124.1, partial genome
102   102   100%   1e-23   100%   KM233045.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-EM121, partial genome
102   102   100%   1e-23   100%   KM233044.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-EM120, partial genome
102   102   100%   1e-23   100%   KM233043.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-EM119, partial genome
102   102   100%   1e-23   100%   KM233042.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-EM115, partial genome
102   102   100%   1e-23   100%   KM233041.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-EM113, partial genome
102   102   100%   1e-23   100%   KM233040.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-EM112, partial genome
102   102   100%   1e-23   100%   KM233039.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-EM111, partial genome
102   102   100%   1e-23   100%   KM233038.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-EM110, partial genome
102   102   100%   1e-23   100%   KM233037.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-EM106, partial genome
102   102   100%   1e-23   100%   KM233036.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-EM104, partial genome
102   102   100%   1e-23   100%   KM233035.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3687.1, partial genome

        102   102   100%   1e-23   100%   KM034563.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3686.1, partial genome

        102   102   100%   1e-23   100%   KM034562.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3683.1, partial genome

        102   102   100%   1e-23   100%   KM034561.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3682.1, partial genome

        102   102   100%   1e-23   100%   KM034560.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3680.1, partial genome

        102   102   100%   1e-23   100%   KM034559.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3679.1, partial genome

        102   102   100%   1e-23   100%   KM034558.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3677.2, partial genome

        102   102   100%   1e-23   100%   KM034557.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3677.1, partial genome

        102   102   100%   1e-23   100%   KM034556.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3676.2, partial genome

        102   102   100%   1e-23   100%   KM034555.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3676.1, partial genome

        102   102   100%   1e-23   100%   KM034554.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-G3670.1, partial genome

102   102   100%   1e-23   100%   KM034553.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-EM098, partial genome

5   102   102   100%   1e-23   100%   KM034552.1

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-EM096, partial genome

            102   102   100%   1e-23   100%   KM034551.1

0

Zaire ebolavirus isolate Ebola virus H.sapiens-wt/SLE/2014/ManoRiver-EM095, partial genome

            102   102   100%   1e-23   100%   KM034550.1

5   Zaire ebolavirus isolate H.sapiens-wt/SLE/2014/ManoRiver-EM095B, partial genome

            102   102   100%   1e-23   100%   KM034549.1

Mutant Zaire ebolavirus, complete sequence

102   102   100%   1e-23   100%

0

Other Embodiments

From the foregoing description, it will be apparent that variations and modifications may be made to the invention described herein to adopt it to various usages and conditions. Such embodiments are also within the scope of the following claims.

5   The recitation of a listing of elements in any definition of a variable herein includes definitions of that variable as any single element or combination (or subcombination) of listed elements. The recitation of an embodiment herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof.

This application may be related to International Patent Application No.

30   PCT/US2013/035750, filed April 9, 2013, which claims the benefit of U.S. Provisional Application No.: 61/621,975, filed April 9, 2012, the entire contents of which are incorporated herein by reference.

This application may be related to International Patent Application No. PCT/US2011/047049, filed August 9, 2011, which claims the benefit of U.S. Provisional

35   Application No.: 61/373,695, filed August 13, 2010, the entire contents of which are incorporated herein by reference.

All patents and publications mentioned in this specification are herein incorporated by reference to the same extent as if each independent patent and publication was specifically and individually indicated to be incorporated by reference.

It is to be understood that, if any prior art publication is referred to herein, such reference does not constitute an admission that the publication forms a part of the common general knowledge in the art, in Australia or any other country.

In the claims which follow and in the preceding description of the invention, except where the context requires otherwise due to express language or necessary implication, the word "comprise" or variations such as "comprises" or "comprising" is used in an inclusive sense, i.e. to specify the presence of the stated features but not to preclude the presence or addition of further features in various embodiments of the invention.

Claims:

1.   A method of detecting a specific target polynucleotide in an isothermal amplification reaction coupled with reverse transcription, the method comprising:

5   (a) contacting a target polynucleotide molecule in a sample with a primer in the presence of a reverse transcriptase and dNTPs under conditions permissive for cDNA synthesis, thereby generating a cDNA;

      (b) contacting the cDNA with

            (i) forward and reverse primers each comprising a modified nucleotide (m);

10   wherein the polynucleotide molecule is Ebola virus (EBOV) and the forward and reverse primers for the detection of EBOV are selected from the group consisting of:

            Forward primer:

            GACTCGATATCGAGTCGCTTCCAmCAGTTATCmUmAmCmCmG (SEQ

15   ID NO: 1), and

            Reverse Primer:

            GACTCGATATCGAGTCGAAATGCmAACGAmCmAmCmCmU (SEQ ID

NO: 2); or

            wherein the polynucleotide molecule is human immunodeficiency virus (HIV)

20   and the forward and reverse primers for the detection of HIV are selected from the group consisting of:

            Forward primers:

            GACTCGATATCGAGTCTGACTAGmCGGAGGmCmTmAmGmAmAmG

            (SEQ ID NO: 6), and

25   GACTCGATATCGAGTCTGACTAGmCAGAGGmCmTmAmGmAmAmG (SEQ

            ID NO: 7), and

            Reverse Primers:

            GACTCGATATCGAGTCTATTGACmGCTCmTmCmGmCmAmC (SEQ ID

NO: 8), and GACTCGATATCGAGTCTACTGACmGCTCmTmCmGmCmAmC

30   (SEQ ID NO: 9); or

            wherein the polynucleotide molecule is dengue virus and the forward and reverse primers for the detection of dengue virus are selected from the group consisting of:

Forward primer:

GACTCGATATCGAGTCCAAAAACmAGCATATTmGmAmCmGmC (SEQ ID
NO: 11), and

Reverse Primer:

GACTCGATATCGAGTCAGACAGCmAGGATCmTmCmTmGmG (SEQ
ID NO: 12), and

GACTCGATATCGAGTCAGACAGCmAGGATCmTmGmTmGmG (SEQ ID NO:
13); or

wherein the polynucleotide molecule is influenza B virus and the forward and
reverse primers for the detection of influenza B virus are selected from the group
consisting of:

Forward primers:

GACTCGATATCGAGTCAAATGCAmGATGGTCTCmAmGmCmTmA
(SEQ ID NO: 15),

GACTCGATATCGAGTCAAATGCAmAATGGTCTCmAmGmCmTmA (SEQ ID
NO: 16), and

GACTCGATATCGAGTCAAATGCAmGATGGTTTCmAmGmCmTmA (SEQ ID
NO: 17), and

Reverse Primers:

GACTCGATATCGAGTCCTCCTTTmTCCCATTCCATmTmCmAmTmT
(SEQ ID NO: 18),

GACTCGATATCGAGTCCTCCCTTmTCCCATTCCATmTmCmAmTmT (SEQ ID
NO: 19), and

GACTCGATATCGAGTCCTCCTTTmCCCCATTCCATmTmCmAmTmT (SEQ ID
NO: 20); or

wherein the polynucleotide molecule is bovine diarrhea virus and the forward
and reverse primers for the detection of bovine diarrhea virus are selected from the
group consisting of:

Forward primers:

GACTCGATATCGAGTCGGCCCACmTGTATTGCTmAmCmTmGmAmA
mA (SEQ ID NO: 22), and

GACTCGATATCGAGTCGGCCCACmTGCACTGCTmAmCmTmAmAmAmA
(SEQ ID NO: 23), and

Reverse Primer:

88

GACTCGATATCGAGTCTGTGATCmAACTCCmAmTmGmTmGmCmC

(SEQ ID NO: 24) ,

(ii) dNTPs,

(iii) a detectable oligonucleotide probe, and

(iv) a strand-displacement polymerase

under conditions permissive for the isothermal amplification of the cDNA; and

(c) detecting a signal specific for detectable oligonucleotide probe hybridization to the

amplicon, wherein detection of the signal indicates the presence or quantity of the target

polynucleotide present in the sample and failure to detect the signal indicates the absence of

target polynucleotide in the sample.

2.   A method of detecting an RNA virus in a sample, the method comprising

(a) contacting an RNA virus polynucleotide molecule in a sample with a primer in the

presence of a reverse transcriptase and dNTPs under conditions permissive for cDNA

synthesis, thereby generating a cDNA;

(b) contacting the cDNA with

(i) forward and reverse primers each comprising a modified nucleotide (m);

wherein the RNA virus polynucleotide is Ebola virus (EBOV) and the forward

and reverse primers for the detection of EBOV are selected from the group consisting

of:

Forward primer:

GACTCGATATCGAGTCGCTTCCAmCAGTTATCmUmAmCmCmG (SEQ

ID NO: 1), and

Reverse Primer:

GACTCGATATCGAGTCGAAATGCmAACGAmCmAmCmCmU (SEQ ID

NO: 2); or

wherein the RNA virus polynucleotide is human immunodeficiency virus

(HIV) and the forward and reverse primers for the detection of HIV are selected from

the group consisting of:

Forward primers:

GACTCGATATCGAGTCTGACTAGmCGGAGGmCmTmAmGmAmAmG

(SEQ ID NO: 6), and

GACTCGATATCGAGTCTGACTAGmCAGAGGmCmTmAmGmAmAmG (SEQ

ID NO: 7), and

Reverse Primers:

GACTCGATATCGAGTCTATTGACmGCTCmTmCmGmCmAmC (SEQ ID NO: 8), and GACTCGATATCGAGTCTACTGACmGCTCmTmCmGmCmAmC (SEQ ID NO: 9); or

wherein the RNA virus polynucleotide is dengue virus and the forward and reverse primers for the detection of dengue virus are selected from the group consisting of:

Forward primer: GACTCGATATCGAGTCCAAAAACmAGCATATTmGmAmCmGmC (SEQ ID NO: 11), and

Reverse Primer:

GACTCGATATCGAGTCAGACAGCmAGGATCmTmCmTmGmG (SEQ ID NO: 12), and

GACTCGATATCGAGTCAGACAGCmAGGATCmTmGmTmGmG (SEQ ID NO: 13); or

wherein the RNA virus polynucleotide is influenza B virus and the forward and reverse primers for the detection of influenza B virus are selected from the group consisting of:

Forward primers:

GACTCGATATCGAGTCAAATGCAmGATGGTCTCmAmGmCmTmA (SEQ ID NO: 15),

GACTCGATATCGAGTCAAATGCAmAATGGTCTCmAmGmCmTmA (SEQ ID NO: 16), and

GACTCGATATCGAGTCAAATGCAmGATGGTTTCmAmGmCmTmA (SEQ ID NO: 17), and

Reverse Primers:

GACTCGATATCGAGTCCTCCTTTmTCCCATTCCATmTmCmAmTmT (SEQ ID NO: 18),

GACTCGATATCGAGTCCTCCCTTmTCCCATTCCATmTmCmAmTmT (SEQ ID NO: 19), and

GACTCGATATCGAGTCCTCCTTTmCCCCATTCCATmTmCmAmTmT (SEQ ID NO: 20); or

90

wherein the RNA virus polynucleotide is bovine diarrhea virus and the

forward and reverse primers for the detection of bovine diarrhea virus are selected

from the group consisting of:

Forward primers:

GACTCGATATCGAGTCGGCCCACmTGTATTGCTmAmCmTmGmAmA

mA (SEQ ID NO: 22), and

GACTCGATATCGAGTCGGCCCACmTGCACTGCTmAmCmTmAmAmAmA

(SEQ ID NO: 23), and

Reverse Primer:

GACTCGATATCGAGTCTGTGATCmAACTCCmAmTmGmTmGmCmC

(SEQ ID NO: 24),

(ii) dNTPs,

(iii) a detectable oligonucleotide probe, and

(iv) a strand-displacement polymerase

under conditions permissive for the isothermal amplification of the cDNA; and

(c) detecting a signal specific for detectable oligonucleotide probe hybridization to the

amplicon, wherein detection of the signal indicates the presence or quantity of the RNA virus

polynucleotide molecule present in the sample and failure to detect the amplicon indicates the

absence of an RNA virus.

3.   A method of diagnosing a human or animal subject with an RNA virus, the method

comprising

(a) contacting a sample of the subject with an agent capable of extracting an RNA virus

present in the sample and an agent capable of stabilizing the extracted polynucleotide

molecule against degradation;

(b) contacting the polynucleotide molecule with a reverse transcriptase primer in the presence

of a reverse transcriptase and dNTPs under conditions permissive for cDNA synthesis,

thereby generating a cDNA copy of the polynucleotide molecule;

(c) contacting the cDNA with

(i) forward and reverse primers each comprising a modified nucleotide (m);

wherein the polynucleotide molecule is Ebola virus (EBOV) and the forward and reverse

primers are selected from the group consisting of:

Forward primer:

91

GACTCGATATCGAGTCGCTTCCAmCAGTTATCmUmAmCmCmG (SEQ ID NO: 1),

and

Reverse Primer:

GACTCGATATCGAGTCGAAATGCmAACGAmCmAmCmCmU (SEQ ID NO: 2); or

wherein the polynucleotide molecule is human immunodeficiency virus (HIV) and the

forward and reverse primers are selected from the group consisting of:

Forward primers:

GACTCGATATCGAGTCTGACTAGmCGGAGGmCmTmAmGmAmAmG (SEQ ID NO:

6), and GACTCGATATCGAGTCTGACTAGmCAGAGGmCmTmAmGmAmAmG (SEQ

ID NO: 7), and

Reverse Primers:

GACTCGATATCGAGTCTATTGACmGCTCmTmCmGmCmAmC (SEQ ID NO: 8), and

GACTCGATATCGAGTCTACTGACmGCTCmTmCmGmCmAmC (SEQ ID NO: 9); or

wherein the polynucleotide molecule is dengue virus and the forward and reverse primers are

selected from the group consisting of:

Forward primer: GACTCGATATCGAGTCCAAAAACmAGCATATTmGmAmCmGmC

(SEQ ID NO: 11), and

Reverse Primer:

GACTCGATATCGAGTCAGACAGCmAGGATCmTmCmTmGmG (SEQ ID NO: 12), and

GACTCGATATCGAGTCAGACAGCmAGGATCmTmGmTmGmG (SEQ ID NO: 13); or

wherein the polynucleotide molecule is influenza B virus and the forward and reverse primers

are selected from the group consisting of:

Forward primers:

GACTCGATATCGAGTCAAATGCAmGATGGTCTCmAmGmCmTmA (SEQ ID NO: 15),

GACTCGATATCGAGTCAAATGCAmAATGGTCTCmAmGmCmTmA (SEQ ID NO: 16),

and GACTCGATATCGAGTCAAATGCAmGATGGTTTCmAmGmCmTmA (SEQ ID NO:

17), and

Reverse Primers:

GACTCGATATCGAGTCCTCCTTTmTCCCATTCCATmTmCmAmTmT (SEQ ID NO:

18), GACTCGATATCGAGTCCTCCCTTmTCCCATTCCATmTmCmAmTmT (SEQ ID

NO: 19), and GACTCGATATCGAGTCCTCCTTTmCCCCATTCCATmTmCmAmTmT

(SEQ ID NO: 20); or

wherein the polynucleotide molecule is bovine diarrhea virus and the forward and reverse

primers are selected from the group consisting of:

92

Forward primers:

GACTCGATATCGAGTCGGCCCACmTGTATTGCTmAmCmTmGmAmAmA (SEQ ID NO: 22), and

GACTCGATATCGAGTCGGCCCACmTGCACTGCTmAmCmTmAmAmAmA (SEQ ID NO: 23), and

Reverse Primer:

GACTCGATATCGAGTCTGTGATCmAACTCCmAmTmGmTmGmCmC (SEQ ID NO: 24),

ii) dNTPs,

iii) a detectable oligonucleotide probe, and

iv) a strand-displacement polymerase

under conditions permissive for the isothermal amplification of the cDNA, thereby generating amplicons; and

(d) detecting the amplicons, wherein the presence of an RNA viral amplicon diagnoses an RNA viral infection in the subject and failure to detect the amplicon diagnoses the absence of an RNA viral infection in the subject.

4.   The method of any one of claims 1-3, wherein the polynucleotide molecule is obtained by contacting the sample with one or more of an agent capable of extracting an RNA molecule present in the sample and an agent capable of stabilizing an RNA molecule against degradation, optionally wherein the agent capable of extraction is one or a combination of sodium dodecyl sulfate, sodium lauryl sulfate, Guanidinium thiocyanate, and/or guanidine hydrochloride; and/or

wherein no detectable signal is present in a control assay lacking a target polynucleotide at seven minutes, ten minutes, and/or fifteen minutes following initiation of the assay; and/or

wherein the primer used in step (a) has the same sequence or a different sequence than the forward or reverse primer used in step (b); and/or

wherein steps (a)-(c) are carried out in a single reaction; and/or

wherein the cDNA of step (a) is generated in a first reaction vessel, then transferred to a second reaction vessel where step (b) is carried out; and/or

wherein the reverse transcriptase enzyme used in step (a) and the strand-displacement DNA polymerase used in step (b) are the same or different enzyme; and/or

wherein the sample is a bodily fluid, optionally selected from the group consisting of saliva, sweat, tears, fluids accumulating in a bodily cavity, urine, ejaculate, vaginal secretion, cerebrospinal fluid, lymph, feces, sputum, decomposition fluid, vomit, sweat, breast milk, blood, serum, and plasma, optionally wherein the bodily cavity is peritoneal cavity or pericardial cavity; and/or

wherein the limit of detection is 10 or 20 copies per reaction; and/or

wherein the method is carried out in about 5, 7, 10, 15, 20, 25 or thirty minutes; and/or

wherein steps (a)-(d) are carried out in the context of the biological sample; and/or

wherein the polynucleotide molecule is not purified or isolated away from the biological sample.

5.   The method of any one of claims 1-4, wherein the method is carried out at a point of care or diagnosis in a portable battery powered device; and/or

wherein no separate reverse transcriptase primer is required, but the forward and/or reverse primers are used; and/or

wherein the sample is a biological sample or an environmental sample, optionally wherein the biological sample is obtained from a subject, bat, bush meat, or a domestic animal; or wherein the biological sample is a swab of a mucosal membrane selected from the group consisting of buccal, nasal, eye, rectal, and vaginal or skin; or wherein the biological sample is a tissue sample obtained from a subject, necropsy, or culture media, optionally wherein the necropsy is of a human, primate, bat, or other mammal; or wherein the environmental sample is a material that may be contaminated with a biological fluid of a subject having or having a propensity to develop an Ebola viral infection; or wherein the environmental sample is bedding, a seat cushion, a rug, an air condition filter or other material; and/or

wherein the polymerase are 5'-exo⁻ derivatives of Bst DNA polymerase I, Gst DNA polymerase I, Gka DNA polymerase I, Gca DNA polymerase I, Gan DNA polymerase I, Gbo DNA polymerase I, Gsp70 DNA polymerase I, GspT3 DNA polymerase I, Gsp52 DNA polymerase I and/or fragments thereof; and/or

wherein the nicking enzyme is one or more of Nt.BstNBI, Nt.BspD6I, Nt.BspQI, Nt.BsmAI, Nt.AlwI, N.Bst9I, or N.BstSEI; and/or

wherein the reverse transcriptase is M-MLV RT, AMV RT, RSV RT, and/or mutants/derivatives thereof.

94

6.   The method of any one of claims 1-5, wherein the polynucleotide molecule is EBOV

and the probe having the following sequence: gctacACGACTTTYGCTGAAGgtagc;

optionally

wherein the probe is

5'-CALRed610nm- gctacACGACTTTYGCTGAAGgtagc BHQ2- 3' or

5'-FAM or FITC - gctacACGACTTTYGCTGAAGgtagc-BHQ1-3'; or

wherein the polynucleotide molecule is HIV and the probe comprises the following sequence:

cgcaagGGAGAGAGATGGGTGcttgcg; or

wherein the polynucleotide molecule is Dengue virus and the probe comprises the following

sequence: cgcatcTGGTCTTTCCCAGCgatgcg; or

wherein the polynucleotide molecule is influenza B and the probe comprises the following

sequence: gccaaGCTATGAACACAGCAAActtggc; or

wherein the polynucleotide molecule is bovine diarrhea virus and the probe comprises the

following sequence: cgctacATCTCTGCTGTACATGgtagcg.

7.   The method of any one of claims 1-6, wherein the detectable probe comprises a

molecular beacon; or

        wherein the detectable probe has a fluorescent dye at the 5' end, and a quencher at the

3' end or a fluorescent dye at the 3' end, and a quencher at 5' end; optionally,

        wherein the quencher is BHQ1, BHQ2 or DABsyl; and/or

        wherein the fluorescent dye is CALRed610nm, FAM or FITC.

8.   The method of any one of claims 1-7, wherein the one or more 2' modified nucleotide

is one or more of 2'-O-methyl, 2'-methoxyethoxy, 2'-fluoro, 2'-hydroxyl, 2'-alkyl, 2'-allyl, 2'-

O-[2-(methylamino)-2-oxoethyl], 4'-CH_2-O-2'-bridge, 4'-(CH_2)_2-O-2'-bridge, 2'-LNA, and 2'-

O-(N-methylcarbamate).

9.   A kit for detecting an RNA virus polynucleotide molecule comprising:

        (i) forward and reverse primers each comprising a modified nucleotide (m),wherein

the RNA virus polynucleotide is Ebola virus (EBOV) and the forward and reverse primers are

selected from the group consisting of:

Forward primer:

GACTCGATATCGAGTCGCTTCCAmCAGTTATCmUmAmCmCmG (SEQ ID

NO: 1), and

Reverse Primer:

GACTCGATATCGAGTCGAAATGCmAACGAmCmAmCmCmU (SEQ ID NO: 2);

or

wherein the RNA virus polynucleotide is human immunodeficiency virus (HIV) and

the forward and reverse primers are selected from the group consisting of:

Forward primers:

GACTCGATATCGAGTCTGACTAGmCGGAGGmCmTmAmGmAmAmG (SEQ

ID NO: 6), and GACTCGATATCGAGTCTGACTAGmCAGAGGmCmTmAmGmAmAmG

(SEQ ID NO: 7), and

Reverse Primers:

GACTCGATATCGAGTCTATTGACmGCTCmTmCmGmCmAmC (SEQ ID NO:

8), and GACTCGATATCGAGTCTACTGACmGCTCmTmCmGmCmAmC (SEQ ID NO:

9); or

wherein the RNA virus polynucleotide is dengue virus and the forward and reverse

primers are selected from the group consisting of:

Forward primer:

GACTCGATATCGAGTCCAAAAACmAGCATATTmGmAmCmGmC (SEQ ID NO: 11),

and

Reverse Primer:

GACTCGATATCGAGTCAGACAGCmAGGATCmTmCmTmGmG (SEQ ID NO:

12), and GACTCGATATCGAGTCAGACAGCmAGGATCmTmGmTmGmG (SEQ ID NO:

13); or

wherein the RNA virus polynucleotide is influenza B virus and the forward and

reverse primers are selected from the group consisting of:

Forward primers:

GACTCGATATCGAGTCAAATGCAmGATGGTCTCmAmGmCmTmA (SEQ ID

NO: 15), GACTCGATATCGAGTCAAATGCAmAATGGTCTCmAmGmCmTmA (SEQ ID

NO: 16), and GACTCGATATCGAGTCAAATGCAmGATGGTTTCmAmGmCmTmA

(SEQ ID NO: 17), and

Reverse Primers:

96

GACTCGATATCGAGTCCTCCTTTmTCCCATTCCATmTmCmAmTmT (SEQ ID NO: 18), GACTCGATATCGAGTCCTCCCTTmTCCCATTCCATmTmCmAmTmT (SEQ ID NO: 19), and GACTCGATATCGAGTCCTCCTTTmCCCCATTCCATmTmCmAmTmT (SEQ ID NO: 20); or

5   wherein the RNA virus polynucleotide is bovine diarrhea virus and the forward and reverse primers are selected from the group consisting of:

Forward primers:

GACTCGATATCGAGTCGGCCCACmTGTATTGCTmAmCmTmGmAmAmA (SEQ ID NO: 22), and

0   GACTCGATATCGAGTCGGCCCACmTGCACTGCTmAmCmTmAmAmAmA (SEQ ID NO: 23), and

Reverse Primer:

GACTCGATATCGAGTCTGTGATCmAACTCCmAmTmGmTmGmCmC (SEQ ID NO: 24),

5   (ii) a detectable probe that specifically binds an RNA virus amplicon,

(iii) a reverse transcriptase enzyme,

(iv) a nicking enzyme, and

(v) a strand-displacement polymerase.

0   10.   The kit of claim 9,

wherein the RNA virus polynucleotide is EBOV and the probe comprises the following sequence: gctacACGACTTTYGCTGAAGgtagc; optionally wherein the probe is

5'-CALRed610nm- gctacACGACTTTYGCTGAAGgtagc BHQ2- 3' or

5'-FAM or FITC - gctacACGACTTTYGCTGAAGgtagc-BHQ1-3', optionally wherein the

25   3' quencher is replaced by DABsyl; or

wherein the RNA virus polynucleotide is HIV and the probe comprises the following sequence: cgcaagGGAGAGAGATGGGTGcttgcg; or

wherein the RNA virus polynucleotide is Dengue virus and the probe comprises the

30   following sequence: cgcatcTGGTCTTTCCCAGCgatgcg; or

wherein the RNA virus polynucleotide is influenza B virus and the probe comprises the following sequence: gccaaGCTATGAACACAGCAAActtggc; or

wherein the RNA virus polynucleotide is bovine diarrhea virus and the probe comprises the following sequence: cgctacATCTCTGCTGTACATGgtagcg.

11.   The kit of claim 9 or claim 10, wherein the probe has a fluorescent dye at the 5' end and a quencher at the 3' end or fluorescent dye at the 3' end and a quencher at the 5' end; optionally,

wherein the quencher is BHQ1, BHQ2 or DABsyl; and/or

wherein the fluorescent dye is CALRed$_{610nm}$, FAM or FITC.

12.   The kit of any one of claims 9-11, wherein the kit further comprises a capillary tube that may or may not comprise lyophilized lysis or RNA stabilization reagents for viral polynucleotide extraction; and/or

wherein the kit further comprises one or more vessels comprising a buffer suitable for carrying out a reverse transcriptase and/or amplification reaction; and/or

wherein the kit further comprises vessels comprising the reverse transcriptase enzyme, nicking enzyme, and strand-displacement polymerase in lyophilized form.

FIG. 1

Candidate Assays

Ebola.F1
Ebola.F2
Ebola.F3
Ebola.F4
Ebola.F5
Ebola.F6
Ebola.F7
Ebola.F8

Assay 1
Assay 2

Top Beacon Selected

Ebola.Probe.T
Y Base
6,580
6,560
6,540

TTCCACAGTTATCTACCGAGGAAGGACTTTCGCTGAAGGTGTGTTGCATTTCTGATAC
AAGGTGTCAATAGATGGCTCCTTGCTGAAAGCGACTTCCACAGCAACGTAAAGACTATG

Ebola.Probe.B
R Base

Ebola.R5
Ebola.R6
Ebola.R7
Ebola.R8
Ebola.R4
Ebola.R1
Ebola.R2
Ebola.R3

Assay 1/2

FIG. 2

Screened Assays

Top Beacon	Zeb.Probe.T	gctacACGACTTTYGCTGAAGgtagc	
	Zeb.Probe.B	gctacCTTCAGCRAAAGTCGgtagc	
Assay 1	Zeb.P1F7	GACTCGATATCGAGTCCTTCCACWGTTATCTWXXYW	W = mA
Assay 2	Zeb.P1F8	GACTCGATATCGAGTCGCTTCCAXAGTTATCZWXXY	X = mC
	Zeb.P1F2	GACTCGATATCGAGTCACAGTTAZCTACCGAYYWWX	Y = mG
	Zeb.P1R1	GACTCGATATCGAGTCAAATGCAWCGACWXZZ	Z = mT
Assay 1/2	Zeb.P1R2	GACTCGATATCGAGTCGAAATGCWACGAXWXXZ	
	Zeb.P1R3	GACTCGATATCGAGTCAGAAATGXAACGWXWXX	
	Zeb.P2F2	GACTCGCGCGCGGAGTCACAGTTAZCTACCGAYYWWX	
	Zeb.P2F3	GACTCGCGCGCGGAGTCCACAGTTWTCTACCGWYYWW	
	Zeb.P2F4	GACTCGCGCGCGGAGTCCCACAGTZATCTACCYWYYW	
	Zeb.P2R1	GACTCGCGCGCGGAGTCAAATGCAWCGACWXZZ	
	Zeb.P2R2	GACTCGCGCGCGGAGTCGAAATGCWACGAXWXXZ	
	Zeb.P2R3	GACTCGCGCGCGGAGTCAAATGXAACGWXWXX	
	Zeb.gBlock	CCACAGTTATCTACCGAGGAACGACTTTCGCTGAAGGTGTCG	

FIG. 3A

10k Copies gBlock in 18 ng Human cDNA
Assay 1

Fluorescence History

Reaction Set-Up:

5ul 2X MM
5ul sample

Equivalent to:
2000 cp/ul
2,000,000 cp/ml

FIG. 3B

5k Copies gBlock in 18 ng Human cDNA
Assay 1

Fluorescence History

Reaction Set-Up:
5ul 2X MM
5ul sample

Equivalent to:
1000 cp/ul
1,000,000 cp/ml

Select   Zoom

FIG. 3C

FIG. 3D

1.25k Copies gBlock in 18 ng Human cDNA Assay 1

Fluorescence History

Reaction Set-Up:
5ul 2X MM
5ul sample

Equivalent to:
250 cp/ul
250,000 cp/ml

FIG. 3E

625 Copies gBlock in 18 ng Human cDNA
Assay 1

FIG. 3F

312 Copies gBlock in 18 ng Human cDNA
Assay 1

FIG. 3G

156 Copies gBlock in 18 ng Human cDNA
Assay 1

Reaction Set-Up:
5ul 2X MM
5ul sample

Equivalent to:
31.3 cp/ul
31,300 cp/ml

FIG. 3H

78 Copies gBlock in 18 ng Human cDNA
Assay 1

Fluorescence History

Reaction Set-Up:
5ul 2X MM
5ul sample

Equivalent to:
15.5 cp/ul
15,500 cp/ml

FIG. 3I

39 Copies gBlock in 18 ng Human cDNA
Assay 1

Reaction Set-Up:
5ul 2X MM
5ul sample

Equivalent to:
7.8 cp/ul
7,800 cp/ml

FIG. 3J

19.5 Copies gBlock in 18 ng Human cDNA
Assay 1

FIG. 3K

9.8 Copies gBlock in 18 ng Human cDNA
Assay 1

FIG. 3L

FIG. 3M

10K Copies gBlock in 18 ng Human cDNA
Assay 2

Fluorescence History

Reaction Set-Up:
5ul 2X MM
5ul sample

Equivalent to:
2000 cp/ul
2,000,000 cp/ml

FIG. 3N

SUBSTITUTE SHEET (RULE 26)

FIG. 3O

2.5K Copies gBlock in 18 ng Human cDNA
Assay 2

Fluorescence History

Reaction Set-Up:
5ul 2X MM
5ul sample

Equivalent to:
500 cp/ul
500,000 cp/ml

FIG. 3P

1.25K Copies gBlock in 18 ng Human cDNA
Assay 2

Reaction Set-Up:
5ul 2X MM
5ul sample

Equivalent to:
250 cp/ul
250,000 cp/ml

FIG. 3Q

625 Copies gBlock in 18 ng Human cDNA
Assay 2

Reaction Set-Up:
5ul 2X MM
5ul sample

Equivalent to:
125 cp/ul
125,000 cp/ml

FIG. 3R

312 Copies gBlock in 18 ng Human cDNA
Assay 2

Reaction Set-Up:
5ul 2X MM
5ul sample

Equivalent to:
62.5 cp/ul
62,500 cp/ml

FIG. 3S

FIG. 3T

78 Copies gBlock in 18 ng Human cDNA
Assay 2

Reaction Set-Up:
5ul 2X MM
5ul sample

Equivalent to:
15.5 cp/ul
15,500 cp/ml

FIG. 3U

39 Copies gBlock in 18 ng Human cDNA
Assay 2

Reaction Set-Up:
5ul 2X MM
5ul sample

Equivalent to:
7.8 cp/ul
7,800 cp/ml

FIG. 3V

19.5 Copies gBlock in 18 ng Human cDNA
Assay 2

Fluorescence History

Reaction Set-Up:

5ul 2X MM

5ul sample

Equivalent to:

3.9 cp/ul

3,900 cp/ml

FIG. 3W

9.8 Copies gBlock in 18 ng Human cDNA
Assay 2

Reaction Set-Up:
5ul 2X MM
5ul sample

Equivalent to:
1.95 cp/ul
1,950 cp/ml

FIG. 3X

0 Copies gBlock in 18 ng Human cDNA
Assay 2

Fluorescence History

Reaction Set-Up:
5ul 2X MM
5ul sample

Equivalent to:
0 cp/ul
0 cp/ml

One-Step RNAble® Example
Detection of a Human Expressed Gene in a Background of Total Human RNA

FIG. 5

Example One-Step RNAble Using a Synthetic RNA in an Excess Background of Total Human RNA

Fluorescence History

ZEB titration starting at 1x10⁶ copies per reaction (———), 1x10⁴ per reaction (———); 1x10² per reaction (———); and 1x10⁰ per reaction (———), synthetic RNA in a background of a 1ug human RNA. Target specific first strand RT (Maxima) in a homogeneous reaction

FIG. 6A

Capillary containing dried stabilization/lysis reagent for instantaneous uncoating of virion and stabilization of RNA.

Sealed end

Sample Preparation 1

Dispense sample into tube containing MM or dilute then transfer to MM.

Collect data on AmpliFire or similar instrument

10-15 minutes

FIG. 6B

Capillary-based collection of blood.

Sample Preparation 2

FTA elute punch in well, load blood, dry wash, load assay, run with the punch in tube.

Collect data on AmpliFire or similar instrument

10-20minutes

FIG. 6C

Lyophilized Assay Procedure 8-well Strip (or single tube)

FIG. 7A

Sample Preparation 2

RNA Stabilizing/ Virion Destabilizing Reagent

RNA Stabilizing/ Capsid Destabilizing Reagent

Short sonication for disruption of cells and virion

Dispense sample into tube containing MM or dilute then transfer to MM.

10-15 minutes

FIG. 7B

Sample Preparation 3

ClaremontBio Solutions

Protocol for Rapid RNA Isolation

Visual Protocol

① Load Cartridge; Lyse for 2 min — Omnilyse cartridge

② Remove OmniLyse

③ Digest DNA 5 min RT

④ Add Binding Buffers

⑤ Load Syringe

⑥ Add RNAEcpress Column

⑦ Load Column

⑧ Wash Column

⑨ Elute RNA

*Includes optional DNase 1 step for DNA-free RNA

FIG. 8

FIG. 9

Fluorescence History

2 Step RNAble

56°C
room temp

1x10e5 copies per rxn

Fluorescence [533-610]

Time [h:mm:ss]

FIG. 10

Fluorescence History

2 Step RNAble

1x10e4 copies per rxn

FIG. 11A

A. Two-Step RNAble® Reaction with cDNA
GENE ID: 85495 RPPH1 (RNase P RNA component)

Fluorescence History

10 ng human RNA converted to cDNA
with random hexamer primer.

Reaction Set-Up:
5 ul 2x MM
5ul Sample

FIG. 11B

B. One-Step RNAble® RPPH1 Detection with Purified Human RNA

20 ng human RNA utilizing a specific reverse transcription primer

Reaction Set-Up:
5 ul 2x MM
5ul Sample

FIG. 12

Zaire Ebola One-Step RNAble® Reaction in a Crude Blood Prep #4

Crude Blood Prep Method #4

To 20µL whole blood, add:
20µL 0.5% SDS in H_2O.
Mix.
Incubate for 3 minutes at room
temperature.
Add 20µL 2% BSA in H_2O.
Mix.
Incubate for 1 minute at room
temperature.
Add 1uL of crude blood prep. to a
10uL reaction with 1000 copies
synthetic RNA target. Rune reaction
in triplicate at 56° C on LC480.

Fluorescence History

FIG. 13

One-Step RNAble®

Zaire Ebolavirus Mayinga vs. Sudan Ebolavirus Boniface Specificity Example

Fluorescence History

A = 693 copies Zaire
Ebolavirus Mayinga

B = 650 copies Sudan
Ebolavirus Boniface

Results - the Zaire Ebola assay
does not detect Sudan
Ebolavirus Boniface.

Reactions run with
purified RNA from Vero
E6 cells infected with
one fo the two viruses
shown. Quadruplicate
10uL reactions run on
LC480.

FIG. 14

Instrument Comparison Zaire Ebolavirus Mayinga
Roche LightCycler 480 II

FIG. 15

Example Amplification Curves Representing Serially Diluted One-Step RNAble® Zaire Ebolavirus Mayinga RNA

10 Technical Replicates Each

FIG. 16A

HIV One-step RNAble
Candidate assay
gag protein target

F2/R1 Amplicon Map

| | Forward | Probe T → | Reverse | External primer |

5' TGACTAGC**C**GGAGGCTAGAA**C**GGAGAGAGATGGG**T**GCGAGAGGCTCAA**T**ATTAAGAGGCGAAAAATTAGAT GC

5' TGACTAGC**A**GAGGCTAGAAGGAGAGAGATGGG**T**GCGAGAGGCTCA**G**TA

Spacer: ——— 11bp

Amplicon: —————————— 40bp

*Note: bold bases indicate population sequence variations

Hgag(HIV gag target)

Primer	Sequence
Hgag.F2a	GACTCGATATCGAGTCTGACTAGmCGGAGGmCmTmAmGmAmGmAmG
Hgag.F2b	GACTCGATATCGAGTCTGACTAGmCAGAGGmCmTmAmGmAmGmAmG
Hgag.R1a	GACTCGATATCGAGTCTATTGACmGCTCmTmCmGmCmAmC
Hgag.R1b	GACTCGATATCGAGTCTACTGACmGCTCmTmCmGmCmAmC
Hgag.rt3.subC*	GCATCTAATTTTTCGCC (external)
Hgag.probe.T	cgcaagGGAGAGAGATGGGTGcttgcg

Primers: mN indicates methoxy base
Probe sequence: lowercase = stems, uppercase = recognition

*External primer sequence is specific to HIV subtype C (for the purified RNA sample used)

44/50

FIG. 16B

HIV One-step RNAble Candidate assay gag protein target

Copies	1000	500	250	125	NTC
	30.23	33.94	36.48	48.45	-
	30.79	30.39	34.8	40.1	-
	30.85	30.22	37.88	53.18	-
	31.87	32.5	36.06	38.3	-
	30.37	32.91	34.75	38.23	-
Avg.	30.8	32.0	36.0	43.7	N/A
St. dev.	0.6	1.6	1.3	6.8	N/A

Cp values across 5 technical replicates (10uL reactions): Purified HIV RNA (subtype C) from SeraCare, quantified by COBAS TaqMan HIV-1 v2.0 test.

FIG. 17A

Dengue 4 One-step RNAble
Candidate assay
3' UTR target

Amplicon Map

```
                Forward                         ←——Probe B                  Reverse                          External primer
CAAAAACAGCAGCATATTGACAGCTGGGAAAGACCACAGATCCTGCTGTCTCTRCAACATCAATCCAGGCACAGA
CAAAAACAGCAGCATATTGACAGCTGGGAAAGACCACAGATCCTGCTGTCT
Spacer:                              ├── 9bp ──┤
Amplicon:     ├─────────────────────────── 39bp ───────────────────────────┤
```

Den4 (Dengue type 4)

Primer	Sequence
Den4.F2	GACTCGGATATCGAGTCCAAAAACmAGCATATTmGmAmCmGmC
Den4.R1a	GACTCGGATATCGAGTCAGACAGCmAGGATCmTmCmTmGmG
Den4.R1b	GACTCGGATATCGAGTCAGACAGCmAGGATCmTmGmTmGmG
Den4.extRT1	TCTGTGCCTGGATTGAT (external primer)
Den4.probe.B	cgcatcTGGTCTTTCCCAGCgatgcg

Primers: mN indicates methoxy base
Probe sequence: lowercase = stems, uppercase = recognition

FIG. 17B

Dengue 4 One-step RNAble
Candidate assay
3' UTR target
*Preliminary data

Fluorescence History

	20pg RNA	NTC
	27.90	-
	32.19	-
	27.97	-
	34.00	-
Avg.	30.5	N/A
St. dev.	3.1	N/A

Cp values across 4 technical replicates (10uL reactions): Isolated total RNA from cell culture includes both viral and host cell RNA, total copy number is unknown.

FIG. 18A

Influenza B One-step RNAble
Candidate assay
Segment 7 target

Amplicon Map

| Forward | Probe T → | Reverse | External primer |

AAATGCAGATGGTGTCTCAGCTATGAACACAGCAAAAACAATGAATGGCAAAAGGAGAGAGACGTCCAAAA

AAATGCAATATGGTGTCTCAGCTATGAACACAGCAAACACAATGAATGGCAAACCAATGAATGGCAAACGGAGAGAGACGTTCAAAA

AAATGCAGATGGTTTCAGCTATGAACACAGCAAAACCAATGAATGGCCAAAGGAG

Spacer: ----------- 13bp

Amplicon: ---------------------------------- 48bp

FluB (Influenza B)

Primer	Sequence
FluB.F2a	GACTCGATATCGAGTCAAATGCAmGmGATGGTCTCmAmGmCmTmA
FluB.F2b	GACTCGATATCGAGTCAAATGCAmAATGGTCTCmAmGmCmTmA
FluB.F2c	GACTCGATATCGAGTCAAATGCAmGATGGTTTCmAmGmCmTmA
FluB.R3a	GACTCGATATCGAGTCTCCTTTmTCCCATTCCATmTmCmAmTmT
FluB.R3b	GACTCGATATCGAGTCTCCTTTmTCCCATTCCATmTmCmAmTmT
FluB.R3c	GACTCGATATCGAGTCTCCTTTmCCCCATTCCATmTmCmAmTmT
FluB.extRT1a	TTTTGGACGTCTTCTCC
FluB.extRT1b	TTTTGAACGTCTTCTCC
FluB.probe.T	gccaaGCTATGAACACAGCAAActtggc

FIG. 18B

Influenza B One-step RNAble
Candidate assay
Segment 7 target
*Preliminary data

Fluorescence History

	Sample 1	Sample 2
	39.89	42.05
	40.83	41.72
	41.29	43.92
	42.75	42.77
Avg.	41.2	42.6
St. dev.	1.2	1.0

---- Sample 1: 27pg total BEI RNA (viral and host cell)
—— Sample 2: 36pg total BEI RNA (viral and host cell)

Cp values across 4 technical replicates (10ul reactions): Isolated total RNA from cell culture includes both viral and host cell RNA, total copy number is unknown. Samples 1 and 2 are different viral isolates.

FIG. 19A

BVDV1 One-step RNAble
Candidate assay
Polyprotein gene target

Amplicon Map

Forward   Probe T →   Reverse   External primer

F1a GGCCCACTGTATTGCTACTGAAAATCTCTGCTGTACATGGCACATGGAGTTGATCACAAATGAACTTTTATACAAAACATA

F1b GGCCCACTGGAGATGCTACTAAAAATCTCTGCTGTACATGGCACATGGAGTTGATCACA

Spacer: —————————— 15bp

Amplicon: ——————————————— 50bp

BVDV1

Primer	Sequence
BVDV1.F1a	GACTCGGATATCGAGTCGGGCCCACmTGTATTGCTmAmCmTmGmAmAmA
BVDV1.F1b	GACTCGGATATCGAGTCGGGCCCACmTGCACTGCTmAmCmTmAmAmAmA
BVDV1.R1	GACTCGGATATCGAGTCTGTGATCmAACTCCmAmCmAmTmGmCmC
BVDV1.RT1v	TATGTTTTGTATAAAAGTTCATTTG
BVDV1.ProbeT	cgctacATCTCTGCTGTACATGgtagcg

FIG. 19B

BVDV1 One-step RNAble
Candidate assay
Polyprotein gene target

<110> ENVIROLOGIX INC.

<120> COMPOSITIONS AND METHODS FOR DETECTING AN RNA VIRUS

<130> 049224.1047WO1 (00102)

<140> PCT/US2015/056491
<141> 2015-10-20

<150> 62/104,008
<151> 2015-01-15

<150> 62/066,277
<151> 2014-10-20

<160> 75

<170> PatentIn version 3.5

<210> 1
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
     primer

<220>
<223> Description of Combined DNA/RNA Molecule: Synthetic
     primer

<220>
<221> modified_base
<222> (24)..(24)
<223> Methoxy base

<220>
<221> modified_base
<222> (32)..(36)
<223> Methoxy base

<400> 1
gactcgatat cgagtcgctt ccacagttat cuaccg   36

<210> 2
<211> 33
<212> DNA

2015336086   16 Nov 2020

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<220>
<223> Description of Combined DNA/RNA Molecule: Synthetic
      primer

<220>
<221> modified_base
<222> (24)..(24)
<223> Methoxy base

<220>
<221> modified_base
<222> (29)..(33)
<223> Methoxy base

<400> 2
gactcgatat cgagtcgaaa tgcaacgaca ccu   33

<210> 3
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      probe

<400> 3
gctacacgac tttygctgaa ggtagc   26

<210> 4
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      probe

<220>
<223> 5'-CALRed610nm-modified

<220>

<223> 3'-BHQ2-modified

<400> 4
gctacacgac tttygctgaa ggtagc   26

<210> 5
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      probe

<220>
<223> 5'-FAM or FITC-modified

<220>
<223> 3'-BHQ1-modified

<400> 5
gctacacgac tttygctgaa ggtagc   26

<210> 6
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<220>
<221> modified_base
<222> (24)..(24)
<223> Methoxy base

<220>
<221> modified_base
<222> (30)..(36)
<223> Methoxy base

<400> 6
gactcgatat cgagtctgac tagcggaggc tagaag   36

<210> 7
<211> 36

<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<220>
<221> modified_base
<222> (24)..(24)
<223> Methoxy base

<220>
<221> modified_base
<222> (30)..(36)
<223> Methoxy base

<400> 7
gactcgatat cgagtctgac tagcagaggc tagaag   36

<210> 8
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<220>
<221> modified_base
<222> (24)..(24)
<223> Methoxy base

<220>
<221> modified_base
<222> (28)..(33)
<223> Methoxy base

<400> 8
gactcgatat cgagtctatt gacgctctcg cac   33

<210> 9
<211> 33
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
      primer

<220>
<221> modified_base
<222> (24)..(24)
<223> Methoxy base

<220>
<221> modified_base
<222> (28)..(33)
<223> Methoxy base

<400> 9
gactcgatat cgagtctact gacgctctcg cac   33

<210> 10
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      probe

<400> 10
cgcaagggag agagatgggt gcttgcg   27

<210> 11
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<220>
<221> modified_base
<222> (24)..(24)
<223> Methoxy base

<220>
<221> modified_base
<222> (32)..(36)
<223> Methoxy base

<400> 11

```
gactcgatat cgagtccaaa aacagcatat tgacgc                              36


<210> 12
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
     primer


<220>
<221> modified_base
<222> (24)..(24)
<223> Methoxy base

<220>
<221> modified_base
<222> (30)..(34)
<223> Methoxy base

<400> 12
gactcgatat cgagtcagac agcaggatct ctgg                                34


<210> 13
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
     primer


<220>
<221> modified_base
<222> (24)..(24)
<223> Methoxy base

<220>
<221> modified_base
<222> (30)..(34)
<223> Methoxy base

<400> 13
gactcgatat cgagtcagac agcaggatct gtgg                                34


<210> 14
```

<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      probe

<400> 14
cgcatctggt ctttcccagc gatgcg   26

<210> 15
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<220>
<221> modified_base
<222> (24)..(24)
<223> Methoxy base

<220>
<221> modified_base
<222> (33)..(37)
<223> Methoxy base

<400> 15
gactcgatat cgagtcaaat gcagatggtc tcagcta   37

<210> 16
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<220>
<221> modified_base
<222> (24)..(24)
<223> Methoxy base

<220>

```
<221> modified_base
<222> (33)..(37)
<223> Methoxy base

<400> 16
gactcgatat cgagtcaaat gcaaatggtc tcagcta                                    37


<210> 17
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer


<220>
<221> modified_base
<222> (24)..(24)
<223> Methoxy base

<220>
<221> modified_base
<222> (33)..(37)
<223> Methoxy base

<400> 17
gactcgatat cgagtcaaat gcagatggtt tcagcta                                    37


<210> 18
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer


<220>
<221> modified_base
<222> (24)..(24)
<223> Methoxy base

<220>
<221> modified_base
<222> (35)..(39)
<223> Methoxy base
```

<400> 18
gactcgatat cgagtcctcc ttttcccatt ccattcatt   39

<210> 19
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
     primer

<220>
<221> modified_base
<222> (24)..(24)
<223> Methoxy base

<220>
<221> modified_base
<222> (35)..(39)
<223> Methoxy base

<400> 19
gactcgatat cgagtcctcc ctttcccatt ccattcatt   39

<210> 20
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
     primer

<220>
<221> modified_base
<222> (24)..(24)
<223> Methoxy base

<220>
<221> modified_base
<222> (35)..(39)
<223> Methoxy base

<400> 20
gactcgatat cgagtcctcc tttccccatt ccattcatt   39

```
<210> 21
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      probe

<400> 21
gccaagctat gaacacagca aacttggc                                    28


<210> 22
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer


<220>
<221> modified_base
<222> (24)..(24)
<223> Methoxy base

<220>
<221> modified_base
<222> (33)..(39)
<223> Methoxy base

<400> 22
gactcgatat cgagtcggcc cactgtattg ctactgaaa                        39


<210> 23
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer


<220>
<221> modified_base
<222> (24)..(24)
<223> Methoxy base
```

2015336086   16 Nov 2020

<220>
<221> modified_base
<222> (33)..(39)
<223> Methoxy base

<400> 23
gactcgatat cgagtcggcc cactgcactg ctactaaaa   39

<210> 24
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<220>
<221> modified_base
<222> (24)..(24)
<223> Methoxy base

<220>
<221> modified_base
<222> (30)..(36)
<223> Methoxy base

<400> 24
gactcgatat cgagtctgtg atcaactcca tgtgcc   36

<210> 25
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      probe

<400> 25
cgctacatct ctgctgtaca tggtagcg   28

<210> 26
<211> 18958
<212> DNA
<213> Zaire ebolavirus

<400> 26

```
cggacacaca aaaagaaaga agaatttta ggatctttg tgtgcgaata actatgagga         60

agattaataa ttttcctctc attgaaattt atatcggaat ttaaattgaa attgttactg        120

taatcacacc tggtttgttt cagagccaca tcacaaagat agagaacagc ctaggtctcc        180

gaagggaaca agggcaccag tgtgctcagt tgaaaatccc ttgtcaacat ctaggtctta        240

tcacatcaca agttccacct cagactctgc agggtgatcc aacaacccta atagaaaaat        300

tattgttaac ggacagcatt agttcacagt caaacaagca agattgagaa ttaaccttga        360

ttttgaactt caacacctag aggattggag attcaacaac cctaaaactt ggggtaaaac        420

attggaaata gttgaaagac aaattgctcg gaatcacaaa attccgagta tggattctcg        480

tcctcagaaa gtctggatga cgccgagtct tactgaatct gacatggatt accacaagat        540

cttgacagca ggtctgtccg ttcaacaggg gattgttcgg caaagagtca tcccagtgta        600

tcaagtaaac aatcttgagg aaatttgcca acttatcata caggcctttg aagcaggtgt        660

tgattttcaa gagagtgcgg acagtttcct tctcatgctt tgtcttcatc atgcgtacca        720

aggagatcac aaactttct tggaaagtgg tgcagtcaag tatttggaag ggcacgggtt        780

ccgttttgaa gtcaagaaac gtgatggggt gaagcgcctt gaggaattgc tgccagcagt        840

atctagtgga aaaaacatta agagaacact tgctgccatg ccggaagagg agacgactga        900

agctaatgcc ggtcagtttc tctcttttgc aagtctattc cttccgaaat tggtagtagg        960

agaaaaggct tgccttgaga aagttcaaag gcaaattcaa gtacatgcag agcaaggact       1020

gatacaatat ccaacagctt ggcaatcagt aggacacatg atggtgattt tccgtttgat       1080

gcgaacaaat ttttgatca aatttctcct aatacaccaa gggatgcaca tggttgccgg       1140

gcatgatgcc aacgatgctg tgatttcaaa ttcagtggct caagctcgtt tttcaggttt       1200

attgattgtc aaaacagtcc ttgatcatat cctacaaaag acagaacgag gagttcgtct       1260

ccatcctctt gcaaggactg ccaaggtaaa aaatgaggtg aactccttta aggctgcact       1320

cagctccctg gccaagcatg gagagtatgc tcctttcgcc cgacttttga acctttctgg       1380

agtaaataat cttgagcatg gtcttttccc tcaactatcg gcaattgcac tcggagtcgc       1440

cacagcacac gggagcaccc tcgcaggagt aaatgttgga gaacagtatc aacagctcag       1500

agaggctgcc actgaagctg agaagcaact ccaacaatat gcagaatctc gcgaacttga       1560
```

```
ccatcttgga cttgatgatc aggaaaagaa aattcttatg aacttccatc agaaaaagaa     1620

cgaaatcagc ttccagcaaa caaacgctat ggtaactcta agaaaagagc gcctggccaa     1680

gctgacagaa gctatcactg ctgcatcact gcccaaaaca agtggacctt acgatgatga     1740

tgacgacatt ccctttccag acccatcaa tgatgacgac aatcctggcc atcaagatga      1800

tgatccgact gactcacagg atacgaccat tcccgatgtg gtggttgatc ccgatgatgg     1860

aagctacggc gaataccaga gttactcgga aaacggcatg aatgcaccag atgacttggt     1920

cctattcgat ctagacgagg acgacgagga cactaagcca gtgcctaaca gattgaccaa     1980

gggtggacaa cagaaaaaca gtcaaaaggg ccagcataca gagggcagac agacacaatc     2040

caggccaact caaaatgtcc caggccctcg cagaacaatc caccacgcca gtgctccact     2100

cacggacaac gacagaggaa atgaaccctc cggctcaacc agccctcgca tgctgacacc     2160

aattaacgaa gaggcagacc cactggacga tgccgacgac gagacgtcta gtcttccgcc     2220

cttggagtca gacgatgaag aacaggacag ggacgaaact tccaaccgca cacccactgt     2280

cgccccaccg gctcccgtat acagagatca ctctgaaaag aaagaactcc cgcaagatga     2340

gcagcaagat caggaccaca ctcaagaggc caggaaccag acagtgaca acacccagcc      2400

agaacactct tttgaggaga tgtatcgcca cattctaaga tcacagggac catttgatgc     2460

tgttttgtat tatcatatga tgaaggatga gcctgtagtt ttcagtacta gtgatggcaa     2520

agagtacacg tatccggact cccttgaaga ggaatatcca ccatggctca ctgaaaaaga     2580

ggccatgaat gaagagaata gatttgttac attggatggt caacaatttt attggccggt     2640

aatgaatcac aagaataaat tcatggcaat cctgcaacat catcagtgaa tgagaatgga     2700

ataatgggat gatttaaccg acaaatagct aacattaaat agtcaagaaa cgcaaacagg     2760

aagaattttt gatgtctaag gtgtgaatta ttatcacaat aaaagtgatt cttatttttg     2820

aatttaaagc tagcttatta ttactagccg tttttcaaag ttcaatttga gtcttaatgc     2880

aaataggcgt taagccacag ttatagccat aattgtaact caatatctta gctagcgatt     2940

tatctaaatt aaattacatt atgctttat aacttaccta ctagcctgcc caacatttac      3000

acgatcgttt tataattaag aaaaaactaa tgatgaagat taaaaccttc atcatcctta     3060

cgtcaattga attctctagc actcgaagct tattgtcttc aatgtaaaag aaaagctggt     3120
```

```
ccaacaagat gacaactaga acaaagggca ggggccatac tgtggccacg actcaaaacg    3180

acagaatgcc aggccctgag cttctcgggct ggatctccga gcagctaatg accggaagaa    3240

ttcctgtaag cgacatcttc tgtgatattg agaacaatcc aggattatgt tacgcatccc    3300

aaatgcaaca aacaaagcca aacccgaaga tgcgcaacag tcaaacccaa acggacccaa    3360

tttgcaatca tagtttgag gaggtagtac aaacattggc ttcattggct actgttgtgc     3420

aacaacaaac tatcgcatca gaatcattag aacaacgtat tacgagtctt gagaatggtc     3480

taaagccagt ttatgatatg gcaaaaacaa tctcctcatt gaacagggtt tgtgctgaga    3540

tggttgcaaa atatgatctt ctggtgatga caaccggtcg ggcaacagca accactgcgg    3600

caactgaggc ttattgggct gaacatggtc aaccaccacc tggaccatca ctttatgaag    3660

aaagtgcaat tcggggtaag attgaatcta gagatgagac cgtccctcaa agtgttaggg    3720

aggcattcaa caatctagac agtaccactt cactaactga ggaaaatttt gggaaacctg    3780

acatttcagc aaaggatttg agaaacatta tgtatgatca cttgcctggt tttggaactg    3840

cttttccacca attagtacaa gtgatttgta aattgggaaa agatagcaac tcattggata    3900

tcattcatgc tgagttccag gccagcctgg ctgaaggaga ctctcctcaa tgtgccctaa    3960

ttcaaattac aaaaagagtt ccaatcttcc aagatgctgc tccacctgtc atccacatcc    4020

gctctcgagg tgacattccc cgagcttgcc agaaaagctt gcgtccagtc ccgccatcac    4080

ccaagattga tcgaggttgg gtatgtgttt ccagcttca agatggtaaa acacttggac    4140

tcaaaatttg agccaatctc ccttccctcc gaaagaggcg accaatagca gaggcttcaa    4200

ctgctgaact acagggtacg ttacattaat gatacacttg tgagtatcag ccctagataa    4260

tataagtcaa ttaaacgacc aagccaaaat tgttcatatc ccgctagcag cttaaaatat    4320

aaatgaaata ggagctatat ctctgacagt attataatca attgttatta agtaacccaa    4380

accaaaaatg atgaagatta agaaaaacct acctcgactg agagagtgtt tttccattaa    4440

ccttcatctt gtaaacgttg agcaaaattg ttacgaatat gaggcgggtt atattgccta    4500

ctgctcctcc tgaatatatg gaggccatat accctgtcag gtcaaattca acaattgcta    4560

ggggtggcaa caacaataca ggcttcctga caccggagtc agtcaatgga gacactccat    4620

cgaatccact caggccaatt gctgatgaca ccatcgacca tgctagccac acaccaggca    4680
```

```
gtgtgtcatc agcattcatc cttgaagcta tggtgaatgt catatcgggc cccaaagtgc      4740

taatgaagca aattccaatt tggcttcctc taggtgtcgc tgatcaaaag acctacagct      4800

ttgactcaac tacggccgcc atcatgcttg cttcatatac tatcacccat ttcggcaagg      4860

caaccaatcc acttgtcaga gtcaatcggc tgggtcctgg aatcccggat caccccctca      4920

ggctcctgcg aattggaaac caggccttcc tccaggagtt cgttcttccg ccagtccaac      4980

taccccagta tttcacccttt gatttgacag cactcaaact gatcacccaa ccactgcctg      5040

ctgcaacatg gaccgatgac actccaacag gatcaaatgg agcgctgcgt ccaggaattt      5100

cgtttcatcc aaaacttcgc cccattcttt tacctaacaa aagtgggaag aaggggaaca      5160

gtgccgatct aacatctcca gagaaaatcc aagcaataat gacttcactc caggacttta      5220

agatcgttcc aattgatcca accaaaaata tcatgggtat cgaagtgcca gaaactctgg      5280

tccacaagct gaccggtaag aaggtgactt ctaaaaatgg acaaccaatc atccctgttc      5340

ttttgccaaa gtacattggg ttggacccgg tggctccagg agacctcacc atggtaatca      5400

cacaggattg tgacacgtgt cattctcctg caagtcttcc agctgtgatt gagaagtaat      5460

tgcaataatt gactcagatc cagtttttaca gaatcttctc agggatagtg ataacatcta      5520

tttagtaatc cgtctattag aggagatact tttaattgat caatatacta aaggtgcttt      5580

acaccattgt cttttttctc tcctaaatgt agaacttaac aaaagactca caatatactt      5640

gtcttaaaga gattgattga tgaaagatca tgactaataa cattacaaat aatcctacta      5700

taatcaatac ggtgattcaa atattaatct ttctaattgc acatactctc tgcccctatc      5760

ctcaaattgc ctacatgcct acatctgagg atagccagtg tgacttggat tggagatgta      5820

gggaagaaat cggaacccat ctccaggttg ttcacaatcc aagcacagac atcgcccttc      5880

taattaagaa aaaatcggcg atgaagatta agccgacagt gagcgcaatc ttcatctctc      5940

ttagattatt tgttttccag agtaggggtc atcaggtcct ttccaatcat ataaccaaaa      6000

taaacttcac tagaaggata ttgtgaggca acaacacaat gggtattaca ggaatattgc      6060

agttacctcg tgatcgattc aagaggacat cattctttct ttgggtaatt atccttttcc      6120

aaagaacatt ttccatccca cttggagtca tccacaatag cacattacaa gttagtgatg      6180

tcgacaaact agtttgtcgt gacaaactgt catccacaaa tcaattgaga tcagttggac      6240
```

Page 15

tgaatctcga agggaatgga gtggcaactg acgtgccatc tgcaactaaa agatggggct   6300

tcaggtccgg tgtccctcca aaggtggtca attatgaagc tggtgaatgg gctgaaaact   6360

gctacaatct tgaaatcaaa aaacctgacg ggagtgagtg tctaccagca gcgccagacg   6420

ggattcgggg cttcccccgg tgccggtatg tgcacaaagt atcaggaacg ggaccgtgtg   6480

ccggagactt tgccttccac aaagagggtg ctttcttcct gtatgatcga cttgcttcca   6540

cagttatcta ccgaggaacg actttcgctg aaggtgtcgt tgcatttctg atactgcccc   6600

aagctaagaa ggacttcttc agctcacacc ccttgagaga gccggtcaat gcaacggagg   6660

acccgtccag tggctactat tctaccacaa ttagatatca ggctaccggt tttggaacca   6720

atgagacgga gtacttgttc gaggttgaca atttgaccta cgtccaactt gaatcaagat   6780

tcacgccaca gttttttgctc cagctgaatg agacaatata tgcaagtggg aaaaggagca   6840

acaccacggg aaaactaatt tggaaggtca accccgaaat tgatacaaca atcggggagt   6900

gggccttctg ggaaactaaa aaaacctcac tagaaaaatt cgcagtgaag agttgtcttt   6960

cacagctgta tcaaacggag ccaaagacat cagtggtcag agtccggcgc gaacttcttc   7020

cgacccagag acctacacaa caactgaaga ccacaaaatc atggcttcag aaaattcctc   7080

tgcaatggtt caagtgcaca atcaaggaag ggaagctgca gtgtcgcatc tgataaccct   7140

tgccacaatc tccacgagtc ctcaatcccc tacaaccaaa ccaggtcagg acaacagcac   7200

ccataataca cccgtgtata aacttgacat ctctgaggca actcaagttg aacaacatca   7260

tcgcagaaca gacaacgaca gcacagcctc cgacactccc cccgccacga ccgcagccgg   7320

acccccaaaa gcagagaaca tcaacacgag caagagcgct gactccctgg accccgccac   7380

cacgacaagt ccccaaaact acagcgagac cgctggcaac aacaacactc atcaccaaga   7440

taccggagaa gagagtgccg gcagcgggaa gctgggcttg attgccaata ctattgctgg   7500

agtcgcaggg ctgatcacag gcgggagaag aactcgaaga gaagcaattg tcaatgctca   7560

acccaaatgc aaccccaatc tacattactg gactactcag gatgaaggtg ctgcaatcgg   7620

attggcctgg ataccatatt tcgggccagc agccgaggga atttacacag aggggctaat   7680

gcacaatcaa gatggtttaa tctgtggatt gaggcagctg gccaatgaga cgactcaagc   7740

tcttcaactg ttcctgagag ccacaactga gctacgcacc ttttcaatcc tcaaccgtaa   7800

ggcaattgat ttcttgctgc agcgatgggg cggcacatgc cacattttgg gaccggactg   7860

ctgtatcgaa ccacatgatt ggaccaagaa cataacagac aaaattgatc agattattca   7920

tgattttgtt gataaaaccc ttccggacca gggggacaat gacaattggt ggactggatg   7980

gagacaatgg ataccggcag gtattggagt tacaggcgtt ataattgcag ttattgcttt   8040

attctgtata tgcaaatttg tcttttagtt tttcttcaga ttgcttcatg gcaaagctca   8100

gcctcaaatc aatgagatta ggatttaatt atatggatca cttgaatcta agattacttg   8160

acaaatgata atataataca ctggagcttt aaatatagcc aatgtgattc taactccttt   8220

aaactcacaa ttaatcataa acaaggtttg acatcaatct agttatatct ttgagaatga   8280

taaacttgat gaagattaag aaaaaggtaa tctttcgatt atctttagtc ttcatccttg   8340

attctacaat catgacagtt gtctttagtg acaagggaaa gaagcctttt tagtaagttg   8400

taataatcag atctgcgaac cggtagagtt taattgcaac ctaacacaca taaagcattg   8460

gtcaaaaagt caatagaaat ttaaacagtg agtggagaca actttcaaat ggaagctcca   8520

tacgagagag gacgcccccg agctgccaga cagcattcaa gggatggaca cgaccatcat   8580

gttcgagcac gatcatcatc cagagagaat tatcgaggtg agtaccgtca atcaaggagc   8640

gcctcacaag tgcgcgttcc tactgtattt cataagagga gagttgaacc attaacagtt   8700

cctccagcac ctaaagacat atgtccgacc ttgaaaaaag gattttgtg tgacagtagt   8760

ttttgcaaaa aagatcacca gttggaaagt ttaactgata gggaattact cctactaatc   8820

gcccgtaaga cttgtggatc agtagaacaa caattaaata taactgcacc caaggactcg   8880

cgcttagcaa atccaacggc tgatgatttc cagcaagagg aaggtccaaa aattaccttg   8940

ttgacactga tcaagacggc agaacactgg gcgagacaag acatcaggac cacagaggat   9000

tcaaaattaa gagcattgtt gactctatgt gctgtgatga cgaggaaatt ctcaaaatcc   9060

cagctgagtc ttttatgtga gacacacctg aggcgcgagg ggcttgggca agatcaggca   9120

gaacccgttc tcgaagtata tcaacgatta cacagtgata aaggaggcag tttcgaagct   9180

gcactatggc aacaatggga tcgacaatcc ctaattatgt ttatcactgc attcttgaat   9240

atcgctctcc agttaccgtg tgaaagttct gctgtcgttg tttcagggtt aagaacattg   9300

gttcctcaat cagataatga ggaagcttca accaacccgg ggacatgctc atggtctgat   9360

```
gatggtaccc cttaataagg ctgactaaaa cactatataa ccttctactt gatcacaata    9420

ctccgtatac ctatcatcat atattcaatc aagacggtat cctttaaaac ttattcagta    9480

ctataatcac tctcgtttca aattaataag atatgcataa ttgctttaat atatgaagag    9540

gtatgataca accctaacag tgatcaaaga aaatcataat ctcttatcgc tcgtaatata    9600

acctgccaag catacctctt gcacaaagtg attcttgtac acaaataatg ttttactcta    9660

caggaggtag caacgatcca tcccatcaaa aaataagtat tttatgactt actaatgatc    9720

tcttaaaata ttaagaaaaa ctgacggaac acaaattctt tctgcttcaa gttgtggagg    9780

aggtctttgg tattggctat tgttatatta caatcaataa caagcttgta aaaatattgt    9840

tcttgtttca agaggtagat tgtgaccgga aacgctaaac taatgatgaa gattaatgcg    9900

gaggtctgat aagaataaac cttattattc agattaggcc ccaagaggca ttcttcatct    9960

ccttttagca aagtactatt tcagggtagt ccaattagtg acacgtcttt tagctgtata    10020

tcagtcgccc ctgagatacg ccacaaaagt gtctctaagc taaattggtc tgtacacatc    10080

tcatacattg tattaggggc aataatatct aattgaactt agccgtttaa aatttagtgc    10140

ataaacctgg gctaactcca ccaggtcaac tccattggct gaaaagaagc ccacctacaa    10200

cgaacatcac tttgagcgcc cttacaatta aaaaatagga acgtcgttcc aacaattgag    10260

cgcaaggttt caaggttgaa ctgagagtgc ctaaacacca aaatatcgat aattcagaca    10320

ccaagcaaga cctgagaagg aaccatggct aaagctacgg gacgatacaa tctaatatcg    10380

cccaaaaagg acctggagaa aggggttgtc ttaagcgacc tctgtaactt cctagttagt    10440

caaactattc aagggtggaa ggtctattgg gctggtattg agtttgatgt gactcacaaa    10500

ggaatggccc tattgcatag actgaaaact aatgactttg cccctgcatg gtcaatgaca    10560

aggaatctat ttcctcattt atttcaaaat ccgaattcca caattgagtc accactgtgg    10620

gcattgagag tcatccttgc agcaggggta caggaccagc tgattgacca gtctttgatt    10680

gaacccttag caggagccct tggtctgatc tctgattggc tgctaacaac caacactaac    10740

catttcaaca tgcgaacaca acgtgttaag gaacaattga gcctaaaaat gctgtcgttg    10800

attcgatcca atattctcaa gtttattaac caattggatg ctctacatgt cgtgaactac    10860

aacgggttgt tgagcagtat tgaaattgga actcaaaatc atacaatcat tataactcga    10920
```

```
actaacatgg gttttctggt ggagctccaa gaacccgaca aatcggcaat gaaccgcaag     10980

aagcctgggc cggcgaaatt ttccctcctt catgagtcca cactgaaagc atttacacaa     11040

gggtcctcga cacgaatgca aagtttgatt cttgaattta atagctctct tgctatctaa     11100

ttaagatgga atacttcata ttgagctaac tcatatatgc tgactcaata gttatcttga     11160

catctctgct ttcataatca gatatataag cataataaat aaatactcat atttcttgat     11220

aatttgttta accacagata aatcctaact gtaagccagc ttccaagttg acacccttac     11280

aaaaaccagg actcagaatc cctcaaataa gagattccaa gacaacatca tagaattgct     11340

ttattatatg aataagcatg ttatcaccag aaatccaata tactaaatag ttaattgtaa     11400

ctgaacccgc aggtcacgtg tgttaggttt cacagattat atatattact aactccatac     11460

ccgtaattaa cattagataa gtagattaag aaaaacgctt gaggaagatt aagaaaaact     11520

gcttattggg tctttccgtg ttttagatga agcagttgac attcttcctc ttgatattaa     11580

atggctacac aacataccca atacccagac gccaggttat catcaccaat tgtattggac     11640

caatgtgacc tagtcactag agcttgcggg ttatattcat catactccct taatccgcaa     11700

ctacgcaact gtaaactccc gaaacatatc taccgtttaa aatatgatgt aactgttacc     11760

aagttcttaa gtgatgtacc agtggcgaca ttgccaatag atttcatagt cccaattctt     11820

ctcaaggcac tgtcaggcaa tgggttctgt cctgttgagc cgcggtgtca acagttctta     11880

gatgaaatca ttaagtacac aatgcaagat gctctcttcc tgaaatatta tctcaaaaat     11940

gtgggtgctc aagaggactg tgttgatgac cactttcaag agaaaatctt atcttcaatt     12000

cagggcaatg aattttttaca tcaaatgttc ttctggtatg acctggctat tttgactcga     12060

aggggtagat aaatcgagg aaactctaga tcaacatggt ttgttcatga tgatttaata     12120

gacatcttag gctatgggga ctatgttttt tggaagatcc caatttcaat gttacccctg     12180

aacacacaag gaatcccccca tgctgctatg gattggtatc aggcatcagt attcaaagaa     12240

gcggttcaag ggcatacaca cattgtttct gtttctactg ccgacgtctt gataatgtgc     12300

aaagatttaa ttacatgtcg attcaacaca actctaatct caaagatagc agaggttgag     12360

gatccagttt gttctgatta tcccgatttt aagattgtgt ctatgcttta ccagagcgga     12420

gattacttac tctccatatt agggtctgat gggtataaaa ttattaagtt cctcgaacca     12480
```

Page 19

8969417_1

```
ttgtgcttgg ccaaaattca attatgctca aagtacaccg agaggaaggg ccgattctta    12540

acacaaatgc atttagctgt aaatcacacc ctggaagaaa ttacagaaat gcgtgcacta    12600

aagccttcac aggatcaaaa gatccgtgaa ttccatagaa cattgataag gctggagatg    12660

acgccacaac aactttgtga gctatttcc attcaaaaac actgggggca tcctgtgcta     12720

catagtgaaa cagcaatcca aaaagttaaa aaacatgcca cggtgctaaa agcattacgc    12780

cctatagtga ttttcgagac atattgtgtt tttaaatata gtattgcaaa acattatttt    12840

gatagtcaag gatcttggta cagtgttact tcagatagga atttaacgcc aggtcttaat    12900

tcttatatca aaagaaatca attcccccg ttgccaatga ttaaagaact actatgggaa     12960

ttttaccacc ttgaccatcc tccacttttc tcaaccaaaa ttattagtga cttaagtatt    13020

tttataaaag acagagctac cgcagtggaa aggacatgct gggatgcagt attcgagcct    13080

aatgttctag gatataatcc acctcacaaa ttcagtacta aacgtgtacc agaacaattt    13140

ttagagcaag aaaactttc tattgagaat gttctttcct acgcgcaaaa actcgagtat    13200

ctactaccac aataccggaa tttttctttc tcattgaaag agaaagagtt gaatgtaggt    13260

agaactttcg gaaaattgcc ttatccgact cgcaatgttc aaacactttg tgaagctctg    13320

ttagctgatg gtcttgctaa agcatttcct agcaatatga tggtagtcac agagcgtgag    13380

caaaaagaaa gcttattgca tcaagcatca tggcaccaca caagtgatga ttttggtgag    13440

catgccacag ttagagggag tagctttgta actgatttag agaaatacaa tcttgcattt    13500

agatatgagt ttacagcacc ttttatagaa tattgtaacc gttgctatgg tgttaagaat    13560

gttttttaatt ggatgcatta tacaatcccc cagtgttata tgcatgtcag tgattattat   13620

aatccaccgc ataacctcac tctggaaaat cgagacaacc cccccgaagg gcccagttca    13680

tacagaggtc atatgggagg gattgaagga ctgcaacaaa aactctggac aagtatttca    13740

tgtgctcaaa tttctttagt tgaaataaag actggtttta agttacgctc agctgtgatg    13800

ggtgacaatc agtgcattac cgtttatca gtcttcccct tagagactga cgcagacgag     13860

caggaacaga gcgccgaaga caatgcagcg agggtggccg ccagcctagc aaaagttaca    13920

agtgcctgtg gaatcttttt aaaacctgat gaaacatttg tacattcagg tttttatctat   13980

tttggaaaaa aacaatattt gaatgggggtc caattgcctc agtcccttaa aacggctaca    14040
```

agaatggcac cattgtctga tgcaattttt gatgatcttc aagggaccct ggctagtata   14100

ggcactgctt ttgaacgatc catctctgag acacgacata tctttccttg caggataacc   14160

gcagctttcc atacgttttt ttcggtgaga atcttgcaac atcatcacct cgggttcaat   14220

aagggttttg accttggaca gttgacactt ggcaaacctc tggatttcgg aacaatatca   14280

ttggcactag cggtaccgca ggtgcttgga gggttatcct tcttgaatcc tgagaaatgt   14340

ttctaccgga atttaggaga tccagttacc tcaggcttat tccagttaaa aacttatctc   14400

cgaatgattg agatggatga tttattctta cctttaattg cgaagaaccc tgggaactgc   14460

actgccattg actttgtgct aaatcctagc ggattaaatg tccccgggtc gcaagactta   14520

acttcatttc tgcgccagat tgtgcgtagg actatcaccc taagtgcgaa aaacaaactt   14580

attaatactt tatttcatgc gtcagctgac ttcgaagacg aaatggtttg taaatggcta   14640

ttatcatcaa ctcctgttat gagtcgtttt gcggccgata tcttttcacg cacgcccagt   14700

gggaagcgat tgcaaattct aggatacctg gaaggaacac gcacattatt agcctctaag   14760

atcatcaaca ataatacaga aacaccggtt ttggacagac tgaggaaaat aacattgcaa   14820

aggtggagtc tatggtttag ttatcttgat cattgtgata atatcctggc agaggcttta   14880

acccaaataa cttgcacagt tgatttagca cagatcctga gggaatattc atgggcacat   14940

attttagagg ggagacctct tattggagcc acacttccat gtatgattga gcaattcaaa   15000

gtggtttggc tgaaacccta cgaacaatgt ccgcagtgtt caaatgcaaa gcaacctggt   15060

gggaaaccat tcgtgtcagt ggcagtcaag aaacatattg ttagtgcatg gccgaacgca   15120

tcccgaataa gctggactat cggggatgga atcccataca ttggatcaag gacagaagat   15180

aagataggac aacctgctat taaaccaaaa tgtccttccg cagccttaag agaggccatt   15240

gaactggcgt cccgtttaac atgggtaact caaggcagtt cgaacagtga tttgctaata   15300

aaaccatttt tggaagcacg agtaaattta agtgttcaag aaatacttca aatgacccct   15360

tcacattact caggaaatat tgttcacagg tacaacgatc aatatagtcc tcattctttc   15420

atggccaatc gtatgagtaa ttcagcgacg cgattgattg tttctactaa cactttaggt   15480

gagttttcag gaggtggcca gtctgcacgc gacagcaata ttattttcca gaatgttata   15540

aattatgcag ttgcactgtt cgatattaaa tttagaaaca ctgaggctac agatatccaa   15600

```
tataatcgtg ctcaccttca tctaactaag tgttgcaccc gggaagtacc agctcagtat    15660

ttaacataca catctacatt ggatttagat ttaacaagat accgagaaaa cgaattgatt    15720

tatgacaata atcctctaaa aggaggactc aattgcaata tctcattcga taacccattt    15780

ttccaaggta aacggctaaa cattatagaa gatgatctta ttcgactgcc tcacttatct    15840

ggatgggagc tagccaagac catcatgcaa tcaattattt cagatagcaa caattcgtct    15900

acagacccaa ttagcagtgg agaaacaaga tcattcacta cccatttctt aacttatccc    15960

aagataggac ttctgtacag ttttggggcc tttataagtt attatcttgg caatacaatt    16020

cttcggacta agaaattaac acttgacaat tttttatatt acttaactac ccaaattcat    16080

aatctaccac atcgctcatt gcgaatactt aagccaacat tcaaacatgc aagcgttatg    16140

tcacggttaa tgagtattga tcctcatttt tctatttaca taggcggtgc ggcaggtgac    16200

agaggactct cagatgcggc caggttattt ttgagaacgt ccatttcatc ttttcttgca    16260

tttataaaag agtggataat taatcgcgga acaattgtcc ctttatggat agtatatccg    16320

ctagagggtc aaaacccaac acctgttaat aatttcctcc atcagatcgt agaactgctg    16380

gtgcatgatt catcaagaca acaggctttt aaaactacca taagtgatca tgtacatcct    16440

cacgacaatc ttgtttacac atgtaagagt acagccagca atttcttcca tgcgtcattg    16500

gcgtactgga gaagcaggca cagaaacagc aatcgaaaat acttggcaag agactcttca    16560

actggatcaa gcacaaacaa cagtgatggt catattgaga gaagtcaaga acaaaccacc    16620

agagatccac atgatggcac tgaacggaat ctagtcctac aaatgagcca tgaaataaaa    16680

agaacgacaa ttccacaaga aagcacgcac cagggtccgt cgttccagtc atttctaagt    16740

gactctgctt gtggtacagc aaatccaaaa ctaaatttcg atagatcgag acataatgtg    16800

aaatctcagg atcataactc ggcatccaag agggaaggtc atcaaataat ctcacaccgt    16860

ctagtcctac ctttctttac attgtctcaa gggacgcgcc aattaacgtc atccaatgag    16920

tcacaaaccc aagacgagat atcaaagtac ttacggcaat tgagatccgt cattgatacc    16980

acagtttatt gtaggtttac cggtatagtc tcgtccatgc attacaaact tgatgaggtc    17040

ctttgggaaa tagagagttt taagtcggct gtgacgctag cagagggaga aggtgctggt    17100

gccttactat tgattcagaa ataccaagtt aagaccttat ttttcaacac gctagctact    17160
```

Page 22

gagtccagta tagagtcaga aatagtatca ggaacgacta ctcctaggat gcttctacct   17220

gttatgtcaa aattccataa tgaccaaatt gagattattc ttaacaattc ggcaagccaa   17280

ataacagaca taacaaatcc tacttggttc aaagaccaaa gagcaaggct acctaggcaa   17340

gtcgaggtta taaccatgga tgcagagacg acagaaaata taaacagatc gaaattgtac   17400

gaagctgtat ataaattgat cttacaccat attgatccca gcgtattgaa agcagtggtc   17460

cttaaagtct ttctaagtga tactgagggt atgttatggc taaatgataa tttagccccg   17520

tttttttgcca ctggttattt aattaagcca ataacgtcaa gtgctagatc tagtgagtgg   17580

tatctttgtc tgacgaactt cttatcaact acacgtaaga tgccacacca aaaccatctc   17640

agttgtaaac aggtaatact tacggcattg caactgcaaa ttcaacggag cccatactgg   17700

ctaagtcatt taactcagta tgctgactgc gatttacatt taagttatat ccgccttggt   17760

tttccatcat tagagaaagt actataccac aggtataacc tcgtcgattc aaaaagaggt   17820

ccactagtct ctatcactca gcacttggca catcttagag cagagattcg agaattgact   17880

aatgattata atcaacagcg acaaagtcgg actcaaacat atcactttat tcgtactgca   17940

aaaggacgaa tcacaaaact agtcaatgat tatttaaaat tctttcttat tgtgcaagca   18000

ttaaaacata atgggacatg gcaagctgag tttaagaaat taccagagtt gattagtgtg   18060

tgcaataggt tctatcatat tagagattgc aattgtgaag aacgtttctt agttcaaacc   18120

ttatatctac atagaatgca ggattctgaa gttaagctta tcgaaaggct gacagggctt   18180

ctgagtttat tcccggatgg tctctacagg tttgattgaa ttaccgtgca tagtatcctg   18240

atacttgtga aggttgatta tcaacgtaca gattataaaa aactcacaaa ttgctctcat   18300

acatcatatt gatcgaattt caataaataa ctatttaaat aacgaaagaa gtccttatat   18360

tatacactat atttagcctc tctccctgcg tgataatcaa aaaattcaca atgcagcatg   18420

tgtgacatat tacttccgcg atgaatctaa cgcaacataa taaactctgc actctttata   18480

attaagcttt aacaaaaggt ctgggctcat attgttattg atataataat gttgtatcaa   18540

tatcctgtca gatggaatag tgttttggtt gataacacga cttcttaaaa caaaattgat   18600

cttcaagatt aagttttta taattatcat tactttaatt tgtcgatttta aaaatggtga   18660

tagccttaat ctttgtgtaa aataagagat taggtgtaat aactttaaca ttttgtctag   18720

Page 23

taagctacta tttcatacag aatgataaaa ttaaaagaaa aggcatgact gtaaaatcag   18780

aaataccttc tttacaatat agcagactag ataataatct tcgtgttaat gataattaag   18840

acattgacca cgctcatcag gaggctcgcc aggataaacg ttgcaaaaag gattcctgga   18900

aaaatggtcg cacacaaaaa tttaaaaata aatctatttc ttcttttttg tgtgtcca   18958

<210> 27
<211> 341
<212> DNA
<213> Homo sapiens

<400> 27
atagggcgga gggaagctca tcagtggggc cacgagctga gtgcgtcctg tcactccact   60

cccatgtccc ttgggaaggt ctgagactag ggccagaggc ggccctaaca gggctctccc   120

tgagcttcgg ggaggtgagt tcccagagaa cggggctccg cgcgaggtca gactgggcag   180

gagatgccgt ggaccccgcc cttcggggag gggcccggcg gatgcctcct ttgccggagc   240

ttggaacaga ctcacggcca gcgaagtgag ttcaatggct gaggtgaggt accccgcagg   300

ggacctcata acccaattca gactactctc ctccgcccat t   341

<210> 28
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
     oligonucleotide

<220>
<221> modified_base
<222> (6)..(12)
<223> a, c, t, g, unknown or other

<400> 28
gagtcnnnnn nn   12

<210> 29
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<220>
<221> modified_base
<222> (6)..(10)
<223> a, c, t, g, unknown or other

<400> 29
ggatcnnnnn   10

<210> 30
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<220>
<221> modified_base
<222> (6)..(10)
<223> a, c, t, g, unknown or other

<400> 30
gagtcnnnnn   10

<210> 31
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<220>
<221> modified_base
<222> (6)..(7)
<223> a, c, t, g, unknown or other

<400> 31
gactcnngag tc   12

<210> 32
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<220>
<221> modified_base
<222> (6)..(9)
<223> a, c, t, g, unknown or other

<400> 32
gactcnnnng agtc   14

<210> 33
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<220>
<221> modified_base
<222> (6)..(11)
<223> a, c, t, g, unknown or other

<400> 33
gactcnnnnn ngagtc   16

<210> 34
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<220>
<221> modified_base
<222> (1)..(4)
<223> a, c, t, g, unknown or other

```
<220>
<221> modified_base
<222> (10)..(15)
<223> a, c, t, g, unknown or other

<220>
<221> modified_base
<222> (21)..(24)
<223> a, c, t, g, unknown or other

<400> 34
nnnngactcn nnnnngagtc nnnn                                          24


<210> 35
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide


<220>
<221> modified_base
<222> (1)..(4)
<223> a, c, t, g, unknown or other

<220>
<221> modified_base
<222> (10)..(13)
<223> a, c, t, g, unknown or other

<220>
<221> modified_base
<222> (19)..(22)
<223> a, c, t, g, unknown or other

<400> 35
nnnngactcn nnngagtcnn nn                                            22


<210> 36
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer
```

```
<400> 36
cttcttagct tggggcagta tca                                                23


<210> 37
<211> 500
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      polynucleotide

<400> 37
aagatgactg caggagtcaa tgcgcagttg gtcccggcag accaggcgaa cattaccgaa        60

ttttacaaca agtccctttc atcctacaag gagaatgagg agaacatcca gtgtgggggag      120

aacttcatgg acatggagtg cttcatgatt ctgaacccca gtcagcagct ggcaattgcc       180

gtcttgtctc tcacactggg caccttcaca gttctggaga acttgctggt gctgtgtgtc       240

accacagtta tctaccgagg aacgactttc gctgaaggtg tcgttgcatt tctgattcct       300

tcactcccgc agcctccgct gccggccctc ttaccacttc atcattagcc tggccgtggc       360

cgaccttctg gggagtgtca tttttgtcta cagctttgtt gactttcatg tgttccaccg       420

caaggacagc cccaacgtct ttctcttcaa attgggtggg gtcaccgcct ccttcacggc       480

ctctgtaggc agcctcttcc                                                   500


<210> 38
<211> 89
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> 38
gacugcagga gucugcugcu uccacaguua ucuaccgagg aacgacuuuc gcugaaggug        60

ucguugcauu ucugauuccu ucacucccg                                         89


<210> 39
<211> 36
<212> DNA
```

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<220>
<223> Description of Combined DNA/RNA Molecule: Synthetic
      primer

<220>
<221> modified_base
<222> (24)..(24)
<223> Methoxy base

<220>
<221> modified_base
<222> (31)..(36)
<223> Methoxy base

<400> 39
gactcgatat cgagtccacg agcugagtgc guccug   36

<210> 40
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<220>
<223> Description of Combined DNA/RNA Molecule: Synthetic
      primer

<220>
<221> modified_base
<222> (24)..(24)
<223> Methoxy base

<220>
<221> modified_base
<222> (31)..(35)
<223> Methoxy base

<400> 40
gactcgatat cgagtcagac cttcccaagg gacau   35

2015336086   16 Nov 2020

```
<210> 41
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      probe

<400> 41
ccacgcctgt cactccactc cgcgtgg                                    27


<210> 42
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<400> 42
cctctggccc tagtctcag                                            19


<210> 43
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<400> 43
gcatctaatt tttcgcc                                              17


<210> 44
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<400> 44
tctgtgcctg gattgat                                              17
```

```
<210> 45
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<400> 45
ttttggacgt cttctcc                                                17


<210> 46
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<400> 46
ttttgaacgt cttctcc                                                17


<210> 47
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<400> 47
tatgttttgt ataaaagttc atttg                                       25


<210> 48
<211> 16
<212> DNA
<213> Zaire ebolavirus

<400> 48
acgactttyg ctgaag                                                 16


<210> 49
<211> 16
<212> DNA
```

<213> Zaire ebolavirus

<400> 49
acgactttcg ctgaag   16

<210> 50
<211> 56
<212> DNA
<213> Zaire ebolavirus

<400> 50
tccacagtta tctaccgagg aacgactttc gctgaaggtg tcgttgcatt tctgat   56

<210> 51
<211> 59
<212> DNA
<213> Zaire ebolavirus

<400> 51
ttccacagtt atctaccgag gaacgacttt cgctgaaggt gtcgttgcat ttctgatac   59

<210> 52
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      probe

<220>
<221> modified_base
<222> (14)..(14)
<223> Methoxy base

<400> 52
gctacacgac tttggctgaa ggtagc   26

<210> 53
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      probe

<400> 53
gctaccttca gcraaagtcg gtagc   25

<210> 54
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
     primer

<220>
<221> modified_base
<222> (24)..(24)
<223> Methoxy base

<220>
<221> modified_base
<222> (32)..(36)
<223> Methoxy base

<400> 54
gactcgatat cgagtccttc cacagttatc taccga   36

<210> 55
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
     primer

<220>
<221> modified_base
<222> (24)..(24)
<223> Methoxy base

<220>
<221> modified_base
<222> (32)..(36)
<223> Methoxy base

<400> 55
gactcgatat cgagtcgctt ccacagttat ctaccg   36

```
<210> 56
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer


<220>
<221> modified_base
<222> (24)..(24)
<223> Methoxy base

<220>
<221> modified_base
<222> (32)..(36)
<223> Methoxy base

<400> 56
gactcgatat cgagtcacag ttatctaccg aggaac                        36


<210> 57
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer


<220>
<221> modified_base
<222> (24)..(24)
<223> Methoxy base

<220>
<221> modified_base
<222> (29)..(33)
<223> Methoxy base

<400> 57
gactcgatat cgagtcaaat gcaacgacac ctt                           33


<210> 58
<211> 33
<212> DNA
<213> Artificial Sequence
```

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<220>
<221> modified_base
<222> (24)..(24)
<223> Methoxy base

<220>
<221> modified_base
<222> (29)..(33)
<223> Methoxy base

<400> 58
gactcgatat cgagtcgaaa tgcaacgaca cct   33

<210> 59
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<220>
<221> modified_base
<222> (24)..(24)
<223> Methoxy base

<220>
<221> modified_base
<222> (29)..(33)
<223> Methoxy base

<400> 59
gactcgatat cgagtcagaa atgcaacgac acc   33

<210> 60
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

```
<220>
<221> modified_base
<222> (24)..(24)
<223> Methoxy base

<220>
<221> modified_base
<222> (32)..(36)
<223> Methoxy base

<400> 60
gactcgcgcg cgagtcacag ttatctaccg aggaac                               36


<210> 61
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer


<220>
<221> modified_base
<222> (24)..(24)
<223> Methoxy base

<220>
<221> modified_base
<222> (32)..(36)
<223> Methoxy base

<400> 61
gactcgcgcg cgagtccaca gttatctacc gaggaa                               36


<210> 62
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer


<220>
<221> modified_base
```

<222> (24)..(24)
<223> Methoxy base

<220>
<221> modified_base
<222> (32)..(36)
<223> Methoxy base

<400> 62
gactcgcgcg cgagtcccac agttatctac cgagga   36

<210> 63
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<220>
<221> modified_base
<222> (24)..(24)
<223> Methoxy base

<220>
<221> modified_base
<222> (29)..(33)
<223> Methoxy base

<400> 63
gactcgcgcg cgagtcaaat gcaacgacac ctt   33

<210> 64
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<220>
<221> modified_base
<222> (24)..(24)
<223> Methoxy base

<220>

16 Nov 2020

2015336086

<221> modified_base
<222> (29)..(33)
<223> Methoxy base

<400> 64
gactcgcgcg cgagtcgaaa tgcaacgaca cct   33

<210> 65
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
     primer

<220>
<221> modified_base
<222> (24)..(24)
<223> Methoxy base

<220>
<221> modified_base
<222> (29)..(33)
<223> Methoxy base

<400> 65
gactcgcgcg cgagtcagaa atgcaacgac acc   33

<210> 66
<211> 55
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
     primer

<400> 66
ccacagttat ctaccgagga acgactttcg ctgaaggtgt cg   48

<210> 67
<211> 71
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

oligonucleotide

<400> 67
tgactagcgg aggctagaag gagagagatg ggtgcgagag cgtcaatatt aagaggcgaa   60

aaattagatg c   71

<210> 68
<211> 48
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> 68
tgactagcag aggctagaag gagagagatg ggtgcgagag cgtcagta   48

<210> 69
<211> 71
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> 69
caaaaacagc atattgacgc tgggaaagac cagagatcct gctgtctctr caacatcaat   60

ccaggcacag a   71

<210> 70
<211> 47
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> 70
caaaaacagc atattgacgc tgggaaagac cacagatcct gctgtct   47

<210> 71
<211> 73
<212> DNA

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
     oligonucleotide

<400> 71
aaatgcagat ggtctcagct atgaacacag caaaaacaat gaatggaatg ggaaaaggag   60

aagacgtcca aaa   73

<210> 72
<211> 73
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
     oligonucleotide

<400> 72
aaatgcaaat ggtctcagct atgaacacag caaagacaat gaatggaatg ggaaagggag   60

aagacgttca aaa   73

<210> 73
<211> 60
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
     oligonucleotide

<400> 73
aaatgcagat ggtttcagct atgaacacag caaaagcaat gaatggaatg gggaaaggag   60

<210> 74
<211> 81
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
     oligonucleotide

<400> 74
ggcccactgt attgctactg aaaatctctg ctgtacatgg cacatggagt tgatcacaaa   60

tgaactttta tacaaaacat a   81

<210> 75
<211> 58
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> 75
ggcccactgc actgctacta aaaatctctg ctgtacatgg cacatggagt tgatcaca   58